

DTIC FILE COPY

AD-A222 091

# ANNUAL PROGRESS REPORT

DTIC  
ELECTED  
MAY 17 1990  
FY-89



VOLUME 1



DISTRIBUTION STATEMENT A

Approved for public release  
Distribution Unlimited

DEPARTMENT OF CLINICAL INVESTIGATION  
WALTER REED ARMY MEDICAL CENTER  
WASHINGTON, D. C. 20307 - 5001

CLINICAL INVESTIGATION PROGRAM

RCS MED-300 (RI)

90 05 15 055

SECURITY CLASSIFICATION OF THIS PAGE

Form Approved  
OMB No. 0704-0188

REPORT DOCUMENTATION PAGE			
1a. REPORT SECURITY CLASSIFICATION <b>UNCLASSIFIED</b>		1b. RESTRICTIVE MARKINGS	
2a. SECURITY CLASSIFICATION AUTHORITY <b>N/A</b>		3. DISTRIBUTION/AVAILABILITY OF REPORT	
2b. DECLASSIFICATION/DOWNGRADING SCHEDULE <b>N/A</b>		AS IT APPEARS ON THE REPORT	
4. PERFORMING ORGANIZATION REPORT NUMBER(S)  <b>RCS MED-300(RI)</b>		5. MONITORING ORGANIZATION REPORT NUMBER(S)	
6a. NAME OF PERFORMING ORGANIZATION  <b>DEPT OF CLINICAL INVESTIGATION</b>	6b. OFFICE SYMBOL  <b>HSHL-CI</b>	7a. NAME OF MONITORING ORGANIZATION  <b>FORT SAM HOUSTON, TX 78234-6060</b>	
6c. ADDRESS (City, State, and ZIP Code)  <b>WALTER REED ARMY MEDICAL CENTER WASHINGTON, D.C. 20307-5001</b>		7b. ADDRESS (City, State, and ZIP Code)	
8a. NAME OF FUNDING / SPONSORING ORGANIZATION  <b>COMMANDER</b>	8b. OFFICE SYMBOL  <b>HSHL-CG</b>	9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER	
8c. ADDRESS (City, State, and ZIP Code)  <b>WALTER REED ARMY MEDICAL CENTER WASHINGTON, D.C. 20307-5001</b>		10. SOURCE OF FUNDING NUMBERS	
11. TITLE (Include Security Classification)  <b>CLINICAL INVESTIGATION PROGRAM TCS MED-300(RI)</b>	PROGRAM ELEMENT NO.	PROJECT NO.	TASK NO.
12. PERSONAL AUTHOR(S)  <b>H. LINTON WRAY, COLONEL, MEDICAL CORPS, CHIEF, DEPARTMENT OF CLINICAL INVESTIGATION</b>		WORK UNIT ACCESSION NO.	
13a. TYPE OF REPORT  <b>ANNUAL</b>	13b. TIME COVERED  <b>FROM Q1 OCT 88 TO Q3 SEP 89</b>	14. DATE OF REPORT (Year, Month, Day)  <b>90/01/02</b>	15. PAGE COUNT  <b>593</b>
16. SUPPLEMENTARY NOTATION  The findings in this report are not to be considered as an official Department of the Army position unless so designated by other authorized documents.			
17. COSATI CODES		18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)	
FIELD	GROUP	SUB-GROUP	<b>APR - ANNUAL PROGRESS REPORT</b> <b>PI - PRINCIPAL INVESTIGATOR</b> <b>IRB - INSTITUTIONAL REVIEW BOARD</b>
			<b>HUC - HUMAN USE COMMITTEE</b> <b>AUC - ANIMAL USE COMMITTEE</b>
19. ABSTRACT (Continue on reverse if necessary and identify by block number)			
<p>This annual report identifies approved clinical research activities conducted at WRAMC (during FY89) which were approved and reviewed annually by the Human Use Committee/ Institutional Review Board or the Animal Use Committee as appropriate. A Detail Summary for each protocol, a list of publications and presentations are enclosed.</p>			
20. DISTRIBUTION/AVAILABILITY OF ABSTRACT  <input type="checkbox"/> UNCLASSIFIED/UNLIMITED <input checked="" type="checkbox"/> SAME AS RPT <input type="checkbox"/> DTIC USERS		21. ABSTRACT SECURITY CLASSIFICATION  <b>UNCLASSIFIED</b>	
22a. NAME OF RESPONSIBLE INDIVIDUAL  <b>JANE K. SWEENEY, PhD, PT, LTC(P), SP</b>		22b. TELEPHONE (Include Area Code)  <b>(202) 576-1390</b>	22c. OFFICE SYMBOL  <b>HSHL-CI</b>

**FORWARD**

This Annual Progress Report (APR) documents the continuing review during FY-89 of research approved by the Clinical Investigation Committee (CIC), the Animal Use Committee (AUC), and the Human Use Committee/Institutional Review Board (HUC/IRB) of Walter Reed Army Medical Center (WRAMC). The review of each research protocol is initiated by the Department of Clinical Investigation (DCI) on the anniversary month of its approval. At that time, a request is sent to the principal investigator for submission of a progress report. This report consists of a detail summary sheet (DSS), an updated consent form, if needed, and a completed questionnaire regarding the continuing review of human subject participation or animal use. Members of the HUC/IRB or AUC review the progress reports throughout the year, and one of the following recommendations is made: (1) approval, (2) request additional information, or (3) request termination of the protocol. The members' recommendations are presented monthly to the HUC/IRB or AUC for final approval.

The FY-89 APR process at WRAMC was administered by the Chief, Army Medical Specialist Corps Clinical Investigation and Research Service, Department of Clinical Investigation, in coordination with the Research Review Service. Due to the ongoing nature of the APR process, an overlap of fiscal years is inevitable in presenting the data. A total of 474 protocols are included in this document.

TABLE OF CONTENTS

	VOL	PAGE
I. Unit Summary		
A. Objective . . . . .	I	3
B. Technical Approach . . . . .	I	3
C. Organization Scheme . . . . .	I	4
D. DCI Staff . . . . .	I	5
E. DCI Financial Support . . . . .	I	9
F. Research Activity . . . . .	I	10
II. Protocol Expenses by Department . . . . .	I	25
III. Protocol List by Department . . . . .	I	30
IV. List of Publications, Presentations, and Abstracts by Department . . . . .	I	75
V. Author Index . . . . .	I	88
VI. Investigator Index . . . . .	I	92
VII. Subject Index . . . . .	I	100
VIII. Detail Summary Sheets . . . . .	II	1-236
IX. Detail Summary Sheets (continued) . . . . .	II	237-474

## I. UNIT SUMMARY

### A. OBJECTIVE

To implement and manage the clinical investigation program at Walter Reed Army Medical Center (WRAMC) by promoting, supporting, coordinating, planning, conducting and publishing ethical, scientific inquiry into clinical health problems of beneficiaries of the military health care system, to include studies in humans and animals.

### B. TECHNICAL APPROACH

The clinical investigation program at WRAMC is conducted in accordance with the following:

AR 40-7	Use of Investigational Drugs in Humans and the Use of Schedule I Controlled Drug Substances
AR 40-38	Clinical Investigation Program
AR 70-18	The Use of Animals in DOD Programs
TB MED 525	Control of Hazards to Health from Ionizing Radiation Used by the Army Medical Department
HSC 40-23	Management of Clinical Investigation Protocols and Reports
WRAMC 70-1	Clinical Investigation Program, WRAMC Research Activities
45 CFR 46	Protection of Human Subjects
21 CFR A,D,& F	Food and Drug Administration


STATEMENT "A" per Jan Kinsey  
Dept. of Clinical Investigation/HSHL-CI  
Walter Reed Army Medical Center  
Washington, DC 20307-5001  
TELECON                    5/16/90

VG



Accesion For	
NTIS CRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification _____	
By <u>per call</u>	
Distribution /	
Availability Codes	
Dist	Avail and/or Special
A-1	

C. ORGANIZATION SCHEME



D. DCI STAFF (positions as of 30 September 1989)

DESCRIPTION	GRADE	MOS	BRANCH NAME	ACTIVITY
<u>OFFICE OF THE CHIEF</u>				
Chief	06	61C	MC	Wray, HL
Secretary	07	0318	GS	Brock, ME
<u>RESEARCH REVIEW SERVICE</u>				
Chief	05	60F	MC	Derderian, S
Biostatistician	13	1530	GS	Vacant
Statistician	12	1530	GS	Howard, R
Computer Programmer	11		GS	vacant
Research Coordinator	09	1087	GS	Hawkins, EJ
Editorial Asst	05	1087	GS	Green, I
Computer Room Supv	E4	01H10	SP	Gomez, R
<u>RESEARCH ADMINISTRATIVE SERVICES</u>				
Chief	12	0501	GS	Burton, M
Tech Writer/Editor	09	1086	GS	vacant
Supply Technician	06	2005	GS	Thomas, D
Clerk Typist	05	0303	GS	Smith, A
Med Records Tech	05	0675	GS	Morgan, D
Nurse Specialist	12		GS	Abt, MB
<u>Grant Personnel</u>				
Nurse Specialist	12	0610	GS	Myers, D
Clinical Nurse	11	0610	GS	Bailey, C
Secretary	05		GS	Hopkins, S

DESCRIPTION	GRADE	MOS	BRANCH NAME	ACTIVITY
Operations Asst	06		GS Glover, C	OB-GYN
Bio Lab Tech	06		GS Dawson, E	Thoracic Surgery
Clerk Med Typ	05	0318	GS Sandfer, P	Pediatrics
Gen Health Sci	12	0601	GS Summers, W	AA&SC
Clinical Nurse	11	0610	GS vacant	Surgical Research

ARMY MEDICAL SPECIALIST CORPS CLINICAL INVESTIGATION AND RESEARCH SERVICE

Chief	05	65B9A	SP	Sweeney, JK	DCI
Secretary	06	0318	GS	Countee, K	DCI

RESEARCH OPERATIONS SERVICE

Chief	05	68F	MS	Lippert, L	DCI
Med Lab NCO	E7	92B40	NC	Sheldon, G	DCI
Bio Lab Tech	11	0404	GS	Kapur, J	DCI

General Support Lab

Chief	03	68C00	MS	Schaudies, RP	DCI
Chemist	11	1320	GS	Abdel Rahim, M	Biochemistry, DCI
Bio Lab NCO	E6	92B30	NC	Walker, M	DCI
Bio Sci Asst	E4	01H10	AMEDD	Caliboso, W	Surg Research, DCI
Med Lab Spec	E4	92B20	NC	Curry, BJ	Cell Biology, DCI

Animal Support Lab Research

Bio Lab Tech	10	0404	GS	Bailey, L	Animal Research, DCI
--------------	----	------	----	-----------	----------------------

DESCRIPTION	GRADE	MOS	BRANCH NAME	ACTIVITY
<u>INFECTIOUS DISEASE RESEARCH LABORATORY</u>				
Microbiologist	12	0403	GS	Dobek, A
Microbiologist	12	0403	GS	Soprey, R
<u>TRANSPLANT IMMUNOLOGY LABORATORY</u>				
Chief	04	60M9B	MC	vacant
Med Lab NCO	E6	92B30	NC	Toro, L
<u>KYLE METABOLIC RESEARCH LABORATORY</u>				
C, Nutrition Care	03	65C00	SP	Coffey, L
Supv Res Chem	14	1320	GS	Carr, F
Physiologist	12	0413	GS	Lukes, Y
Chemist	12	1320	GS	Nicholson, D
Chemist	11	1320	GS	Lahiri, S
Bio Lab Tech	09	0404	GS	Butler, V
Med Tech	11	0644	GS	Barnes, S
Med Tech	05	0645	GS	Martin, J
Editorial Asst	C7	1087	GS	Coleman, E
Secretary	05	0318	GS	Simms, S
Med Lab NCO	E6	92B30	NC	Ansley, R
Chemist	12	1320	GS	Tseng, Y
Resch Asst	11	0610	GS	Solomon, B

DESCRIPTION	GRADE	MOS	BRANCH NAME	ACTIVITY	
Med Tech	11	0644	GS	Anderson, J	DCI
Med Lab Spec	E4	92B10	NC	Kaseem, L	DCI

LAB SUPPORT UNIT

Research Chemist	12	0644	GS	Salata, K	Allergy/Immun
Chemist	11	1320	GS	Maydonovich, C	GI
Med Tech	11	0644	GS	Armstrong, J	Rheumatology
Med Tech	11	0644	GS	Burgess, D	Pediatrics
Bio Sci NCC	E5	1H20	NC	Andrada, F	Pulmonary
Med Lab Spec	E5	1H20	NC	Cortez, F	Pulmonary
Med Tech	11	0644	GS	Berger, T	Allergy/Immun

KYLE METABOLIC UNIT NURSING SERVICE

Supv Clin Nurse	11	00610	GS	Horton, E	KMU,DCI
Clinical Nurse	11	00610	GS	Bethae, J	KMU,DCI
Clinical Nurse	11	00610	GS	Crull, M	KMU,DCI
Clinical Nurse	10	00610	GS	Flowers, A	KMU,DCI
Clinical Nurse	11	00610	GS	Parchment, V	KMU,DCI
Clinical Nurse	11	00610	GS	Mathis, P	KMU,DCI
Nurse Asst	05	00620	GS	Keeve, M	KMU,DCI
Clinical Nurse	11	00610	GS	Stockton, J	KMU,DCI
Clinical Nurse	10	00610	GS	Brodie-Coley, Y	KMU,DCI
Clinical Nurse	9/11	00610	GS	vacant	KMU,DCI
Clinical Nurse	9/11	00610	GS	vacant	KMU,DCI
Clinical Nurse	9/11	00610	GS	vacant	KMU,DCI

E. DCI FINANCIAL SUPPORT

	<u>FY-86</u>	<u>FY-87</u>	<u>FY-88</u>	<u>FY-89</u>
CIVILIAN PERSONNEL	\$ 935,096	\$ 947,549	\$1,000,206	\$1,000,402
CONSUMABLE SUPPLIES	528,300	652,020	708,411	707,272
CIVILIAN CONTRACTS	123,779	121,579	115,000	88,898
TDY	34,645	23,182	28,401	35,186
CAPITAL EXPENSE EQUIP. PRG	52,633	38,734	32,000	57,860
MEDCASE	429,970	945,657	694,078	557,178
OTHER				
Grants	617,355	532,560	254,102	298,467
MILITARY	335,592	831,253*	432,504	429,718
TOTAL	\$3,057,307	\$4,092,534	\$3,264,702	\$3,174,981

\* Includes Benefits

F. RESEARCH ACTIVITY

1. Accomplished in FY-89

With a mission to empower WRAMC researchers from planning to publication, the Department of Clinical Investigation (DCI) supported a record total of 671 active studies this year (Table I). A record 197 of these studies were newly approved. The 474 other studies were ongoing for at least one year and are summarized in this report. Ninety-six percent (96%) of the investigations were conducted by Medical Corps officers at WRAMC, and about 1% were conducted at Army Community Hospitals in the Walter Reed Health Service Region (Table II). Human studies accounted for 93% of the investigations, with 36% involving research therapies including investigational drugs or devices and cooperative oncology group studies (Table III). Animal studies accounted for 5%, and laboratory studies accounted for 2%. Clinical investigation productivity by WRAMC researchers included 73 published abstracts, 22 published articles, and 61 conference presentations (Table IV). Thirty-three (33) Clinical Investigation Recognition Seminars (now in its third year) were presented by WRAMC researchers and provided local dissemination of WRAMC research presented at regional and national conferences.

The DCI was involved in many transitions during this year, both in personnel and in its initiatives to improve by striving to help all researchers from planning to publication (DCI is SHARPP). The Chief, Transplant Immunology Laboratory, the Senior Statistician, and the Supervisor, Laboratory Animal Facility left the department, and only one of these vacancies was filled in FY-89. The Surgical Research Service was established within the Department of Surgery with COL Samuel A. Cucinell as Chief.

TABLE I. WRAMC Protocol Activity

<u>PROTOCOLS</u>	<u>FY-85</u>	<u>FY-86</u>	<u>FY-87</u>	<u>FY-88</u>	<u>FY-89</u>
ONGOING at the beginning of FY	395	383	408	456	474
NEWLY APPROVED (+)	142	159	170	145	197
TOTAL ACTIVE During FY	537	542	578	601	671
COMPLETED (-)	127	123	78	114	118
TERMINATED (-)	27	11	44	13	32
ONGOING at the end of FY	383	408	456	474	521

TABLE II. WRAMC FY-89 Active Investigations by AMEDD Officer Corps

<u>CORPS</u>	<u>GRAD TX PROG</u>	<u>OFFICERS IN TX</u>	<u>ACTIVE STUDIES</u>
	# (%)	# (%)	# (%)
Medical	51 (81)	408 (90)	635 (96)
Nursing	0 (0)	0 (0)	9 (1)
Medical Service	7 (11)	24 (5)	12 (2)
Specialist	2 (3)	13 (3)	3 (<1)
Dental	3 (5)	6 (2)	1 (<1)
Veterinary	0 (0)	0 (0)	2 (<1)
	<hr/> 63 (100)	<hr/> 451 (100)	<hr/> 662 (100)

Army Community Hospitals

9

TABLE III. WRAMC FY-89 Active Investigations by Subject

<u>SUBJECT</u>	<u>ACTIVE STUDIES</u>
	# (%)
Human	622 (93)
Invest New Drug	42 (6)
Invest Device	8 (1)
Cooperative Oncology Group	194 (29)
Descriptive - Expedited	127 (19)
Greater Risk	251 (38)
Animal	37 (5)
Laboratory	12 (2)
	<hr/> 671(100)

TABLE IV. WRAMC Clinical Investigation Publications and Presentations

	<u>FY-85</u>	<u>FY-86</u>	<u>FY-87</u>	<u>FY-88</u>	<u>FY-89*</u>
Published Articles	72	79	55	104	22
Abstracts	74	119	86	106	73
Presentations	64	75	55	93	61

\* The decrease in fiscal year figures is a result of a restructured method of data collection which narrowed the accounting criteria but still allowed for overlap in fiscal years resultant from the ongoing APR process.


## DCI Quality Improvement Questionnaire

The DCI Quality Improvement Questionnaire was completed by 252 of 474 investigators submitting annual progress reports from FY89 (compared to 310 of 456 investigators for FY88). The following eleven questions were presented:

1. DCI is doing all they can to support my research efforts.
2. DCI is providing adequate clerical support.
3. DCI is providing adequate statistical consultation.
4. DCI is making available adequate computer support.
5. DCI is providing adequate technical support.
6. DCI is providing adequate equipment and other logistical support.
7. DCI is providing adequate research space.
8. DCI is providing adequate financial support.
9. DCI conducts an adequate preliminary review of research applications.
10. DCI conducts an adequate annual review of research protocols.
11. Overall, DCI lives up to its slogan of being SHARPP  
(Striving to Help All Researchers from Planning to Publication).

The answers range from 'Strongly AGREE' (score = 5) to 'Strongly DISAGREE' (score = 1), with the option of 'Not Applicable':

### Evaluation of Performance, FY88 - FY89 By Type of Service



\* Scale from 1 to 5  
Score of '5' represents strong  
agreement with level of service


Ten of the eleven service areas had average scores greater than 4.00 in FY89. The overall average score for FY89 was 4.18, an increase from the 4.13 score for FY88 (not statistically significant,  $P = .14$ , by two sample  $t$ -test). The three greatest changes were all improvements: clerical support (2), DCI 'doing all they can' (1) and statistical consultation (3).

Summarizing a score of 4 or 5 as a 'Positive' response, and a score of 1 or 2 as a 'Negative' response, the 11:1 ratio of positive to negative replies in FY88 increased to a 14:1 ratio in FY89. Nine of the eleven areas queried showed an improvement in FY89.

In addition to the overall increase in positive responses and decline in negative responses between FY88 and FY89, there was a decline in the number of 'Not Sure' and 'Not Applicable' replies.

### Overall Summary of Responses

FY88 - FY89



This survey of the effectiveness of services offered by the Department of Clinical Investigation directs our planning for FY90.

The Bailey K. Ashford Clinical Research Award finalists who presented their research at the third annual symposium were CPT Joseph J. Drabick, Fellow in Infectious Disease; CPT Patrick A. Cambier, Resident in Medicine; MAJ Dane K. Wukich, Resident in Orthopaedic Surgery; MAJ Garrison V. Morin, Resident in Otolaryngology/Head and Neck Surgery; and MAJ Raymond W. Phillips, Fellow in Gastroenterology. The recipient of the Bailey K. Ashford Clinical Research Medal awarded at the WRAMC Graduation Exercises was MAJ Garrison V. Morin for his research entitled "Wound Healing: Relationship of Wound Closing Tension to Tensile Strength and Scar Width."

The Research Review Service reviewed a record number of new protocols for approval. They implemented a quality improvement audit program which involved the initial auditing of twelve investigator study files for compliance with DA regulations and WRAMC Human Use Committee/Institutional Review Board guidelines. Results and recommendations of the audits were presented to the Human Use Committee. The Research Review Service, along with the Research Administrative Services, was successful in contracting to purchase a local area network linking all major clinical investigation activities to a minicomputer system with state-of-the-art graphics and enhanced statistical computing power.

The Research Administrative Services processed nearly 2900 purchase orders including over 11,000 line items for WRAMC investigators despite intense personnel turbulence during FY-89. New persons were recruited for two of the three clerical staff positions. The MEDCASE program grew to \$557,178 by the end of the fiscal year. A video imaging system was obtained for the Army Audiology

and Speech Center through the QRIP program. The Sleep Disorders Laboratory was relocated to the Pulmonary Disease Clinic.

The Research Operations Service initiated and completed a number of procedural upgrades to streamline and enhance the effectiveness of laboratory research support. Among those initiatives were to completely overhaul and expand the Laboratory Safety Manual, revise the Laboratory Animal Facility Standard Operating Procedures, develop mission statements for the General Support Laboratory and the Research Operations Service, and thoroughly document procedures for property accountability and equipment maintenance. The plans for accreditation of the animal facility were enhanced by identification of a consultant, LTC Bradford Goodwin, and by incorporating his recommendations into the animal facility design plan. LTC Lloyd E. Lippert, Chief, Research Operations, was selected as the Secretary of the Society of Armed Forces Medical Laboratory Scientists.

The Army Medical Specialist Corps (AMSC) Clinical Investigation and Research Service designed and directed the annual Mary Lipscomb Hamrick AMSC Research Course at the Xerox International Center for Training and Development in Leesburg, Virginia, from 31 July through 4 August. The course was attended by 48 officers, including 15 faculty. Fifteen of 44 submitted abstracts of AMSC research were selected for presentation. The instructional focus for the course included research methods, statistics, scientific writing, and research protocol review for clinical studies in Army hospitals.

The Kyle Metabolic Unit (KMU) Nursing Service reopened in June as a DCI service, reversing the persistent trend of diminishing patient bed capacity at WRAMC. Under the creative leadership of Ms. Ellen G. Horton, Head Nurse of the KMU Nursing Service, the patient census progressively increased despite problems with nurse staffing problems.

Two recently hired researchers in the Army Audiology and Speech Center were successful in obtaining substantial extramural research funding. Dr. Marjorie Leek, Hearing Scientist and Senior Researcher, obtained a 5 year, \$225,000 NIH grant, and Dr. David Fabry, Research Audiologist, was awarded a \$15,000 Nontenured Faculty Research Award by the 3M Corporation.

In recognition of the relevance and leadership role of the Kyle Metabolic Unit and of COL Leonard Wartofsky in basic research and clinical investigations related to the thyroid, the Office of the American Thyroid Association was moved to WRAMC with COL Wartofsky as its Secretary. The Kyle Metabolic Unit Laboratory began hosting Visiting Foreign Fellows with Dr. Wenyi Cai, M.D., Ph.D., from the Republic of China beginning a one year study period under the auspices of the Uniformed Services University of the Health Sciences. Individuals from Ethiopia and Hungary are to follow in this program.

Members of the Nursing Research Service of the Department of Nursing were deeply involved in three initiatives addressing nursing recruitment and retention. The first was development of an Army Nurse Corps survey, funded by the Office of the Surgeon General and supported by the Soldier Support Center, to determine satisfiers and dissatisfiers which may impact on active duty retention.

Second, a very similar survey of all registered nurses at WRAMC was conducted to ascertain how satisfied or dissatisfied they were with working conditions and to solicit recommended solutions. Third, LTC Jane Hudak served on the Health Professionals Special Pay Study task force and assisted in writing the "Report to Congress on Armed Forces Health Professions Special Pay--Military Nurse Corps."

The WRAMC Clinical Investigation Program encompassed all clinical departments and separate services, as well as the administrative directorates. The program supported 64 postgraduate training programs with research conducted by house staff and students, as well as assigned and affiliated staff. The medical training programs had substantial involvement in research, with 36 of the 51 programs having a total of 618 approved protocols. Fifty-nine of 408 Medical Corps interns, residents and fellows were principal investigators, with a total of 70 approved protocols. One hundred sixty-three of the assigned or affiliated Medical Corps staff were principal investigators, with a total 486 approved protocols. Assigned Medical Corps staff numbered 236. The 13 non-medical training programs with 53 trainees, including 10 Chaplain Corps trainees, were also involved in research with 6 programs having 12 approved protocols. WRAMC had a total of 265 principal investigators.

Many individuals associated with the WRAMC Clinical Investigation Program were recognized by outside organizations for their research accomplishments. The awards are listed below:

1. CPT Patrick A. Cambier, MC, Internal Medicine Resident - Best Associate's Paper at the Army Regional Meeting of the American College of Physicians in October 1988 for his study, "Objective Benefit of Diltiazem in the Treatment of Raynaud's Phenomenon: A Controlled Double Crossover Study."

2. CPT Svetislava J. Vukelja, MC, Hematology/Oncology Fellow - Best Fellow's Research Award in Hematology/Oncology at the Army Regional Meeting of the American College of Physicians in October 1988 for her study, "Mean Platelet Volume in the Evaluation of Thrombocytopenia."
3. CPT M. Frank Lyons, MC, Fellow in Gastroenterology - William Beaumont Research Award at the Army Regional Meeting of the American College of Physicians in October 1988 for his study, "Fleet<sup>R</sup> Hypertonic Phosphate Enemas Cause Hyperphosphatemia and Acidemia in Patients with Ulcerative Colitis After Routine Colonic Cleansing."
4. LCDR Michael S. Opsahl, MC, Reproductive Endocrinology Fellow - The Chairman's Award for the best paper on Endocrinology and Infertility from a teaching hospital at the 27th Annual Meeting of the Armed Forces District, American College of Obstetricians & Gynecologists in November 1988 for his study, "Lymphocyte Subsets in Fertile and Infertile Women."
5. MAJ Paul G. Perlik, MC, Chief, Hand Surgery, Founders' Award at the 30th Annual Meeting of the Society of Military Orthopaedic Surgeons in December 1988 for his paper, "The Use of Magnetic Resonance Imaging to Assess Vascularity of Scaphoid Nonunions."
6. LTC Thomas E. Wiswell, MC, Neonatal Service, Department of Pediatrics - Election to membership in the Society of Pediatric Research in December 1988.
7. MAJ Garrison V. Morin, MC, Resident, Otolaryngology/Head and Neck Surgery Service, Department of Surgery - the Military Regional Award for the Committee on Trauma presented by the American College of Surgeons in February 1989 for his paper, "Wound Healing: Relationship of Tensile Strength to Closing Tension in Rats."
8. LTC(P) Jane K. Sweeney, SP, Chief, Army Medical Specialist Corps Clinical Investigation and Research Service - the 1989 Dissertation Award by the section on Pediatrics, American Physical Therapy Association in February 1989 for her doctoral dissertation, "Physiological and Behavioral Effects of Neurological Assessment in Preterm and Full-Term Neonates."
9. CPT R. Paul Schaudies, MS, Chief, General Support Laboratory, Department of Clinical Investigation - Outstanding Young Research Scientist Award at the meeting of the Society of Armed Forces Medical Laboratory Scientists in March 1989 for his research accomplishments.
10. LTC Thomas E. Wiswell, MC, Neonatal Service, Department of Pediatrics - the Ogden Bruton Award for Research at the 25th Annual Uniformed Services Pediatric Seminar in March 1989 for his work, "The Effect of Different High Frequency Ventilator Strategies on the Propagation of Tracheobronchial Histopathologic Changes."
11. COL Joan T. Zajtchuk, MC, Chief, Otolaryngology/Head and Neck Surgery Service, Department of Surgery - Honorable Mention in the Candidate's Thesis Competition held by the American Laryngological, Rhinological and Otological Society, Inc. in April 1989 for her thesis, "Mucosal Leishmaniasis in Brazil."

12. CPT Patrick A. Cambier, MC, Internal Medicine Resident - National Finalist for Associate's Award at the meeting of the American College of Physicians in April 1989 for his paper, "Objective Benefit of Diltiazem in the Treatment of Raynaud's Phenomenon: A Controlled Double Crossover Study."
13. MAJ Raymond W. Phillips, MC, Fellow in Gastroenterology, Department of Medicine - the Glaxo Research Award presented at the 90th Annual Research Meeting of the American Gastroenterology Association in May 1989 for his work, "Beta-Carotene Normalizes Rectal Mucosal Ornithine Decarboxylase Activity in Patients with Colon Carcinoma."
14. LTC William Hopkinson, MC, Orthopaedics Service, Department of Surgery - the O'Donoghue Award in Sports Medicine at the meeting of the American Orthopaedic Society in June 1989 for his paper, "The Efficacy of a Prophylactic Knee Brace to Reduce Knee Injuries in Football: A Prospective, Randomized Study at West Point."
15. MAJ Melissa W. Sinnott, SP, Director, Education and Research, Occupational Therapy Section, Physical Medicine and Rehabilitation Service - Abstract of the Year Award for Occupational Therapy Research at the Mary Lipscomb Hamrick AMSC Research Course in August 1989 for her abstract, "Clinical Specialization in Occupational Therapy: A Pluralistic View of Practice."
16. MAJ Garrison V. Morin, MC, Resident, Otolaryngology/Head and Neck Surgery Service, Department of Surgery - 1st Place Research Paper Award presented by the Society of Military Otolaryngologists in September 1989 for his paper, "Wound Healing: Relationship of Tensile Strength to Closing Tension in Rats."

## 2. Planned for FY-90

The start-up of the DCI Editorial Office with one staff position will allow the department to begin to address the most critical and chronic need identified by ongoing survey of WRAMC researchers. The installation and subsequent development of applications of the recently purchased computer network will greatly enhance the department's ability to provide statistical and data analysis support, as well as graphics and administrative support. CPT R. Paul Schaudies, Chief, General Support Laboratory, is leaving the department to attend the AMEDD Officers Advanced Course. He has been a tremendous asset to the department during his four and one half year assignment. The establishment of a WRAMC Clinical Investigation Special Fund in the Henry M. Jackson Foundation will

provide a much needed new avenue to fund expansion of the clinical investigation program.

The planned relocation of the Kyle Metabolic Unit will relieve some of the space problems of the WRAMC intensive care and operating areas on the fourth floor of Building 2. Definitive plans to renovate Building 7 to accommodate an AAALAC-approved Laboratory Animal Facility as well as a major portion of DCI should be completed to include transition space for the DCI activities currently housed in Building 7.

### 3. Ongoing and Future Issues

The time required to obtain approval of research studies continues to be an important area of concern at WRAMC. DCI will continue to monitor the time required for each component of the review and approval process and will implement changes to reach the present goal of a mean approval time for all WRAMC studies of less than 50 days. Ongoing efforts to obtain extramural funding through the Medical Research and Development Command and the Jackson Foundation are the best prospects to increase research funding at WRAMC. Clinical investigation education will receive more emphasis, working to develop better programs in all areas from animal research, study design, and statistics, to ethics and conflict of interest.

TABLE V: Human Use Committee/Institutional Review Board Members

Thomas A. Klein, COL, MC	Chairman, HUC/IRB Chief, Department of Obstetrics and Gynecology, Rep, Deputy Commander
H. Linton Wray, COL, MC	Co-Chairman, HUC/IRB Chief, DCI
Robert Smallridge, COL, MC*	Rep, Director, WRAIR
Wayne Johnston, COL, JA	Center Judge Advocate
Sarkis Derderian, LTC, MC	Assistant Chief, DCI
Valerie Biskey, LTC, AN	Rep, Chief, Department of Nursing
Richard Patterson, LTC, SP	Chief, Education and Research, Nutrition Care Directorate
Frank Lombardo, MAJ, SP	Rep, Chief, Pharmacy Service
Robert Hill, MAJ, CH	Rep, Chief, Department of Ministry and Pastoral Care
Eric Marks, M.D.*	Rep, Department of Medicine, Uniformed Services University of the Health Sciences
Laurel Meaney, DAC	Patients' Rights Representative

\*Non-affiliated member

TABLE VI: Clinical Investigation Committee Members

H. Linton Wray, COL, MC	Chairman Chief, DCI
Samuel Cucinell, COL, MC	Rep, Chief, Department of Surgery
Charles Yeager, COL, MC	Rep, Radiation Control Committee, Radiation Therapy
Wayne Johnston, COL, JA	Center Judge Advocate
Jane Sweeney, LTC(P), SP	C, AMSC Clinical Investigation and Research, DCI
Sarkis Derderian, LTC, MC	Co-Chairman Assistant Chief, DCI
Patricia Rikli, LTC, AN	Rep, Chief, Nursing Research Svc
Jack Moore, LTC, MC	Rep, Chief, Dept of Medicine
Robin Howard, DAC	Biostatistician, DCI

TABLE VII: Rotating Senior Investigators, CIC

INVESTIGATOR

Thomas Wiswell, LTC, MC	Dept of Pediatrics
Harlan Bridenbaugh, COL, MC	Dept of Psychiatry
Bahmann Jabbari, COL, MC	Neurology Service
Brian Walden, Ph.D., DAC	Audiology & Speech Center
Edward Squire, LTC, MC	Allergy-Immunology Service
Steven Shay, COL, MC	Gastroenterology Service

**TABLE VIII: Animal Use Committee/Clinical Investigation Committee Members**

Charles Raflo, COL, VC	Attending Veterinarian Director, Div Vet Med, WRAIR
Hernando Mena, LTC, MC	Asst. Chairman, Dept Neuropath (AFIP)
Lloyd Lippert, LTC, MS	C, Research Operations Svc, DCI

**TABLE IX: HIV Research/Clinical Investigation Committee Members**

Edmond, Tramont, COL, MC	Director, HIV Research Program
--------------------------	--------------------------------

EXPENSES FOR PROTOCOLS OF CURRENT AND PREVIOUS FISCAL YEARS,  
BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

<u>DEPARTMENT/ SERVICE</u>	<u>PROTOCOL NUMBER*</u>	<u>PRIOR FY's (\$)</u>	<u>CURRENT FY (\$)</u>	<u>TOTAL (\$)</u>
HIV RESEARCH	9269	7,001	384	7,385
	TOTAL	7,001	384	7,385
ALLERGY/IMMUNOLOGY SERVICE	3214	16,761	8,538	25,299
	3221	13,332	8,195	21,527
	3225	0	1,430	1,430
	3340	0	5,606	5,606
	TOTAL	30,093	23,769	53,862
DEPARTMENT OF CLINICAL INVESTIGATION	9027	22,744	10,502	33,246
	9261	76,008	23,904	99,912
	9262	98,554	8,926	107,480
	9263	0	864	864
	9267	0	577	577
	9271	8,008	542	8,550
	9272	0	29,024	29,024
	TOTAL	205,314	74,339	279,653
DEPARTMENT OF MEDICINE				
Endocrine-Metabolic Service	1300-88	0	2,400	2,400
	1301-88	0	3,653	3,653
	1302-88	0	14,231	14,231
	1305-88	0	10,400	10,400
	1307-88	0	596	596
	1323-80	83,629	22,576	106,205
	1330-81	0	15,400	15,400
	1338-82	4	5,998	6,002
	1339-82	3,024	9,800	12,824
	1349-84	837	17,634	18,471
	1351-84	538	0	538
	1353-84	6,800	0	6,800
	1354-84	7,924	9,868	17,792
	1356-84	3,854	498	4,352
	1359-85	40,273	4,163	44,436
	1361-85	79,217	0	79,217
	1363-85	6,559	6,841	13,400
	1367-86	167	7,014	7,181
	1369-86	1,634	2,719	4,353
	1371-86	555	6,958	7,513
	1372-86	38,173	2,561	40,734
	1373-86	5,432	1,662	7,094
	1376-86	17,766	157	17,923
	1377-86	0	1,081	1,081
	1382-86	0	50	50

\* Protocol is not listed if total expense is zero.

EXPENSES FOR PROTOCOLS OF CURRENT AND PREVIOUS FISCAL YEARS,  
BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

<u>DEPARTMENT/ SERVICE</u>	<u>PROTOCOL NUMBER*</u>	<u>PRIOR FY's (\$)</u>	<u>CURRENT FY (\$)</u>	<u>TOTAL (\$)</u>
<b>DEPARTMENT OF MEDICINE</b>				
Endocrine-Metabolic Service (continued)				
1383-86	1,056	260	1,316	
1384-86	0	4,234	4,234	
1385-87	36,195	20,213	56,408	
1386-87	0	3,979	3,979	
1387-87	13,021	11,833	24,854	
1390-87	0	2,650	2,650	
1392-87	0	371	371	
1393-87	77,234	26,610	103,844	
1394-87	11,696	9,174	20,870	
1395-87	13,877	44,478	58,355	
1398-87	0	101	101	
1399-87	0	24,061	24,061	
TOTAL	449,465	294,224	743,689	
<b>DEPARTMENT OF MEDICINE</b>				
Gastroenterology Service				
1400-88	0	2,658	2,658	
1401	0	226	226	
1432	185	1,678	1,863	
1435	75	239	314	
1448	6,055	153	6,208	
1450	12,016	734	12,750	
1453	0	49	49	
1462	1,121	1,800	2,921	
1466	95	218	313	
1470	944	623	1,567	
1471	1,028	521	1,549	
1483	1,653	676	2,329	
1487	1,143	15	1,158	
1488	650	118	768	
1489	118	312	430	
1490	1,623	95	1,718	
1491	0	42	42	
1492	0	1,040	1,040	
1494	0	355	355	
1495	0	2,038	2,038	
1496	0	503	503	
1497	0	1,250	1,250	
1499	0	1,768	1,768	
TOTAL	26,706	17,111	43,817	
<b>DEPARTMENT OF MEDICINE</b>				
Hematology-Oncology Service				
1602-81	5,626	549	6,175	
1616-82	1,716	428	2,144	

\* Protocol is not listed if total expense is zero.

EXPENSES FOR PROTOCOLS OF CURRENT AND PREVIOUS FISCAL YEARS,  
BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

<u>DEPARTMENT/ SERVICE</u>	<u>PROTOCOL NUMBER*</u>	<u>PRIOR FY's (\$)</u>	<u>CURRENT FY (\$)</u>	<u>TOTAL (\$)</u>
<b>DEPARTMENT OF MEDICINE</b>				
<b>Hematology-Oncology Service (continued)</b>				
	1647-87	0	250	250
	1649-87	0	2,992	2,992
	1657-88	0	<u>13,650</u>	<u>13,650</u>
	<b>TOTAL</b>	<u>7,342</u>	<u>17,869</u>	<u>25,211</u>
<b>DEPARTMENT OF MEDICINE</b>				
<b>Infectious Disease Service</b>				
	1933	12,347	489	12,836
	1940	0	8,473	8,473
	1956	5,556	1,680	7,236
	9103	853	<u>1,359</u>	<u>2,212</u>
	<b>TOTAL</b>	<u>18,756</u>	<u>12,001</u>	<u>30,757</u>
<b>DEPARTMENT OF MEDICINE</b>				
<b>Nephrology Service</b>				
	1152	0	1,332	1,332
	1154	0	206	206
	1156	0	<u>1,131</u>	<u>1,131</u>
	<b>TOTAL</b>	<u>0</u>	<u>2,669</u>	<u>2,669</u>
<b>DEPARTMENT OF MEDICINE</b>				
<b>Pulmonary Disease Service</b>				
	1702	1,466	200	1,666
	1707	0	1,309	1,309
	1710	0	398	398
	1714	120	50	170
	1716	2,848	2,985	5,833
	1717	0	215	215
	1720	1,649	11,818	13,467
	1722	0	100,000	100,000
	1724	0	170	170
	1727	0	195	195
	1728	0	388	388
	1730	0	721	721
	1732	0	<u>924</u>	<u>924</u>
	<b>TOTAL</b>	<u>6,083</u>	<u>119,373</u>	<u>125,456</u>
<b>DEPARTMENT OF MEDICINE</b>				
<b>Rheumatology Service</b>				
	3220R	6,584	5,439	12,023
	3700	0	7,813	7,813
	3701	<u>7,442</u>	<u>6,732</u>	<u>14,174</u>
	<b>TOTAL</b>	<u>14,026</u>	<u>19,984</u>	<u>34,010</u>
<b>NEUROLOGY SERVICE</b>				
	9200	0	<u>6,875</u>	<u>6,875</u>
	<b>TOTAL</b>	<u>0</u>	<u>6,875</u>	<u>6,875</u>

\* Protocol is not listed if total expense is zero.

EXPENSES FOR PROTOCOLS OF CURRENT AND PREVIOUS FISCAL YEARS,  
BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

DEPARTMENT/ SERVICE	PROTOCOL NUMBER*	PRIOR FY's (\$)	CURRENT FY (\$)	TOTAL (\$)
<b>DEPARTMENT OF NURSING</b>				
	7507	0	814	814
	<b>TOTAL</b>	<b>0</b>	<b>814</b>	<b>814</b>
<b>DEPARTMENT OF OBSTETRICS AND GYNECOLOGY</b>				
	4228	0	4,760	4,760
	4242	511	2,330	2,841
	4243	0	50	50
	4259	0	500	500
	<b>TOTAL</b>	<b>511</b>	<b>7,640</b>	<b>8,151</b>
<b>DEPARTMENT OF PATHOLOGY AND AREA LABORATORIES</b>				
	4802	0	1,720	1,720
	<b>TOTAL</b>	<b>0</b>	<b>1,720</b>	<b>1,720</b>
<b>DEPARTMENT OF PEDIATRICS</b>				
	6042	22,305	4,278	26,583
	6043	2,649	3,846	6,495
	6045	0	2,237	2,237
	6050	15,400	6,251	21,651
	6055	3,453	2,719	6,172
	6056	0	5,600	5,600
	6057	5,829	1,509	7,338
	6058	0	588	588
	6059	0	3,031	3,031
	6061	0	350	350
	6215	0	2,248	2,248
	<b>TOTAL</b>	<b>49,636</b>	<b>32,657</b>	<b>82,293</b>
<b>DEPARTMENT OF PEDIATRICS</b>				
Pediatric Oncology Group				
	6213	0	2,116	2,116
	<b>TOTAL</b>	<b>0</b>	<b>2,116</b>	<b>2,116</b>
<b>DEPARTMENT OF PSYCHIATRY</b>				
	7236	0	2,500	2,500
	<b>TOTAL</b>	<b>0</b>	<b>2,500</b>	<b>2,500</b>
<b>DEPARTMENT OF SURGERY</b>				
General Surgery Service				
	2027	0	772	772
	<b>TOTAL</b>	<b>0</b>	<b>772</b>	<b>772</b>
<b>DEPARTMENT OF SURGERY</b>				
Organ Transplant Service				
	2610	0	376	376
	2629	35,330	300	35,630
	2630	212	150	362
	2631	995	1,200	2,195
	<b>TOTAL</b>	<b>36,537</b>	<b>2,026</b>	<b>38,563</b>

\* Protocol is not listed if total expense is zero.

EXPENSES FOR PROTOCOLS OF CURRENT AND PREVIOUS FISCAL YEARS,  
BY DEPARTMENT AND SERVICE, LISTED IN ALPHABETICAL ORDER

DEPARTMENT/ SERVICE	PROTOCOL NUMBER*	PRIOR FY's (\$)	CURRENT FY (\$)	TOTAL (\$)
<b>DEPARTMENT OF SURGERY</b>				
Orthopedics	Surgery Service			
	2410	0	7,995	7,995
	<b>TOTAL</b>	<b>0</b>	<b>7,995</b>	<b>7,995</b>
<b>DEPARTMENT OF SURGERY</b>				
Otolaryngology-Head & Neck Service				
	2569	0	400	400
	2570	0	195	195
	2571	360	600	960
	2573	0	162	162
	2574	0	750	750
	2577	2,564	2,930	5,494
	2583	0	769	769
	2587	0	4,154	4,154
	<b>TOTAL</b>	<b>2,924</b>	<b>9,960</b>	<b>12,884</b>

\* Protocol is not listed if total expense is zero.

**DEPARTMENT/SERVICE INDEX TO LIST OF PROTOCOLS**

	page
HIV RESEARCH .....	31
ALLERGY/IMMUNOLOGY SERVICE .....	32
CLINICAL INVESTIGATION, DEPARTMENT OF .....	33
 DEPARTMENT OF MEDICINE	
Cancer & Leukemia Group B .....	34
Cardiology Service .....	38
Dermatology Service .....	39
Endocrine-Metabolic Service .....	39
Gastroenterology Service .....	43
General Medicine Service .....	46
Hematology-Oncology Service .....	47
Infectious Disease Service .....	49
Nephrology Service .....	49
Pulmonary Disease Service .....	50
Rheumatology Service .....	52
 NEUROLOGY SERVICE .....	84
NURSING, DEPARTMENT OF .....	54
 OBSTETRICS AND GYNECOLOGY, DEPARTMENT OF .....	54
Gynecologic Oncology Group .....	55
 PATHOLOGY AND AREA LABORATORIES, DEPARTMENT OF .....	60
PEDIATRICS, DEPARTMENT OF .....	60
Pediatric Oncology Group .....	62
 PREVENTIVE MEDICINE .....	67
PSYCHIATRY, DEPARTMENT OF .....	67
RADIOLOGY, DEPARTMENT OF .....	67
SOCIAL WORK SERVICE .....	68
 DEPARTMENT OF SURGERY	
Anesthesia-Operative Service .....	68
Critical Care Medicine Service .....	68
General Surgery Service .....	69
Ophthalmology Service .....	69
Organ Transplant Service .....	69
Orthopaedics Surgery Service .....	70
Otolaryngology-Head & Neck Service .....	71
Peripheral Vascular Surgery Service .....	72
Plastic Surgery Service .....	72
Thoracic Surgery Service .....	72
Urology Service .....	73
 VETERINARY SERVICES .....	74
ARMED FORCES INSTITUTE OF PATHOLOGY .....	74
ARMY COMMUNITY HOSPITALS .....	74

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE* (VOL II)</u>
<b>HIV RESEARCH</b>		
1151	Link, Christine CPT MC. Evaluation of Renal Function, Protein Excretion and the Urinary Sediment in Patients with Antibody to the Human Immunodeficiency Virus (HIV) (3/87)	1
1948	Wright, Craig MAJ MC. A Double Blind Randomized Placebo-Controlled Trial of Fansidar Prophylaxis in Patients with HTLV-III Disease (WR Stage 5) (11/86)	2
1951	Rhoads, Joanne MAJ MC. Human Immune Response to HTLV-III Infection (12/86)	3
1952	Oster, Charles COL MC. The Clinical Presentation of HIV Infected Patients at Walter Reed Army Medical Center (1/87)	4
1953	Drabick, Joseph CPT MC. The Generation of Human Monoclonal Antibodies to the HIV (1/87)	5
1955	Hoover, David MAJ MC. T Helper Cell Depleted Mouse Model to Study Immunopathogenesis and Immunotherapy in AIDS (3/87)	6
1958	Hoover, David LTC MC. In Situ Hybridization for Detection of HIV in Langerhans Cells of HIV Infected Patients (7/87)	7
3342	Birx, Deborah MAJ MC. Delayed Type Hypersensitivity Skin Testing: Correlation of Intradermal Injection Vs. Epicutaneous Antigen Placement and CD4 Number in Normals and HIV Seropositive Subjects (8/88)	8
6218	Fischer, Gerald COL MC. Evaluation of Human Immunodeficiency Virus Related Proteins on the Surface of Lymphocytes from Children with Evidence of HIV Exposure or HIV Illnesses (5/88)	9
6220	Fischer, Gerald COL MC. Epidemiology of HIV In Pediatric and Perinatal Patients - A Natural History Study (7/88)	10
6222	Fischer, Gerald COL MC. Core Project: Evaluation of Diagnostic Assays for Human Immunodeficiency Virus (HIV) in Children with Evidence of HIV Exposure or HIV Illnesses (9/88)	11

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>HIV RESEARCH (continued)</b>		
7128	Salazar, Andres COL MC. Neurobehavioral Consequences of HTLV-III Brain Infection and AIDS Encephalopathy (12/86)	12
7139	Salazar, Andres COL MC. Intramuscular Poly-ICLC and Zidovudine in the Management of HIV Infection: An Open Pilot Trial (7/88)	13
8801	Rhoads, Joanne MAJ MC. Identification and Characterization of Human Immunodeficiency Virus in Human Semen (3/88)	14
8802	Oster, Charles COL MC. VA Cooperative Study No. 298, Treatment of AIDS and AIDS Related Complex; Part I: Treatment of Patients with ARC (AZT Vs. Placebo) (4/88)	15
8803	Burke, Donald COL MC. Core Protocol for HIV Developmental Diagnostics (Adults) (5/88)	16
8804	Oster, Charles COL MC. The Natural History of HIV Infection and Disease in United States Military Beneficiaries (5/88)	17
9269	Baker, James MAJ MC. Evaluation of human Immunodeficiency Virus (HIV)-Related Proteins on the Surface of Lymphocytes from Patients with Evidence of HIV Exposure or HIV Illnesses (6/87)	18
<b>ALLERGY/IMMUNOLOGY SERVICE</b>		
3214	Birx, Deborah MAJ MC. In Vitro Lymphocyte Suppression by Calcium Channel Blocking Drugs (4/84)	19
3221	Engler, Renata MAJ MC. The Role of IgG Subclasses in Hymenoptera Hypersensitivity and Immunotherapy (8/84)	20
3224	Smith, Laurie. Assessment of Target Organ Reactivity in Anaphylaxis (1/85)	21
3225	Baker, James MAJ MC. Development of Human Hybridoma IgE Antibodies for Use in Clinical Applications (11/85)	22
3229	Squire, Edward LTC MC. Delayed-type Hypersensitivity Skin Testing: Correlation with Skin Biopsy and In Vitro Lymphocyte Testing in Normal Volunteers. (8/86)	23

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

PROTOCOL NUMBER	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>ALLERGY/IMMUNOLOGY SERVICE (continued)</b>		
3330	Squire, Edward LTC MC. Skin Testing for Anergy and Quality of Candida Extracts (3/86)	24
3335	Squire, Edward LTC MC. Do Aeroallergens Exacerbate Atopic Dermatitis (9/87)	25
3336	Yang, Edward MAJ MC. The Effect of Human Breast Milk Cell Supernatants on In Vitro Immunoglobulin Secretion (11/87)	26
3337	Squire, Edward LTC MC. What is the Dose Response to Ipratropium Bromide (IB) Among Steroid Dependent Asthmatics? (2/88)	27
3338	Herrera, Alma MAJ MC. Comparison of Skin Test Reactivity to Dilutions of Histamine Using the Volar Surface of the Arm Vs. the Back (3/88)	28
3339	Squire, Edward LTC MC. Comparison of House Dust Mite Educational Programs on Selected Outcome Variables (7/88)	29
3340	Salata, Kalman PhD. Analysis of Carbohydrate Epitopes on Food Allergen Proteins: A Pilot Study (8/88)	30
3341	Squire, Edward LTC MC. Occurrence of Laryngeal Dysfunction Among Patients Initially Diagnosed as Having Bronchial Asthma (8/88)	31
<b>DEPARTMENT OF CLINICAL INVESTIGATION</b>		
9027	Dobek, Arthur PhD. Prevalence of Antibiotic Associated Colitis among Patients on Prolonged Antibiotic Therapy (3/81)	32
9255	Schuster, Brian LTC MC. Evaluation of DIGDOS, an HP-85 Program to Assist in Digoxin Dosing Decisions (10/83)	33
9261	Baker, James MAJ MC. Development of Human Hybridomas for Use in Histocompatibility Testing (8/85)	34
9262	Schaudies, Paul CPT MS. Internalization and Cellular Processing of 125-I-Epidermal Growth Factor (EGF) in Responsive and Unresponsive Cell Lines (10/85)	35

---

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
DEPARTMENT OF CLINICAL INVESTIGATION (continued)		
9263	Derderian, Sarkis LTC MC. Neurohumoral Regulation of Ventilation in Patients with Elevated Adrenocorticotrophic Hormone (ACTH) and Beta Endorphins (BE) (10/85)	36
9266	Baker, James MAJ MC. The Treatment of Graves' Disease with Anti-Idiotype Therapy Using Intravenous Immunoglobulin (5/86)	37
9267	Coffey, Laurie CPT. The Effect of Intervention Strategies on Weight Loss and Other Related Indicators in Overweight Personnel Enrolled in the Army Weight Control Program (9/86)	38
9268	Derderian, Sarkis LTC MC. Pulmonary Function in Patients with Arthritis Associated with Inflammatory Bowel Disease (5/87)	39
9270	Rinke, Wolf LTC SP. Incidence of Bulimia in a Selected United States Army Population (8/87)	40
9271	Derderian, Sarkis LTC MC. The Ventilatory Response to Carbon Dioxide in Compensated Hepatic Cirrhosis (9/87)	41
9272	Lippert, Lloyd LTC MS. Relationship of Major Histocompatibility Complex Class II Genes to Inhibitor Antibody Formation in Hemophilia A (9/88)	42
9273	Burman, Kenneth COL MC. Identification and Characterization of Thyroid Autoantigens (9/88)	43
DENTAL CLINIC		
9409	Ragno, James MAJ DC. The Evaluation of 0.12% Chlorhexidine Rinse on the Prevention of Alveolar Osteitis (5/87)	44
DEPARTMENT OF MEDICINE		
Cancer & Leukemia Group B		
1516-84	Weiss, Raymond MD. CALGB 8364: Immunological Diagnostic Studies in Adult ALL (10/83)	45
1522-84	Weiss, Raymond MD. CALGB 8461: Cytogenetic Studies in Acute Leukemia: A Companion to CALGB 8011, 8323, 8321, and 8411 (9/84)	46

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

PROTOCOL NUMBER	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF MEDICINE</b>		
Cancer & Leukemia Group B (continued)		
1527-85	Weiss, Raymond MD. CALGB 8591: A Phase III Study of Combining Chemotherapy with Surgery and Radiotherapy for Resectable Squamous Cell Carcinoma of the Head and Neck (2/85)	47
1528-85	Weiss, Raymond MD. CALGB 8541: Adjuvant CAF for Pathologic Stage II Node Positive Breast Cancer: A Comparison of Three Dose Regimens (3/85)	48
1536-85	Weiss, Raymond MD. CALGB 8582: A Comparison of Pentostatin and Alpha Interferon in Splenectomized Patients with Active Hairy Cell Leukemia (5/85)	49
1539-85	Weiss, Raymond MD. CALGB 8561: Retrospective Assessment of Psychosocial Sequelae in Long-term Survivors of Advanced Hodgkin's Disease (9/85)	50
1540-85	Weiss, Raymond MD. CALGB 8562: Retrospective Assessment of Psychosocial and Psychosexual Sequelae in Three Treatment Regimens for Advanced Hodgkin's Disease (9/85)	51
1543-86	Weiss, Raymond MD. CALGB 8513: A Phase III Trial of Intensive Treatment for Adult Acute Lymphocytic Leukemia: A Comparison of Combination Chemotherapy plus Alternating Mitoxantrone and Daunorubicin Vs. Combination Chemotherapy plus Daunorubicin (12/85)	52
1544-86	Weiss, Raymond MD. CALGB 8661: The Epidemiology of the Acute Leukemias in Adults with Special Reference to Cytogenetically Determined Subgroups (12/85)	53
1550-86	Weiss, Raymond MD. CALGB 8534: Combination Chemotherapy with Intensive ACE/PCE and Radiation Therapy to the Primary Tumor and Prophylactic Whole Brain Radiation Therapy with or without Warfarin in Limited Small Cell Carcinoma of the Lung (8/86)	54
1551-86	Weiss, Raymond MD. CALGB 8362: Pharmacokinetics of Ara-C in Patients with Acute Myelogenous Leukemia, A Companion to CALGB 8525 (9/86)	55

---

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF MEDICINE</b>		
	Cancer & Leukemia Group B (continued)	
1552-87	Weiss, Raymond MD. CALGB 8694: A Randomized Comparison of m-BACOD and CHOP Chemotherapy in Advanced Stage Large Cell Lymphoma (11/86)	56
1554-87	Weiss, Raymond MD. CALGB 8691: Cytoxan with or without Interferon for Low Grade Lymphoma (12/86)	57
1556-87	Weiss, Raymond MD. CALGB 8693: Evaluation of Adjuvant Therapy in Node Negative Operable Breast Cancer (1/87)	58
1557-87	Weiss, Raymond MD. CALGB 8791: A Randomized Comparison of Pentostatin Vs. Alpha Interferon in Previously Untreated Patients with Hairy Cell Leukemia (3/87)	59
1560-87	Weiss, Raymond MD. CALGB 8642: A Master Protocol to Study Single Agent Chemotherapy Vs. Standard Chemotherapy for Advanced Breast Cancer (6/87)	60
1562-87	Weiss, Raymond MD. CALGB 8742: A Phase II Study of Trimetrexate for Advanced Breast Cancer (6/87)	61
1563-87	Weiss, Raymond MD. CALGB 8662: Monitoring Circulating Breast Cancer-Associated Antigens with the 15-3 Radioimmunoassay (6/87)	62
1564-87	Weiss, Raymond MD. CALGB 8692: Intergroup Study in Metastatic Sarcomas (6/87)	63
1565-87	Weiss, Raymond MD. CALGB 8695: Combination Chemotherapy for Advanced Hodgkin's Disease (6/87)	64
1567-87	Weiss, Raymond MD. CALGB 8711: Idarubicin in Acute Lymphocytic Leukemia, Relapsed or Failed Induction (7/87)	65
1568-87	Weiss, Raymond MD. CALGB 8741: A Dose Response Trial of Megace for Advanced Breast Cancer (7/87)	66
1571-87	Weiss, Raymond MD. CALGB 8721: A Phase II Trial of Sequential High Dose ARA-C and L-Asparaginase for Acute Non-Lymphocytic Leukemia (10/87)	67

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

PROTOCOL NUMBER	PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE	PAGE* (VOL II)
<b>DEPARTMENT OF MEDICINE</b>		
Cancer & Leukemia Group B (continued)		
1572-87	Weiss, Raymond MD. CALGB 8736: Combined Chemotherapy and Radiotherapy for Stage III Lung Cancer (10/87)	68
1573-87	Weiss, Raymond MD. CALGB 8762: Molecular Subtypes in Acute Lymphatic Leukemia with Philadelphia Chromosome (10/87)	69
1574-87	Weiss, Raymond MD. CALGB 8763: Immunoglobulin and T Cell Receptor Gene Rearrangement in Adult Acute Lymphatic Leukemia (10/87)	70
1575-87	Weiss, Raymond MD. CALGB 8765: Analysis of Proto-Oncogene Expression in Acute Myelogenous Leukemia (10/87)	71
1576-87	Weiss, Raymond MD. CALGB 8766: Immunologic and Molecular Diagnostic Studies in Chronic Lymphatic Leukemia (10/87)	72
1577-80	Weiss, Raymond MD. CALGB 8361: Immunologic Diagnostic Studies in AML (blood drawing phase); previously CALGB 7921) CALGB 8321: A Comparative Study of 3 Remission Induction Regimens and 2 Maintenance Regimens for AML (treatment phase); previously CALGB 7921 (1/80)	73
1577-88	Weiss, Raymond MD. CALGB 8722 Comparison of Three Drug Combinations in Acute Non-Lymphocytic Leukemia: Relapsed or Failed Induction (1/88)	74
1578-88	Weiss, Raymond MD. CALGB 8733: Pace and Gamma Interferon for Extensive Stage Small Cell Lung Cancer, Phase II (1/88)	75
1579-88	Weiss, Raymond MD. CALGB 8861: Monitoring Circulating Breast Cancer-Associated 15-3 Antigen in Stage II Breast Cancer (1/88)	76
1580-88	Weiss, Raymond MD. CALGB 8712: Two Types of Interferon for Previously Untreated Chronic Myelogenous Leukemia: A Phase II Study (3/88)	77
1581-80	Weiss, Raymond MD. CALGB 8363: Clonal Excess Determination in Non-Hodgkin's Lymphoma (Blood drawing phase); previously CALGB 7851/7951 (Treatment phase) (4/80)	78

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF MEDICINE</b>		
Cancer & Leukemia Group B (continued)		
1581-88	Weiss, Raymond MD. CALGB 8831: Combined Chemotherapy and Radiotherapy for Stage III Lung Cancer (7/88)	79
1582-88	Weiss, Raymond MD. CALGB 8851: A Phase II Study of Amonafide in Refractory Lymphoma (7/88)	80
1583-88	Weiss, Raymond MD. CALGB 8862: A Pharmacodynamic Study of Amonafide (7/88)	81
1584-88	Weiss, Raymond MD. CALGB 8896: An Intergroup Study of Adjuvant Therapy of Primary Colon Cancer (9/88)	82
1585-88	Weiss, Raymond MD. CALGB 8834: A Randomized Phase II Study of Chemotherapy for Advanced Non-small Cell Lung Cancer (9/88)	83
<b>DEPARTMENT OF MEDICINE</b>		
Cardiology Service		
1236	Zoltick, Jerel MAJ MC. Plasma Beta-endorphin, Cortisol, Catecholamines and Cyclic Nucleotide Responses in Asymptomatic Individuals Undergoing Repeat Treadmill Testing (5/84)	84
1238	Weston, Lawrence CPT MC. Effect of Heart Disease on Quality of Life (3/85)	85
1243	Moore, John LTC MC. Percutaneous Balloon Valvuloplasty for Patients with Mitral Stenosis or Aortic Stenosis: A Pilot Study (10/86)	86
1245	Ross, Terence MAJ MC. A Double Blind Study of the Safety and Efficacy of Multiple Intravenous Infusions of Disodium EDTA in Patients with Obstructive Peripheral Arterial Disease and Intermittent Claudication (7/87)	87
1246	Cambier, Patrick CPT MC. Diltiazem in the Treatment of Raynaud's Phenomenon: An Objective Double-Blind Study (10/87)	88
1247	Martyak, Thomas MAJ MC. An Open Multicenter Single-Dose Safety and Efficacy Study of BW tPA in Patients with Acute Myocardial Infarction (10/87)	89

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

PROTOCOL NUMBER	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	PAGE* (VOL II)
<b>DEPARTMENT OF MEDICINE</b>		
<b>Cardiology Service (continued)</b>		
1248	Ross, Terence MAJ MC. A Study of the Efficacy and Safety of the Modified Mansfield Heart Trak III Low Profile PTCA Catheter (12/87)	90
1249	Rogan, Kevin MAJ MC. Multicenter Study of Silent Ischemia (12/87)	91
1250	Laird, John CPT MC. The Cardiointrogram for Detecting Coronary Artery Disease: A Retrospective Study (2/88)	92
1251	Laird, John CPT MC. Noninvasive Estimation of Prosthetic Aortic Valve Area Using Doppler Ultrasound (3/88)	93
1252	Dykstra, Gary MAJ MC. Assessment of the Effect of Mental Arousal on Cardiac Function (4/88)	94
1253	Rogan, Kevin MAJ MC. Diastolic Dysfunction of the Left Ventricle as a Predictor of Doxorubicin Cardiotoxicity: A Pilot Study (5/88)	95
1254	Weston, Lawrence MAJ MC. Cardiac Arrhythmia Suppression Trial (CAST) (5/88)	96
<b>DEPARTMENT OF MEDICINE</b>		
<b>Dermatology Service</b>		
1805	Benson, Paul MAJ MC. Use of Isotretinoin in Prevention of Basal Cell Carcinoma (5/83)	97
1809	James, William LTC MC. Investigation of Photosensitive Reactions to Piroxicam Via Topical Administration and Ultraviolet Light Exposure (7/84)	98
<b>DEPARTMENT OF MEDICINE</b>		
<b>Endocrine-Metabolic Service</b>		
1300-88	Burman, Kenneth COL MC. Postoperative Evaluation of Patients with Differentiated Thyroid Cancer: A Study Comparing $^{131}\text{I}$ , $^{201}\text{Tl}$ and Magnetic Resonance Imaging (MRI) (1/88)	99

---

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
DEPARTMENT OF MEDICINE		
Endocrine-Metabolic Service (continued)		
1301-88	Ahmann, Andrew MAJ MC. Atrial Natriuretic Peptide (ANP) Effect on Thyroid Function and Growth in Porcine and Ovine Cultured Thyrocytes and Intact Rats (3/88)	100
1302-88	Burman, Kenneth COL MC. Cholestyramine Treatment of Thyrotoxicosis (3/88)	101
1303-88	Burman, Kenneth COL MC. The Clinical Application of In Situ Hybridization to Detect Viral Genomes and Oncogenes in Diseases of the Thyroid and Selected Viral Infections (4/88)	102
1304-88	Solomon, Barbara DAC. The Relationship Between Appraisal Processes and Coping in Middle-Aged Persons with Non-insulin Dependent Diabetes Mellitus (4/88)	103
1305-88	Burman, Kenneth COL MC. A Comparison of the Health, Risk and Physical Performance of Overweight and Normal Weight Soliders (5/88)	104
1306-88	Coffey, Lauri CPT SP. Predicting Energy Requirements in Women with Gestational Diabetes Mellitus (GDM) (5/88)	105
1307-88	Fein, Henry LTC MC. Studies of the Genome of Patients with Thyroid Hormone Resistance (9/88)	106
1323-80	Burman, Kenneth COL MC. Thyrotropin (TSH) Receptors in Human Thyroid Tissue (7/80)	107
1330-81	Burman, Kenneth COL MC. Utilization of Hybridoma Antibodies as a Physiologic Probe of Thyrotropin (TSH) Action (7/81)	108
1338-82	Burman, Kenneth COL MC. Membrane Receptors in Peripheral Circulating Mononuclear Cells (2/82)	109
1339-82	Burman, Kenneth COL MC. Immunology of Thyroid Disease (2/82)	110
1349-84	Burman, Kenneth COL MC. Immunoglobulin Production in Thyroid Disease (11/83)	111

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

PROTOCOL NUMBER	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF MEDICINE</b>		
Endocrine-Metabolic Service (continued)		
1351-84	Wartofsky, Leonard COL MC. Cyclosporin Treatment of Graves' Ophthalmopathy (1/84)	112
1353-84	Burman, Kenneth COL MC. Effect of Short Term Fasting on Immunity (3/84)	113
1354-84	Wartofsky, Leonard COL MC. Prolonged TRH Infusions in Graves' Disease (3/84)	114
1355-84	Burman, Kenneth COL MC. Thyroid Disease in the Elderly (4/84)	115
1356-84	Glass, Allan LTC MC. Ketoconazole-Induced Suppression of Serum Testosterone Levels in Men (7/84)	116
1359-85	Burman, Kenneth COL MC. Newer Investigations into the Immune Mechanisms of Thyroid Disease (1985) (2/85)	117
1361-85	Duncan, William LTC MC. 1,25-Dihydroxyvitamin D Action at the Nuclear Level (5/85)	118
1363-85	Duncan, William LTC MC. 1,25-Dihydroxyvitamin D Receptors in Liver and Skeletal Muscle (7/85)	119
1366-85	Burman, Kenneth COL MC. Pancreatic Islet Transplantation Across Major Histocompatibility Barriers (9/85)	120
1367-86	Burman, Kenneth COL MC. Modification of Diabetogenic Effects of Pentamidine (10/85)	121
1369-86	Burman, Kenneth COL MC. Magnesium Status and Thyroid Disease (10/85)	122
1370-86	Burman, Kenneth COL MC. Effect of Short Term Fasting on Percent Body Fat as Determined by Skinfold Caliper, Circumference Measurements, Bioelectrical Impedance Measurements, and Hydrostatic Weighing and Energy Balance (10/85)	123
1371-86	Glass, Allan LTC MC. Transplantation Antigens on Spermatozoa (11/85)	124

---

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

PROTOCOL NUMBER	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
DEPARTMENT OF MEDICINE		
Endocrine-Metabolic Service (continued)		
1372-86	Glass, Allan LTC MC. Effect of Altered Energy Balance on Sexual Maturation in Rats (11/85)	125
1373-86	Glass, Allan COL MC. Lymphocyte Subsets in Men with Low Sperm Counts (1/86)	126
1376-86	Glass, Allan COL MC. Ketoconazole Effects on Vitamin D in Hypercalcemic Patients (4/86)	127
1377-86	Solomon, Barbara RN DNSC. Quantification of Psychophysiologic Symptoms Before and After Parathyroid Surgery (4/86)	128
1381-86	Smallridge, Robert COL MC. Effect of Obesity on Pharmacokinetics of Atropine in Young Men (8/86)	129
1382-86	Smallridge, Robert COL MC. Long-Term Use of Somatostatin Analogue for Patients with Thyrotropin Secreting Pituitary Tumors (8/86)	130
1383-86	Ahmann, Andrew CPT MC. Bone Mineral Density in Subjects Treated with Thyroid Hormone (8/86)	131
1384-86	Duncan, William MAJ MC. Calcium Supplements and Calciuria in the Elderly (9/86)	132
1385-87	Burman, Kenneth COL MC. Molecular Biology of Thyroid Disease (10/86)	133
1386-87	Burman, Kenneth COL MC. In Vitro Determination of Messenger RNA Isolated from Porcine Thyroid Glands (12/86)	134
1387-87	Duncan, William MAJ MC. Dissolution of Commercial Oral Calcium Carbonate Supplements (1/87)	135
1389-87	Duncan, William MAJ MC. 1,25-Dihydroxyvitamin D <sub>3</sub> Induction of Ornithine Decarboxylase Activity in Regenerating Rat Liver (5/87)	136
1390-87	Burman, Kenneth COL MC. Dynamic Assessment of Zinc Status in Thyroid Disease (5/87)	137

---

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

PROTOCOL NUMBER	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF MEDICINE</b>		
<b>Endocrine-Metabolic Service (continued)</b>		
1391-87	Duncan, William LTC MC. Bone Mineral Density (BMD) in Patients with Chronic Renal Failure (6/87)	138
1392-87	Duncan, William LTC MC. Role of 1,25(OH)2D3 in Liver Regeneration (7/87)	139
1393-87	Carr, Frances PhD. Regulation of Rat TSH Beta Subunit Gene Expression (8/87)	140
1394-87	Burman, Kenneth COL MC. Molecular Biology of Nutrient Alterations in Rats (8/87)	141
1395-87	Burman, Kenneth COL MC. Oncogenes and Thyroid Receptors (9/87)	142
1396-87	Burch, Henry CPT MC. The Effect of Exogenously Administered Levothyroxine on Bone Mineral Content (BMC) (9/87)	143
1397-87	Brennan, Michael LTC MC. Intestinal Absorption of Commercial (Oral) Calcium Carbonate Supplements (10/87)	144
1398-87	Solomon, Barbara DNSc. The Management of Hyperthyroidism Due to Graves' Disease in the United States (11/87)	145
1399-87	Tseng, Yueh-Chu PhD. Growth Factors and the Thyroid Gland (12/87)	146
<b>DEPARTMENT OF MEDICINE</b>		
<b>Gastroenterology Service</b>		
1400-88	Decker, Robert CPT MC. A Pilot Study Evaluating Intestinal and Serum Immunoglobulin Levels in Patients with Acquired Hypogammaglobulinemia and Recurrent/Chronic Diarrhea of Undefined Etiology (2/88)	147
1401	Phillips, Raymond MAJ MC. The Effect of Normalization of Intraesophageal pH on Mucosal Proliferation in Barrett's Esophagus (9/88)	148
1432	Wong, Roy COL MC. Lithium, Nicotinic Acid, Aminophylline, and 16,16 Dimethyl PGE2 as Cytoprotective Agents (9/80)	149

---

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF MEDICINE</b>		
<b>Gastroenterology Service (continued)</b>		
1435	Wong, Roy COL MC. Genetic Linkage in Achalasia (12/80)	150
1448	Wong, Roy COL MC. Effects of Semi-Chronic Ingestion of Lithium and Acetylsalicyclic Acid on Rat Gastric Mucosa and Kidney (5/82)	151
1449	Gage, Thomas COL MC. How Has Cimetidine Affected the Treatment of Peptic Ulcer Disease (5/82)	152
1450	Kikendall, James LTC MC. Adenomatous Colonic Polyps: A Vitamers and MFO Induction (7/82)	153
1453	Decker, Robert MAJ MC. The Effect of Sodium Deprivation on Small Intestinal Water and Electrolyte Transport (10/83)	154
1462	Shay, Steven COL MC. The Evaluation of Postprandial Supine Reflux Events by Simultaneous Esophageal Manometry, Esophageal pH Monitoring, and Gastroesophageal Scintiscanning in Patients with Hiatus Hernia and Esophagitis (8/83)	155
1464	Gage, Thomas. The Effect of Paracentesis on Pulmonary Function in Cirrhotics with Ascites and Dyspnea (2/84)	156
1466	Kikendall, James LTC MC. Validation and Reliability Rating of a Vitamin A Diet History (6/84)	157
1470	Decker, Robert MAJ MC. Intestinal Sodium and Water Transport: Evaluating Solutions to Maximize Absorption (8/84)	158
1471	Wong, Roy COL MC. Serum and Tissue Zinc Levels in the Esophagus (8/84)	159
1473	Johnson, Lawrence COL MC. Sucralfate Used as Adjunctive Therapy in Patients with Erosive Peptic Esophagitis Resulting from Gastroesophageal Reflux: A Random Double Blind Controlled Study (12/84)	160
1478	Shay, Steven COL MC. An Open Label Trial of the Long-term Therapy of Domperidone for Gastric Atony (1/86)	161

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

PROTOCOL NUMBER	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
DEPARTMENT OF MEDICINE		
Gastroenterology Service (continued)		
1483	McNally, Peter MAJ MC. Evaluation of Gastroesophageal Reflux as a Cause of Hoarseness (4/86)	162
1484	Shay, Steven COL MC. An Evaluation of Scintigraphy as a Gastroesophageal Reflux Test and its Comparative Value to Standard Testing Methods in Different Patient Groups within the Symptomatic Gastroesophageal Reflux Population (4/86)	163
1487	Wong, Roy COL MC. Prospective Evaluation of the Effect of Medical Therapy on Plasma and Tissue Zinc Levels in Esophagitis (7/86)	164
1488	Holtzmuller, Kent MD. Campylobacter Pyloridis: Normal Flora or Pathogen (8/86)	165
1489	McNally, Peter MAJ MC. The Evaluation of Post prandial Supine Reflux Events by Simultaneous Esophageal Manometry, Esophageal pH Monitoring and Gastroesophageal Scintiscanning in Patients with Progressive Systemic Sclerosis with Severe Endoscopic Esophagitis (12/86)	166
1490	Herrera, Jorge MAJ MC. A Dose Response Study to Evaluate Safety and Efficacy of Ranitidine in Patients with Gastroesophageal Reflux Disease (12/86)	167
1491	Sodhi, Parminder MAJ MC. Use of Commercially Available Formulas for Feeding in Immediate Postoperative Period (12/86)	168
1492	Moses, Frank LTC MC. Does Chronic Beta Carotene Alter the Response of Gastric Mucosa to Acute Aspirin Injury (2/87)	169
1493	Moses, Frank LTC MC. A Study to Evaluate the Development of Quantitative Analysis of Video-digital Images Obtained During Esophagogastroduodenoscopy (6/87)	170
1494	Lyons, Michael CPT MC. Effect of Hypertonic Phosphate (Fleets) and Colyte Colonic Enemas on Venous pH, Osmolality, Serum Calcium, Phosphate, and Electrolytes in Patients Undergoing Flexible Sigmoidoscopy (6/87)	171

---

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF MEDICINE</b>		
<b>Gastroenterology Service (continued)</b>		
1495	Phillips, Raymond MAJ MC. Effect of Beta-Carotene on Mucosal Proliferation in Patients with Colonic Carcinoma (10/87)	172
1496	Wong, Roy COL MC. The Effects of Non-Steroidal Anti-Inflammatory Drugs on the Secretion of Human Salivary Epidermal Growth Factor (10/87)	173
1497	Holtzmuller, Kent MAJ MC. The Effect of Indomethacin on Rectosigmoid Mucosal Blood Flow and Rectosigmoid Mucosal Prostaglandin Levels in Humans (10/87)	174
1498	Keate, Ray MAJ MC. Pathophysiology and Treatment for Non-Ulcer Dyspepsia (Using Cisapride) (12/87)	175
1499	Stann, Carl MAJ MC. The Effects of IV Ranitidine on Gastric pH in Patients Undergoing Vascular Surgery: An Evaluation of Dose for Effective pH Control (1/88)	176
<b>DEPARTMENT OF MEDICINE</b>		
<b>General Medicine Service</b>		
1012	Weaver, Michael LTC MC. A Study of the Effects on Patient Satisfaction of Teaching Interviewing Skills to Medical Residents (5/85)	177
1016	Harvey, Joan LCDR MC USN. A Linguistic Analysis of Resident-Patient Interaction (8/86)	178
1017	Steinweg, Donald MAJ MC. Alkaline Phophatase Abnormalities in Hip Fractures (11/86)	179
1019	Jeffers, Duane MAJ MC. Clinical Competence Assessment of Internal Medicine Residents Using a Multistep Examination of Diagnosis and Management Skills and a Videotaped Review of Interpersonal Skills (10/87)	180
1020	Diemer, Margretta MAJ MC. History Taking in the Internal Medicine Context: Observation of Resident Skills (10/87)	181
1021	Reed, William MAJ MC. Evaluation of Patient Utilities for Cholesterol Lowering Therapy (8/88)	182

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
DEPARTMENT OF MEDICINE Hematology-Oncology Service		
1602-81 Ward, Frank MAJ MC. Regulation of Granulopoiesis In Vitro Incorporation of 14C-Glucosamine in Normal Human Bone Marrow Granulocytes with Patients' Sera with Primary and Secondary Bone Marrow Granulocyte Disorders (5/81)		183
1616-82 Bednarek, Jana MD. Phenotypic Characterization of Granulocytic Leukemia Blast Cells by High Performance Liquid Chromatographic Analysis of Cellular Proteins (9/82)		184
1638-86 Ward, Frank MAJ MC. WRAMC 8602 Clinical Pharmacokinetic (Phase I) Study of Hexamethylene Bisacetamide in Patients with Advanced Solid Tumors (2/86)		185
1639-86 Wright, Daniel LTC MC. Characterization of Human Antineutrophil Antibodies (3/86)		186
1644-87 Knight, Robert LTC MC. Chromosomal Radiosensitivity During the G2 Cycle Period of Normal Lymphocytes from Individuals with Malignant Lymphoma: A Pilot Study (10/86)		187
1647-87 Vukelja, Svetislava CPT MC. The Value of Electronic Platelet Sizing in the Evaluation of Thrombocytopenia (5/87)		188
1648-87 Reid, Thomas MAJ MC. WRAMC 8701 The Genetic Correlates of Multidrug Resistance in Human Tumors: A Collaborative NCI-WRAMC Pilot Study (7/87)		189
1649-87 Bednarek, Jana PhD. Molecular Basis of the Maturation of Bone Marrow Granulocytes: A Pilot Study of the Isolation and Purification of Granulocyte Maturation Regulators from Normal Human Serum (9/87)		190
1650-87 Lombardo, Fredric MAJ MS. Exploratory Dose Finding Study to Assess the Efficacy and Safety of Intravenous AHR 11190B (Zacopride Hydrochloride) in the Prevention of Cisplatin-Induced Emesis (11/87)		191
1651-88 Redmond, John COL MC. A Retrospective Comparison of Magnetic Resonance Imaging and Myelography to Detect Spinal Metastases and Epidural Cord Compression (3/88)		192

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF MEDICINE</b>		
<b>Hematology-Oncology Service (continued)</b>		
1652-88	Ward, Frank MAJ MC. HLA Typing in a Sibship with Two Brothers with Hairy Cell Leukemia (3/88)	193
1653-88	Perry, James MAJ MC. Limitations of Screening Tests in the Detection of von Willebrand's Disease (4/88)	194
1654-88	Alving, Barbara LTC MC. The Correlation Between Lupus Anticoagulants and Antibodies to Cardiolipin (5/88)	195
1655-88	Giguere, Jeffrey MAJ MC. Retroviral Mediated Genetic Transfer of Radiation Resistance to Ataxia-Telangiectasia Cell Lines (5/88)	196
1656-88	Redmond, John COL MC. Magnetic Resonance Imaging in the Staging and Evaluation of Response to Therapy in Small Cell Carcinoma of the Lung (5/88)	197
1657-88	Ward, Frank MAJ MC. Long Term 5-FU Infusion for Recurrent Head and Neck Cancer, A Phase II Pilot Study (6/88)	198
1658-88	Alving, Barbara LTC MC. Verification of the Heterogeneity of Lupus Anticoagulant Using Purified IgG and IgM from Patients with Lupus Anticoagulant (7/88)	199
1659-88	Kark, John COL MC. Antisickling Effect of Erythrocyte 2,3-DPG Depletion (8/88)	200
1682-80	Weiss, Raymond MD. WRAMC 7910 Group C Drugs for Use as Single Agents in the Treatment of Various Neoplastic Diseases (10/79)	201
9021-82	Kark, John LTC MC. Anion Permeability of Sickle Cell Trait Red Cells (2/82)	202
9022-83	La Russa, Vincent PhD. Studies of the Proliferation and Differentiation of Pluripotent Stem Cells and Committed Hematopoietic Precursors from Normal Bone Marrow Maintained in Continuous Long-term Cultures (10/82)	203
9903	Dunning, David MAJ MC. In Vitro Induction of Terminal Differentiation in Oral-Pharyngeal Leukoplakia with Gamma Interferon and Tumor Necrosis Factor (8/88)	204

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF MEDICINE</b>		
Infectious Disease Service		
1929	Cross, Alan LTC MC. Oropharyngeal Colonization of Neonates with Gram-negative Bacilli (11/83)	205
1933	McClain, Bruce LTC MC. Characterization of Leptospiral Toxins (4/84)	206
1937	Sadoff, Jerald COL MC. Development of Human Monoclonal Antibodies from Peripheral Blood Lymphocytes (10/84)	207
1940	Hoover, David LTC MC. Mediators of Cell Immunity in Patients Infected with Intracellular Microorganisms (7/85)	208
1942	McClain, Bruce LTC MC. Rat Tissue Affinities of Leptospirae (2/86)	209
1949	Hoover, David LTC MC. Passage of <i>L. donovani</i> Amastigotes in Syrian Golden Hamsters (12/86)	210
1956	Cross, Alan COL MC. Neutrophil Function in Patients with Diabetes Mellitus (6/87)	211
1959	Chulay, Jeffrey COL MC. Treatment of Systemic Fungal Infections with Itraconazole (7/87)	212
1962	Johnson, Steven CPT MC. Gonorrhea Infection in the Male: Semiquantitation of the Infectious Inoculum (9/88)	213
9103	Boslego, John LTC MC. Monoclonal Antibodies to <i>N. Gonorrhoeae</i> (7/82)	214
<b>DEPARTMENT OF MEDICINE</b>		
Nephrology Service		
1152	Gouge, Steven MAJ MC. In Vitro Analysis of Removal of Radiocontrast Agents (RCA) by Artificial Membranes (6/87)	215
1154	Howard, Andrew MAJ MC. The Relationship Between the Degree of Anemia and the Degree of Chronic Renal Failure (9/87)	216
1155	Moore, Jack LTC MC. The Effect of Thyroid Hormone Administration in Acute Renal Failure (9/87)	217

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF MEDICINE</b>		
Nephrology Service (continued)		
1156	Gouge, Steven MAJ MC. Retrospective Analysis of the Use of Renal Ultrasound at Walter Reed Army Medical Center (10/87)	218
<b>DEPARTMENT OF MEDICINE</b>		
Pulmonary Disease Service		
1702	Rajagopal, Krishnan LTC MC. Ventilatory Response to Carbon Dioxide in Presenile Dementia (7/80)	219
1705	Abbrecht, Peter PhD. Determinants of Resistive-Loaded Breathing Response (9/80)	220
1707	Rajagopal, Krishnan LTC MC. Relationship Between Respiratory Control Mechanisms and Nocturnal Desaturation in Diffuse Pulmonary Fibrosis (2/81)	221
1708	Rajagopal, Krishnan LTC MC. Respiratory Control Mechanisms in Platyal Myoclonus (2/81)	222
1710	Tamamoteber, Warren MAJ MC. Relationship between Respiratory Control Mechanisms and Nocturnal Desaturation in Obese Subjects (3/81)	223
1711	Derderian, Sarkis LTC MC. Pulmonary Function in Psoriatic Arthritis (3/81)	224
1714	Dillard, Thomas MAJ MC. Mechanisms Limiting Exercise Ventilation in Chronic Obstructive Lung Disease (9/83)	225
1716	Rajagopal, Krishnan LTC MC. Nasal Continuous Positive Airway Pressure (CPAP) in Obstructive Sleep Apnea (OSA) (7/84)	226
1717	Dillard, Thomas MAJ MC. Prediction of Maximum Exercise Response from Resting Pulmonary Function in Patients with Chronic Obstructive Pulmonary Disease (5/85)	227
1720	Derderian, Sarkis LTC MC. Pilot Study On the Use of Conjunctival Oxygen Tension Monitoring in the Sleep Apnea Syndrome (4/87)	228

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF MEDICINE</b>		
<b>Pulmonary Disease Service (continued)</b>		
1721	South-Paul, Jeanette MAJ MC. Comparison of Prepregnancy and Postpartum Fitness Levels: A Pilot Study (6/87)	229
1722	Eliasson, Arn MAJ MC. Flow-volume Loops and Routine Spirometry in Patients with Exercise-induced Asthma (7/87)	230
1724	Dillard, Thomas MAJ MC. Mechanisms of Hypoxia During Simulated Air Travel in Patients with Chronic Obstructive Pulmonary Disease (1/88)	231
1725	Rajagopal, Krishnan LTC MC. Evaluation of Inspiratory Parameters in the Response to Inhaled Bronchodilators (2/88)	232
1726	Rajagopal, Krishnan LTC MC. Physiologic Assessment of Exercise Limitation in Upper Airway Obstruction (2/88)	233
1727	Phillips, Yancy LTC MC. The Effect of Caffeine on Bronchoconstriction Following Eucapnic Voluntary Hyperventilation of Dry Air (3/88)	234
1728	Phillips, Yancy LTC MC. The Role of Respiratory Water Loss Without Heat Flux in Exercise-Induced Asthma (5/88)	235
1729	Phillips, Yancy LTC MC. The Effect of Pre-Procedure Ipratropium or Metaproterenol by Metered Dose Inhaler on Pulmonary Function Following Fiberoptic Bronchoscopy (6/88)	236
1730	Phillips, Yancy LTC MC. Characterization of Ventilatory Patterns, Ventilatory Requirements and Oxygen Consumption During Uncomplicated Labor in Normal Parturients (8/88)	237
1731	McManigle, John MAJ MC. Cold Air Inhalation in Patients with Raynaud's Phenomenon (8/88)	238
1732	Derderian, Sarkis LTC MC. Pleural Pressure Measurements in Normal Healthy Volunteers During the Administration of Nasal Continuous Positive Airway Pressure (NCPAP) (9/88)	239

---

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

PROTOCOL NUMBER	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF MEDICINE</b>		
Rheumatology Service		
3220R	Tesar, Joseph MD. An Experimental Model of Seronegative Lupus - A Study of Biological Role of Anti-Ro/SSA and La/SSB Antibodies (5/84)	240
3700	Katona, Ildy CDR MC USN. Effects of Recombinant Human Y-Interferon (Y-IFN) Human B-Cell Responses to Soluble Activators (10/86)	241
3701	Baunchalk, James CPT MC. Anticardiolipin Antibodies in Patients with SLE (7/87)	242
3702	Strickland, Roger MAJ MC. Comparative Open Label Clinical Trial of Sulfasalazine and Auranofin in the Treatment of Active Rheumatoid Arthritis (9/87)	243
3703	Strickland, Roger MAJ MC. Autoimmune Phenomena in Patients with Inflammatory Osteoarthritis and Primary Nodal Osteoarthritis (5/88)	244
<b>NEUROLOGY SERVICE</b>		
7120	Jabbari, Bahman COL MC. Evaluation of the Effectiveness of Trihexyphenidyl as an Adjunct Drug for Treatment of Epilepsy (2/84)	245
7122	Scherokman, Barbara MD. Measurement of Arachidonic Acid Metabolites in the Cerebrospinal Fluid of Patients with Central Nervous System Cancer (1/85)	246
7124	Salazar, Andres COL MC. A Comparison of Intramuscular ACTH Alone vs. Intrathecal Interferon and Intramuscular ACTH in the Treatment of Acute Exacerbations of Patients with Multiple Sclerosis (5/85)	247
7125	Martin, Alex PhD. Development and Standardization of Tests of Cognitive Function for Dementia: Normal Volunteer Studies (6/86)	248
7126	Jabbari, Bahman COL MC. Evaluation of the Effectiveness of Metoclopramide (Reglan) in Involuntary Movement Disorders (9/86)	249

---

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

PROTOCOL NUMBER	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
NEUROLOGY SERVICE (continued)		
7131	Jabbari, Bahman COL MC. Evaluation of the Effects of Anticholinergic, Dopamine Antagonist and GABA Agonist Medications on Brain Electrical Activity and Nerve Fiber Conduction in the Central Nervous System (6/87)	250
7132	Jabbari, Bahman COL MC. Investigation of the Yield of Somatosensory Evoked Potential Test and Magnetic Resonance Imaging in Myelopathies (7/87)	251
7133	Salazar, Andres COL MC. Human Fibroblast Interferon Vs. Hydergine in the Treatment of Alzheimer's Disease (8/87)	252
7134	Martinez, Arizala MAJ MC. Presence of an Endogenous Anticonvulsant Substance in Human Cerebrospinal Fluid Following a Seizure (9/87)	253
7135	Salazar, Andres COL MC. Beta Interferons in Multiple Sclerosis: A Randomized, Double Blind, Placebo Controlled Multicenter Study of the Relative Efficacies of Three Experimental Treatments as Prophylaxis Against Multiple Sclerosis Exacerbations (12/87)	254
7136	Salazar, Andres COL MC. An Investigation of Frontal Lobe Mediated Knowledge Representation (2/88)	255
7137	Labutta, Robert CPT MC. Patterns of Cerebral Blood Flow Determined by Iodoamphetamine SPECT in Sjogren's Syndrome and Systemic Lupus Erythematosus: A Pilot Study (3/88)	256
7138	Jabbari, Bahman COL MC. Investigation of the Usefulness of Motor Evoked Potentials in Neurological Disorders (5/88)	257
9200	Salazar, Andres COL MC. Anatomical and Functional Sequelae of Head Injuries Incurred in Vietnam (6/80)	258
9202	Salazar, Andres COL MC. Poly ICLC in the Treatment of Chronic Guillain-Barre Syndrome (12/81)	259

---

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

PROTOCOL NUMBER	PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE	PAGE* (VOL II)
DEPARTMENT OF NURSING		
7507	Turner, Barbara LTC AN. Endotracheal Suctioning in Newborns (2/86)	260
7508	Turner, Barbara LTC AN. The Effects of Head Rotation and Hyperoxygenation-Suction Sequences During Endotracheal Suctioning in Newborn Infants (6/86)	261
7510	Schmidt, Judith. The Relationships of Coping and Family Function to Outcomes of Care in Families of Tracheostomy Infants and Children (12/86)	262
7511	Rikli, Patricia LTC AN. Relaxation with Imagery: An Adjunctive Treatment for Nausea and/or Vomiting (1/87)	263
7512	Biskey, Valerie LTC AN. A Comparison of the Effectiveness of Two Tracheobronchial Suctioning Techniques (6/88)	264
DEPARTMENT OF OBSTETRICS AND GYNECOLOGY		
4113	Barnhill, Danny LTC MC. Cooperative Gynecologic Oncology Group (1/74)	265
4228	Hayslip, Clifford MAJ MC. Studies of the Immune Mechanisms in Patients with Endometriosis (10/85)	266
4238	Tramont, Edmund COL MC. Gonococcal Adherence-Human Cervical Receptor Studies (11/86)	267
4241	Opsahl, Michael LCDR MC USN. Longitudinal Studies of Natural Killer Cells in Pregnancy and the Postpartum Period (1/87)	268
4242	Opsahl, Michael CDR MC USN. Cross Sectional Studies of Natural Killer Cells in Pregnancy and the Postpartum Period (1/87)	269
4243	Opsahl, Michael LCDR MC USN. The Effect of Vaginal Lubricants on Sperm Motility in the Postcoital Test (2/87)	270
4258	O'Conner, Dennis LTC MC. Detection of Herpes Simplex and Human Papillomaviruses in Exfoliated, Cervical Epithelial Cells by Means of In Situ Hybridization with Biotinylated DNA Probes (11/87)	271

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

PROTOCOL NUMBER	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF OBSTETRICS AND GYNECOLOGY (continued)</b>		
4259	Ambrose, Anthony COL MC. The Noninvasive Determination of Fetal Heart Rate Variability - Pilot Study (2/88)	272
4260	Ambrose, Anthony COL MC. The Utility of Leopold's Maneuvers in Determining Fetal Presentation at 36 Weeks Gestation (2/88)	273
4262	Barnhill, Danny LTC MC. A Multicenter Randomized Trial of Adjuvant Cisplatin/Bleomycin Plus Whole Pelvis Irradiation Vs. Cisplatin/Bleomycin Alone in High Risk Stage IB and IIA Carcinoma of the Cervix (5/88)	274
<b>DEPARTMENT OF OBSTETRICS AND GYNECOLOGY</b>		
<b>Gynecologic Oncology Group</b>		
4160	Barnhill, Danny LTC MC. GOG 40: A Clinical-Pathological Study of Stage I and II Uterine Sarcomas (3/79)	275
4161	Barnhill, Danny LTC MC. GOG 41: Surgical Staging of Ovarian Carcinoma (3/79)	276
4163	Barnhill, Danny LTC MC. GOG 26C: A Phase II Trial of Cis-platinum in the Treatment of Advanced Gyn Cancer (3/79)	277
4182	Barnhill, Danny LTC MC. GOG 54: Treatment of Women with Malignant Tumors of Ovarian Stroma with Combination Vincristine, Dactinomycin, and Cyclophosphamide (Phase III), and Phase II Evaluation of Adriamycin in Malignant Tumors of Ovarian Stroma Refractory to Primary Chemothera (1/81)	278
4187	Barnhill, Danny LTC MC. GOG 26N: A Phase II Trial of Dihydroxyanthracenedione (DHAD) in Patients with Advanced Pelvic Malignancies (4/81)	279
4194	Barnhill, Danny LTC MC. GOG 26-0: A Phase II Trial of Aziridinylbenzoquinone (AZQ) in Patients with Advanced Pelvic Malignancies (11/81)	280
4196	Barnhill, Danny LTC MC. GOG 63: Clinical Pathological Study of Stages IIB, III, and IVA Carcinoma of the Cervix (4/82)	281

---

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

PROTOCOL NUMBER	PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE	PAGE* (VOL II)
DEPARTMENT OF OBSTETRICS AND GYNECOLOGY		
	Gynecologic Oncology Group (continued)	
4197	Barnhill, Danny LTC MC. GOG 64: A Randomized Comparison of Rapid Vs. Prolonged (24 Hour) Infusion of Cisplatin in the Therapy of Squamous Cell Carcinoma of the Cervix (Phase III) (5/82)	282
4199	Barnhill, Danny LTC MC. GOG 66: Ultrastructural Staging and Therapeutic Considerations in Small Cell Carcinoma of the Cervix (6/82)	283
4203	Barnhill, Danny LTC MC. GOG 26Q: A Phase II Trial of Aminothiadiazole in Patients with Advanced Pelvic Malignancies (1/83)	284
4204	Barnhill, Danny LTC MC. GOG 71: Treatment of Patients with Suboptimal Stage IB Carcinoma of the Cervix (Phase III) (4/83)	285
4205	Barnhill, Danny LTC MC. GOG 75: Postoperative Pelvic Radiation in Stage I and II Mixed Mesodermal Sarcomas of the Uterus (1/84)	286
4206	Barnhill, Danny LTC MC. GOG 70: A Randomized Comparison of Single Agent Chemotherapy, Methotrexate and Methotrexate with Folinic Acid Rescue in "Good Prognosis" Metastatic Gestational Trophoblastic Disease (1/84)	287
4207	Barnhill, Danny LTC MC. GOG 26L: A Phase II Trial of Tamoxifen in Patients with Advanced Epithelial Ovarian Carcinoma (1/84)	288
4208	Barnhill, Danny LTC MC. GOG 73: A Clinicopathologic Study of Primary Malignant Melanoma of the Vulva Treated by Modified Radical Hemivulvectomy (1/84)	289
4209	Barnhill, Danny LTC MC. GOG 74: Early Stage I Vulvar Carcinoma Treated with Ipsilateral Superficial Inguinal Lymphadenectomy and Modified Radical Hemivulvectomy (2/84)	290
4211	Barnhill, Danny LTC MC. GOG 26R: A Phase II Trial of Progesterone in the Treatment of Advanced or Recurrent Epithelial Ovarian Cancers that have failed Combination Chemotherapy (5/84)	291

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
DEPARTMENT OF OBSTETRICS AND GYNECOLOGY		
	Gynecologic Oncology Group (continued)	
4212	Barnhill, Danny LTC MC. GOG 72: Ovarian Tumors of Low Malignant Potential: A Study of the Natural History and a Phase II Trial of Melphalan and Secondary Treatment with Cisplatin in Patients with Progressive Disease (5/84)	292
4222	Barnhill, Danny LTC MC. GOG 26D: A Phase II Trial of VP-16 in Patients with Advanced Pelvic Malignancies (7/85)	293
4224	Barnhill, Danny LTC MC. GOG 26S: A Phase II Trial of Teniposide (VM-26) in Patients with Advanced Pelvic Malignancies (7/85)	294
4225	Barnhill, Danny LTC MC. GOG 71: Treatment of Patients with Suboptimal (Bulky) Stage IB Carcinoma of the Cervix: A Randomized Comparison of Radiation Therapy Vs. Radiation Therapy plus Adjuvant Extrafascial Hysterectomy, Phase III (7/85)	295
4229	Barnhill, Danny LTC MC. GOG 86A: Master Protocol for Phase II Drug Studies in Treatment of Advanced or Recurrent Carcinoma of the Endometrium (4/86)	296
4231	Barnhill, Danny LTC MC. GOG 87A: Master Protocol for Phase II Drug Studies in the Treatment of Recurrent or Advanced Uterine Sarcomas (4/86)	297
4232	Barnhill, Danny LTC MC. GOG 87B: A Phase II Trial of Ifosfamide and the Uroprotector, Mesna, in the Treatment of Recurrent or Advanced Uterine Sarcomas (5/86)	298
4234	Barnhill, Danny LTC MC. GOG 26U: A Phase II Trial of Ifosfamide and the Uroprotector, Mesna, in Patients with Advanced Pelvic Malignancies (8/86)	299
4235	Barnhill, Danny LTC MC. GOG 83: A Clinico-Pathologic Study of Simultaneous Endometrial and Ovarian Carcinomas (9/86)	300
4237	Barnhill, Danny, LTC MC. GOG 26V: A Phase II Trial of N-Methylformamide in Patients with Advanced Pelvic Malignancies (10/86)	301

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
DEPARTMENT OF OBSTETRICS AND GYNECOLOGY		
	Gynecologic Oncology Group (continued)	
4239	Barnhill, Danny LTC MC. GOG 85: A Randomized Comparison of Hydroxyurea Vs. 5-FU Infusion and Bolus Cisplatin as an Adjunct to Radiation Therapy in Patients with Stage IIB, III, and IV A Carcinoma of the Cervix (11/86)	302
4244	Barnhill, Danny LTC MC. GOG 90: Evaluation of Cisplatin, Etoposide and Bleomycin (BEP) Induction Followed by Vincristine, Dactinomycin and Cyclophosphamide (VAC) Consolidation in Advanced Ovarian Germ Cell Tumors, Phase II (3/87)	303
4245	Barnhill, Danny LTC MC. GOG 97: A Phase III Randomized Study of Cyclophosphamide and Cisplatin in Patients with Suboptimal Stage III and IV Epithelial Ovarian Carcinoma Comparing Intensive and Non-Intensive Schedules (4/87)	304
4246	Barnhill, Danny LTC MC. GOG 94: A Phase II Study of the Treatment of Papillary Serous Carcinoma of the Endometrium Stage I and II and Maximally Debulked Advanced Endometrial Carcinoma with Total Abdominal Radiation Therapy (4/87)	305
4247	Barnhill, Danny LTC MC. GOG 95: Randomized Clinical Trial for the Treatment of Women with Selected Stage IC and II (A,B,C) and Selected Stage IAI and IBI and IAII and IBII Ovarian Cancer, Phase III (5/87)	306
4249	Barnhill, Danny LTC MC. GOG 79: Single Agent Weekly Methotrexate Therapy in the Treatment of Nonmetastatic Gestational Trophoblastic Disease, Limited Accession Phase II Trial (6/87)	307
4250	Barnhill, Danny LTC MC. GOG 88: A Randomized Study of Radical Vulvectomy and Bilateral Groin Dissection Vs. Radical Vulvectomy and Bilateral Groin Radiation, Phase III (6/87)	308
4251	Barnhill, Danny LTC MC. GOG 26W: A Phase II Trial of Echinomycin in Patients with Advanced Pelvic Malignancies (6/87)	309
4252	Barnhill, Danny LTC MC. GOG 81A-E: Phase II Trial of Medroxyprogesterone Acetate in Patients with Advanced or Recurrent Endometrial Carcinoma; 81B: Pos for Estrogen or Progesterone Receptors, 81C: Neg for Receptors; 81D: Pos for Either, not Both, 81E: With Unknown Receptors (7/87)	310

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
DEPARTMENT OF OBSTETRICS AND GYNECOLOGY		
	Gynecologic Oncology Group (continued)	
4253	Barnhill, Danny LTC MC. GOG 81F: A Phase II Trial of Tamoxifen Citrate in Patients with Advanced or Recurrent Endometrial Carcinoma Responsive to Progestins (7/87)	311
4254	Barnhill, Danny LTC MC. GOG 93: Evaluation of Intraperitoneal Chromic Phosphate Suspension Therapy Following Negative Second-Look Laparotomy for Epithelial Ovarian Carcinoma, Stage III, Phase III (7/87)	312
4255	Barnhill, Danny LTC MC. GOG 78: Evaluation of Adjuvant Vinblastine, Bleomycin and Cisplatin Therapy in Totally Reducing Choriocarcinoma, Endodermal Sinus Tumor or Embryonal Carcinoma of the Ovary, Pure and Mixed with Other Elements, Phase II (9/87)	313
4256	Barnhill, Danny LTC MC. GOG 86E: A Phase II Trial of Vincristine Given as a Weekly Intravenous Bolus in Advanced or Recurrent Endometrial Carcinoma (9/87)	314
4257	Barnhill, Danny LTC MC. GOG 99: A Phase III Randomized Study of Adjunctive Radiation Therapy in Intermediate Risk Endometrial Adenocarcinoma (10/87)	315
4261	Barnhill, Danny LTC MC. GOG 26Z: Phase II Trial of Leuprolide Acetate in Patients with Advanced Epithelial Ovarian Carcinoma (4/88)	316
4263	Barnhill, Danny LTC MC. GOG 26X: A Phase II Trial of Gallium Nitrate in Patients with Advanced Pelvic Malignancies (6/88)	317
4264	Barnhill, Danny LTC MC. GOG 26Y: A Phase II Trial of Vinblastine in Patients with Advanced Pelvic Malignancies (6/88)	318
4265	Barnhill, Danny LTC MC. GOG 102 A-B (Master Protocol): Intraperitoneal Administration of Cisplatin and 5-FU in Residual Ovarian Carcinoma, Phase II (6/88)	319
4266	Barnhill, Danny LTC MC. GOG 76A: Master Protocol for Phase II Drug Studies in the Treatment of Advanced or Recurrent Squamous Cell Carcinoma of the Cervix. (7/88)	320

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
DEPARTMENT OF OBSTETRICS AND GYNECOLOGY		
Gynecologic Oncology Group (continued)		
4267	Barnhill, Danny LTC MC. GOG 76I: A Phase II Trial of Ifosfamide and the Uroprotector, Mesna, in Patients with Advanced Squamous Cell Carcinoma of the Cervix (8/88)	321
DEPARTMENT OF PATHOLOGY AND AREA LABORATORIES		
4800	Webster, Noel CPT MS. Quantification of Leukocytes and Leukocyte Antigens in Various Red Cell Products (8/88)	322
4801	Dillon, Ruth CPT USAF BSC. Fibrinogen Concentration in Two Methods of Cryoprecipitate Preparation (9/88)	323
4802	Ferguson, Dale 1LT USAF. Detection and Quantitation by Flow Cytometry of Opsonic Protein Binding to Erythrocytes in a Simulated Incompatible Transfusion (9/88)	324
DEPARTMENT OF PEDIATRICS		
6038	Maybee, David COL MC. Collection and Cryopreservation of Spleen Cells for the Production of Monoclonal Antibodies (4/83)	325
6042	Maybee, David COL MC. C-Reactive Protein in Childhood Malignancies (2/84)	326
6043	Figelman, Alan LTC MC. Q-Angles: Their Measurement, Normals and Variations Related to Tanner Staging and the Incidence of Knee Complaints (3/84)	327
6045	Weisman, Leonard LTC MC. Prophylactic Intravenous Immunoglobulin in High Risk Neonates (6/84)	328
6046	Weisman, Leonard LTC, MC. Breast Milk Antibody to Group B Streptococcus (GBS) (10/84)	329
6050	Weisman, Leonard LTC MC. Phase II Oral Colonization and Systemic Group B Streptococcal (GBS) Disease in a Suckling Rat Model (6/85)	330
6051	Poth, Merrily MD. Effect of Adrenarchal Stage on Treatment of Precocious Puberty with Leuprolide, a GnRH Analogue (11/85)	331

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
DEPARTMENT OF PEDIATRICS (continued)		
6054	Hastings, Constance COL MC. Response to Combination Meningococcal Vaccine in Children (5/86)	332
6055	Heiman, Howard MAJ MC. The Effect of Maternal Group B Streptococcal Vaccination on Neonatal Mortality Using a Rat Model (8/86)	333
6056	Keith, Julian LCDR MC USN. The Impact of Maternal Protein-Calorie Deprivation During Late Gestation and in the Early Postpartum Period on Infection Related Mortality after Colonization with Orally Administered Type III Group B Streptococci in the Suckling (8/86)	334
6057	Rogers, William MD. Effects of Etiocholanolone on Thyroid Hormone Metabolism and Response to Cold Stress in Zucker Obese Rats (9/86)	335
6058	Young, Elizabeth CPT MC. Measurement of Fecal Alpha-1-Antitrypsin Excretion in Newborns at Risk for Necrotizing Enterocolitis (9/86)	336
6059	Poth, Merrily MD. Malondialdehyde Production by Neonatal Erythrocytes (9/86)	337
6060	Fischer, Gerald COL MC. Rapid Detection of Group B Streptococci in Cervical-Vaginal and Amniotic Fluid of High Risk Pregnancies (10/86)	338
6061	Edwards, Erwood MAJ MC. Granulopoiesis and Megakaryocytopoiesis in Human Cord Blood (4/87)	339
6062	Wilson, Bruce LTC MC. Sexual Dimorphism of the Human Corpus Callosum: Evaluation by Nuclear Magnetic Resonance Imaging (12/87)	340
6063	Crudo, David MAJ MC. The Effect of Mestinon on Growth in Non-growth Hormone Deficient Short Children (2/88)	341
6156	Weisman, Leonard LTC MC. Perinatal Hyperviscosity (3/83)	342

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE* (VOL II)</u>
DEPARTMENT OF PEDIATRICS (continued)		
6191	Maybee, David COL MC. POG 8616 Intensive Chemotherapies for Stage III Diffuse Undifferentiated Lymphoma (DU NHL Burkitt and Non-Burkitt), A Randomized Phase III Study (1/87)	343
6215	Jesse, Steven CPT MC. The Enteral Absorption of Human IgG by the Neonatal Guinea Pig and Its Retention of Opsonic Activity Type III Group B Streptococcus (5/88)	344
6219	Maybee, David COL MC. Chronic Stress, Change in Social Support, and Uncertainty (7/88)	345
9089	Margileth, Andrew MD. Etiology of Chronic Lymphadenopathy in Children and Adolescents (6/80)	346
9090	Weisman, Leonard LTC MC. Modified Immune Serum Globulin in Neonates (11/80)	347
DEPARTMENT OF PEDIATRICS Pediatric Oncology Group		
6121	Maybee, David COL MC. POG 7799 Rare Tumor Registry (1/80)	348
6144	Maybee, David COL MC. POG 8158 NWTS Long Term Follow-up Study (2/82)	349
6148	Maybee, David COL MC. POG 8104 Comprehensive Care of the Child with Neuroblastoma: A Stage and Age Oriented Study, Phase III (5/82)	350
6157	Maybee, David COL MC. POG 8304 Combination Chemotherapy for Remission Induction and Maintenance for Recurrent Childhood Lymphocytic Leukemia and Children with Occult Testicular Lymphocytic Leukemia, Phase III (7/83)	351
6162	Maybee, David COL MC. POG 8451 Intergroup Rhabdomyosarcoma III (12/84)	352
6165	Maybee, David COL MC. POG 8346 Comprehensive Therapy for Ewing's Sarcoma: Tailored Vs. Standard Radiation Therapy, Phase III (4/85)	353

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF PEDIATRICS</b>		
<b>Pediatric Oncology Group (continued)</b>		
6166	Maybee, David COL MC. POG 8552 A Case-Control Study of Childhood Rhabdomyosarcoma (5/85)	354
6169	Maybee, David COL MC. POG 8493 Infant Leukemia Protocol, Group-Wide Pilot (6/85)	355
6171	Maybee, David COL MC. POG 8315 Laboratory Study and Subclassification of Non-Hodgkin's Lymphoma, A Non-therapeutic Study (7/85)	356
6175	Maybee, David COL MC. POG 8532 Treatment of Intracranial Ependymomas, A Pediatric Oncology Group Phase III Study (1/86)	357
6176	Maybee, David COL MC. POG 8600 Laboratory Methods for POG 8600 ALinC 14 Classification (C) Portion, Laboratory Manual, A Non-Therapeutic Study (4/86)	358
6177	Maybee, David COL MC. POG 8602 Evaluation of Treatment Regimens in Acute Lymphoid Leukemia of Childhood (ALinC14), A POG Phase III Study (5/86)	359
6178	Maybee, David COL MC. POG 8601 ALinC14 Pharmacology, A POG Non-Therapeutic Study (5/86)	360
6179	Maybee, David COL MC. POG 8561 Phase II Study of 6-Mercaptopurine Administered as an Intravenous Infusion for Malignant Solid Tumors and Acute Leukemia (5/86)	361
6181	Maybee, David COL MC. POG 8625/8626 Combined Therapy and Restaging in the Treatment of Stages I, IIA, IIIA Hodgkin's Disease in Pediatric Patients, A Phase II Study (6/86)	362
6182	Maybee, David COL MC. POG 8653/8654 A Study of Childhood Soft Tissue Sarcoma Other Than Rhabdomyosarcoma and Its Variants, A POG Phase III Study (7/86)	363
6183	Maybee, David COL MC. POG 8498 Treatment of Children with Newly Diagnosed Acute Nonlymphoblastic Leukemia Using High-Dose Cytosine Arabinoside and Etoposide + Azacytidine for Intensification of Early Therapy, A POG Pilot Study (7/86)	364

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
DEPARTMENT OF PEDIATRICS		
Pediatric Oncology Group (continued)		
6184	Maybee, David COL MC. POG 8653 Study of Childhood Soft Tissue Sarcomas Other than Rhabdomyosarcoma and Its Variants, A POG Phase III Study (8/86)	365
6187	Maybee, David COL MC. POG 8622 Evaluation of Retinoic Acid in Pediatric Patients with Acute Non-lymphocytic Leukemia, A POG Phase II Study (9/86)	366
6188	Maybee, David COL MC. POG 8650 National Wilm's Tumor Study - 4; A POG Phase III Study (10/86)	367
6189	Maybee, David COL MC. POG 8662 Phase II Trial of Mitoxantrone (DHAD) in ALL (11/86)	368
6192	Maybee, David COL MC. POG 8651 Osteosarcoma Study 2: A Randomized Trial of Pre-Surgical Chemotherapy Vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma, A POG Phase III Study (1/87)	369
6193	Maybee, David COL MC. POG 8615 A Phase III Study of Large Cell Lymphomas in Children and Adolescents, A Comparison of Two Treatment Regimens, ACOP+ Vs. APO (2/87)	370
6194	Maybee, David COL MC. POG 8617/8618 Therapy for B-Cell Acute Lymphoblastic Leukemia and Advanced Diffuse Undifferentiated Lymphomas, A Phase II Study (2/87)	371
6195	Maybee, David COL MC. POG 8633/8634 The Treatment of Children Less Than Three Years of Age with Malignant Brain Tumors Using Postoperative Chemotherapy and Delayed Irradiation, A POG Phase II Study (4/87)	372
6196	Maybee, David COL MC. POG 8741/8742 Treatment of Stage D Neuroblastoma in Children Greater than 365 Days at Diagnosis, A POG Phase II/III Study (4/87)	373
6197	Maybee, David COL MC. POG 8638: Randomized Phase II Study of Carboplatin Vs. CHIP in the Treatment of Children with Progressive or Recurrent Brain Tumors (5/87)	374

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

PROTOCOL NUMBER	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF PEDIATRICS</b>		
<b>Pediatric Oncology Group (continued)</b>		
6198	Maybee, David COL MC. POG 8743: Treatment in "Better Risk" Neuroblastoma, POG Stage B (All Ages), And POG Stage C,D, and DS (IVS) Less Than 365 Days, A POG Phase III Study (5/87)	375
6199	Maybee, David COL MC. POG 8704: T-Cell #3 Protocol, A POG Phase III Study (6/87)	376
6200	Maybee, David COL MC. POG 8631: Medulloblastoma Favorable Prognosis: Randomized Study of Reduced Dose Irradiation to Brain and Spinal Contents Vs. Standard Dose Irradiation, A POG Phase III Study in Conjunction with CCSG (6/87)	377
6201	Maybee, David COL MC. POG 8695: A POG Pilot Study of Front-Loading Chemotherapy in Children with Increased Risk Medulloblastoma (6/87)	378
6202	Maybee, David COL MC. POG 8739: Evaluation of Alpha Interferon in the Treatment of Recurrent Brain Tumors in Children, A POG Phase II Study (7/87)	379
6203	Maybee, David COL MC. POG 8661: Evaluation of CHIP in Malignant Solid Tumors, A POG Phase II Study (7/87)	380
6204	Maybee, David COL MC. POG 8751: Low Dose Methotrexate in the Treatment of Rhabdomyosarcoma, A POG Phase II Study (7/87)	381
6205	Maybee, David COL MC. POG 8759: The Effectiveness of Phase II Agents in Untreated Metastatic Osteosarcoma or Unresectable Primary Osteosarcoma Vs. Previously Treated Recurrent Osteosarcoma, POG Phase II/III Study (8/87)	382
6206	Maybee, David COL MC. POG 8763: Evaluation of Response and Toxicity of Ifosfamide and VP-16-213 in Children with Resistant Malignant Tumors, A POG Phase II Study (8/87)	383
6207	Maybee, David COL MC. POG 8719: Trial of Shortened Therapy without Maintenance for the Treatment of Localized Non-Hodgkin's Lymphoma, A POG Phase III Study (9/87)	384
6208	Maybee, David COL MC. POG 8693: VP-16, AMSA + 5-Azacytidine in Refractory Acute Nonlymphocytic Leukemia A POG Pilot Study (9/87)	385

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
DEPARTMENT OF PEDIATRICS		
	Pediatric Oncology Group (continued)	
6209	Maybee, David COL MC. POG 8726: Alpha-Interferon in Histiocytosis X and Other Non-Malignant Histiocytic Disease, A POG Phase II Study (9/87)	386
6210	Maybee, David COL MC. POG 8761: A Phase II Study of Homoharringtonine for the Treatment of Children with Refractory Nonlymphoblastic Leukemia (9/87)	387
6211	Maybee, David COL MC. POG 8731: A Phase II Study of Low-Dose "Continuous" Oral Methotrexate in the Treatment of Children with Progressive or Recurrent Brain Tumors (10/87)	388
6212	Maybee, David COL MC. POG 8764: Chemotherapy Regimen for Early and Initial Induction Failures in Childhood Acute Lymphoblastic Leukemia, A POG Phase II Study (10/87)	389
6213	Maybee, David COL MC. POG 8823/24: Recombinant Alpha Interferon in Childhood Chronic Myelogenous Leukemia, Phase II (12/87)	390
6214	Maybee, David COL MC. POG 8696/97: Treatment of Hepatoblastoma (HB) with Surgery, Chemotherapy, and Radiation Therapy (4/88)	391
6216	Maybee, David COL MC. POG 8710: Protocol for Second Induction and Maintenance in Childhood Acute Lymphoblastic Leukemia (SIMAL #5), A POG Phase III Study (5/88)	392
6217	Maybee, David COL MC. POG 8725: Randomized Study of Intensive Chemotherapy (MOPP/ABVD Plus/Minus Low Dose Total Nodal Radiation Therapy in the Treatment of Stages IIB, IIIA2, IIIB, IV Hodgkin's Disease in Pediatric Patients, Phase III (5/88)	393
6221	Maybee, David COL MC. POG 8821: Intensive Multiagent Therapy Vs. Autologous Bone Marrow Transplant Early in First CR for Children with Acute Myelocytic Leukemia - A Phase III Study (9/88)	394

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

PROTOCOL NUMBER	PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE	PAGE* (VOL II)
--------------------	--	-------------------

PREVENTIVE MEDICINE

- |      |   |     |
|------|---|-----|
| 3500 | Tomlinson, Pitt COL MC. Effectiveness and Cost Efficacy of Interventions in Health Promotion (5/88) | 395 |
|------|---|-----|

DEPARTMENT OF PSYCHIATRY

- |      |  |     |
|------|--|-----|
| 7234 | West, Pat DAC. The Effect of Two Types of Exercise Programs on Body Boundary in Patients Diagnosed with Schizophreniform Disorder (3/87)                 | 396 |
| 7235 | Chermol, Brian COL MS. Evaluation of Treatment Choices Used in Alcohol Rehabilitation Programs (5/87)  | 397 |
| 7236 | Rock, Nicholas COL MC. Anafranil Protocol 62, Humanitarian Use of Anafranil in Obsessive Compulsive Disorder (7/87)                                      | 398 |
| 7237 | Watanabe, Henry COL MC. The Role of Cognitive and Treatment Factors on Outcome and Attrition in Smoking Cessation (1/88)                                 | 399 |
| 7238 | McCarroll, James LTC MS. Stability of Incidence of Head Injury in the U.S. Army (5/88)   | 400 |
| 7239 | Blair, Sidney CPT MC. Visual Information Processing in Psychiatric Patients (7/88)   | 401 |
| 9106 | Jones, Franklin MD. Differences in Proportions of Diagnosis Between Ethnic Groups: The Case of Puerto Rican Psychiatric Patients in the Military (12/84) | 402 |

DEPARTMENT OF RADIOLOGY

- |      |   |     |
|------|---|-----|
| 4525 | Anderson, Jay COL MC. Intravenous Administration of I-131-6-B Iodomethylnorcholesterol for Adrenal Evaluation and Imaging (11/80)   | 403 |
| 4527 | Anderson, Jay COL MC. Technetium (Tc99m) Antimony Trisulfide Colloid - A Lymphoscintigraphic Agent (11/81)  | 404 |
| 4531 | Anderson, Jay COL MC. Diagnostic Imaging of Adrenal Medulla (Pheochromocytoma, Paragangliomas, and Neuroblastomas) with I-131 MIBG (Metaiodobenzylguanidine Sulfate) (9/84) | 405 |

---

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
DEPARTMENT OF RADIOLOGY (continued)		
4534	Anderson, Jay COL MC. Strontium Sr-89 Chloride for Palliation of Bone Pain in Subjects with Metastatic Bone Disease (6/88)	406
4535	Meglin, Allen CPT MC. Pharyngeal and Esophageal Manifestations of Rheumatoid Arthritis (8/88)	407
SOCIAL WORK SERVICE		
9502	Robichaux, Rene CPT MS. The Relationship Between Father Involvement in Child Care and the Child's Development (11/86)	408
DEPARTMENT OF SURGERY		
Anesthesia-Operative Service		
2023A	Karan, Steven CPT MC. In Vitro Determination of the Response of Skeletal Muscle to Halothane, Caffeine and Halothane Plus Caffeine (12/85)	409
2025A	Dewerd, Gregory MAJ MC. Absorption of Fentanyl by Silicone and Holofiber Membrane Oxygenators (8/87)	410
2026A	Hall, Dennis MAJ MC. The Use of Fetal Scalp Electrodes in Electrophysiologic Neurologic Monitoring (8/88)	411
2032A	Biggerstaff, Michael CPT MC. Pain Control After Thoracotomy and Its Effect on Pulmonary Function (9/88)	412
DEPARTMENT OF SURGERY		
Critical Care Medicine Service		
3001	Snyder, Richard MAJ MC. Incidence of EKG and Cardiac Enzyme Abnormalities as an Indicator of Ischemic Heart Injury in Vascular Patients Undergoing Surgery (4/85)	413
3005	Snyder, Richard MAJ MC. Absorption of Fentanyl by Intravenous Fluid Containers and Tubing (10/87)	414

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF SURGERY</b>		
General Surgery Service		
2021	Daniel, James MAJ MC. Case Control Study of the Etiologic Role of Fecal Mutagens and Related Aspects of Diet in Colorectal Cancer (3/85)	415
2026	Molloy, Mark CPT MC. The Role of Staging Laparotomy in Hodgkin's Disease - A Review of the WRAMC Experience (12/87)	416
2027	Baska, Robert CPT MC. Polyamine Levels in Recurrent Colon Cancer and Ulcerative Colitis (12/87)	417
2028	Baska, Robert. Serologic Analysis of Gastrointestinal Ischemia and its Relationship to Fecal Blood Loss During a One Hundred Mile Ultramarathon (4/88)	418
2029	Little, Julia CPT MC. Breast Cancer in Women 35 and Younger (8/88)	419
2030	Molloy, Mark CPT MC. Risks and Perioperative Complications of Insertion of Long Term Venous Access Devices (8/88)	420
2031	Baska, Robert CPT MC. Gastrointestinal Blood Loss During Marathon Running and the Effect of Cimetidine on its Prevention (9/88)	421
<b>DEPARTMENT OF SURGERY</b>		
Ophthalmology Service		
2310	Thomassen, Thomas LTC MC. Intraocular Lens (1/78)	422
2317	Kramer, Kenyon COL MC. Intraocular Irrigating Solutions: Effect on Corneal Endothelium (4/83)	423
<b>DEPARTMENT OF SURGERY</b>		
Organ Transplant Service		
2610	Fernandez, Carlos MAJ MC. Use of Antilymphocyte Preparation in Renal Transplantation (5/73)	424
2629	Shaver, Timothy MAJ MC. Use of Cyclosporine A Levels in Determination of Therapeutic Dosages (10/83)	425

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF SURGERY</b>		
Organ Transplant Service (continued)		
2630	Shaver, Timothy MAJ MC. The Concomitant Use of Azathioprine and Pretransplant Transfusions (11/83)	426
2631	Fernandez, Carlos MAJ MC. Development of an Extracorporeal Liver Support System (1/86)	427
2632	Shaver, Timothy MAJ MC. Treatment with Liver Transplantation and Human Monoclonal Anti-Hepatitis B Virus IgG of a Hepatitis B Virus Carrier who has End Stage Chronic Active Hepatitis (7/88)	428
<b>DEPARTMENT OF SURGERY</b>		
Orthopedics Surgery Service		
2400	Hopkinson, William LTC MC. Clinical and Biomechanical Investigation of Knee Ligament Laxity with Emphasis on Objective and Functional Short and Long-Term Results (9/80)	429
2401	Hopkinson, William LTC MC. Evaluation of Porous Coated Total Knee and Hip Prostheses in Achieving a Stable Prosthesis Bone Interface (8/83)	430
2404	Hopkinson, William LTC MC. Characterization of the Postoperative Radionuclide Scan Patterns in Patients with Porous Coated Total Hip Prostheses (10/84)	431
2406	Polly, David CPT MC. Selective Magnetic Resonance Imaging of the Knee Compared to Arthroscopy: A Large Scale Clinical Trial (11/86)	432
2408	Callaghan, John MAJ MC. Retrospective Review of Indium-III White Blood Cell Scanning in Orthopedic Patients (2/87)	433
2409	Hopkinson, William LTC MC. Creatine Phosphokinase and Lactic Dehydrogenase Elevations in Total Joint Arthroplasty, Anterior Spinal Fusion and Operative Treatment of Hip Fractures (7/87)	434
2410	Hopkinson, William LTC MC. The Use of Arthroscopic Abrasion Chondroplasty in the Treatment of Osteoarthritis of the Knee (8/87)	435

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF SURGERY</b>		
Orthopedics Surgery Service (continued)		
2411	Van Dam, Bruce LTC MC. Evaluation of Spinal Instrumentation in Posterior Spinal Fusion Using Radionuclide Imaging (9/88)	436
<b>DEPARTMENT OF SURGERY</b>		
Otolaryngology-Head & Neck Service		
2561	Montgomery, Allen PhD. Development of a Procedure for Assessing the Perceptual-Motor Control of Speech (7/84)	437
2569	Prosek, Robert PhD. Parameterization of Electroglossographic Signals for Patients with Voice Disorders (6/85)	438
2570	Erdman, Sue Ann MA. Retest Reliability of the Communication Profile for the Hearing Impaired (10/85)	439
2571	Walden, Brian PhD. Development of a Procedure to Determine the Intelligibility of Continuous Discourse Under Realistic Listening Conditions (10/85)	440
2572	Montgomery, Allen PhD. Improving the Quality of Electrolaryngeal Voice: Evaluation of a New Method for Generating the Driving Signal Based on Computer Simulation of Natural Laryngeal Vibration (10/85)	441
2573	Walden, Brian PhD. Perceived Hearing Aid Benefit by Persons with High Frequency Hearing Loss (10/85)	442
2574	Fabry, David PhD. Evaluation of a Model of Measurement Error for Retesting Speech Recognition (4/86)	443
2577	Walden, Brian PhD. The Effects of Amplification and Visual Cues on Auditory Consonant Recognition Ability (7/86)	444
2578	Montgomery, Allen PhD. Effects of Consonant/Vowel Intensity Ratio on Speech Loudness (10/86)	445
2580	Brammer, Robert LTC MC. A Short Course in Rigid Bronchoesophagology (3/87)	446
2581	Mitchell, Deborah CPT MC. Comparison of Rigid Endoscopy with Flexible Endoscopy and Radiographic Studies in the Diagnosis of Pediatric Airway Obstruction (6/87)	447

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF SURGERY</b>		
<b>Otolaryngology-Head &amp; Neck Service (continued)</b>		
2582	Casler, John CPT MC. The Effect of Skin Undermining and Skin Excision on the Degree of Decreased Wound Closing Tension with SMAS Plication in Fresh Cadavers (11/87)	448
2583	Walden, Brian PhD. The Role of Hearing Impairment in the Visual Biasing of Auditory Speech Perception (12/87)	449
2584	Burgess, Lawrence MAJ MC. Evaluation of Patients with Obstructive Sleep Apnea Syndrome Following Uvulopalatopharyngoplasty (2/88)	450
2585	Mitchell, Deborah CPT MC. Incidence of Maxillary Sinusitis in Nasally Intubated Patients (3/88)	451
2586	Chi-Fishman, Gloria DAC. Acoustic Analysis of Normal and Abnormal Swallows (4/88)	452
2587	Erdman, Sue Ann DAC. Post-treatment Utilization of the Communication Profile for the Hearing Impaired (6/88)	453
2588	Leek, Marjorie PhD. Hearing Loss and the Perception of Complex Sounds (8/88)	454
<b>DEPARTMENT OF SURGERY</b>		
<b>Peripheral Vascular Surgery Service</b>		
2111	Sharefkin, John MD. Normalization of Endothelial Phenotype on Vascular Grafts (5/88)	455
<b>DEPARTMENT OF SURGERY</b>		
<b>Plastic Surgery Service</b>		
2906	Seyfer, Alan COL MC. Intracellular Studies with Epidermal Growth Factor (3/88)	456
<b>DEPARTMENT OF SURGERY</b>		
<b>Thoracic Surgery Service</b>		
2709	Graeber, Geoffrey LTC MC. Adverse Reactions and Anti-Protamine Antibodies in Patients Undergoing Cardiopulmonary Bypass (4/86)	457

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL NUMBER</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>DEPARTMENT OF SURGERY</b>		
	Thoracic Surgery Service (continued)	
2710	Albus, Robert COL MC. Fresh Tissue Procurement for NIH Tissue Culture (4/87)	458
<b>DEPARTMENT OF SURGERY</b>		
	Urology Service	
2814C	McLeod, David COL MC. NPCPP 900 A Comparison of Long-term Adjuvant Chemotherapy with Cyclophosphamide, Estracyt, or no Additional Treatment in Patients with Definitive Surgical Treatment for Adenocarcinoma of the Prostate (4/80)	459
2814D	McLeod, David COL MC. NPCPP 1000 A Comparison of Long-term Adjuvant Chemotherapy with Cyclophosphamide, Estracyt, or no Additional Treatment in Patients who have had Definitive External Beam or Interstitial Radiotherapy for Adenocarcinoma of the Prostate (4/80)	460
2824	McLeod, David COL MC. NPCPP 1700 A Comparison of Diethylstilbestrol (DES) or Orchiectomy vs. Buserelin vs. DES or Orchiectomy Plus Methotrexate in Newly Diagnosed Patients with Clinical Stage D Carcinoma of the Prostate who have not had Hormonal Treatment or Orchiectomy (2/83)	461
2837	McLeod, David COL MC. NPCP 2200 A Comparison of Leuprolide with Leuprolide and Flutamide in Previously Untreated Patients with Clinical Stage D2 Cancer of the Prostate (2/85)	462
2839	McLeod, David COL MC. UCOG 100: A Phase II Trial of Interferon Alpha 2-b (INTRON A) as Adjunct Therapy in Resected Renal Cell Carcinoma at High Risk or Relapse (2/87)	463
2840	McLeod, David COL MC. A Multicenter Fixed-Dose Study of the Safety and Efficacy of Terazosin in the Treatment of Patients with Benign Prostatic Hypertrophy (5/87)	464
2841	McLeod, David COL MC. North American Genitourinary Study Group (12/87)	465
2842	McLeod, David COL MC. A Multicenter Comparison of the Safety and Efficacy of Lomefloxacin and Norfloxacin in the Treatment of Complicated Urinary Tract Infection (9/88)	466

\* Reference is to page number(s) in Volume II.

PROTOCOL NUMBER, PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE  
BY DEPARTMENT AND SERVICE

<u>PROTOCOL</u>	<u>PRINCIPAL INVESTIGATOR, TITLE, AND APPROVAL DATE</u>	<u>PAGE*</u> <u>(VOL II)</u>
<b>VETERINARY SERVICES</b>		
9800	Mouer, Thomas DAC. Mouse Inoculation Test-Rabies Diagnosis (12/86)	467
9801	Mouer, Thomas DAC. Production of Positive and Negative Control Slides and Mouse Brain Suspension for Fluorescent Rabies Antibody Test (12/86)	468
<b>ARMED FORCES INSTITUTE OF PATHOLOGY</b>		
	Biochemistry Division	
7800	Fishbein, William MD. The King Laer Test (11/85)	469
<b>ARMY COMMUNITY HOSPITALS, MEDDACS</b>		
	Walson AH, Fort Dix, NJ	
9087	Mithani, Hasmukhlal MAJ MC. Intraocular Lens Implantation (12/79)	470
<b>ARMY COMMUNITY HOSPITALS</b>		
	Ireland AH, Fort Knox, KY	
8100	Warncke, Ronald LTC MC. Utilization of Goats for Training of DOD Medical Department Officers During Conduct of the Advanced Trauma Life Support Course (ATLS) at the US Army Medical Dept Act, Ft Knox, KY (5/87)	471
<b>ARMY COMMUNITY HOSPITALS</b>		
	Womack ACH, Fort Bragg, NC	
9900	Rowbothom, Linda CPT SP. Advanced Liquid Diet Evaluation (4/87)	472
9901	Dillis, Charlotte MAJ MC. Clinical Testing of the Lightweight Special Forces X-Ray System (5/88)	473
9902	Magruder, Charles CPT MC. Acceptability of Spermicide-Lubricated Condoms Among U.S. Military Personnel (6/88)	474

\* Reference is to page number(s) in Volume II.

DEPARTMENT/SERVICE INDEX TO LIST OF PUBLICATIONS/PRESENTATIONS

	page
ALLERGY/IMMUNOLOGY SERVICE .....	76
CLINICAL INVESTIGATION, DEPARTMENT OF.....	76
HIV RESEARCH .....	76
DEPARTMENT OF MEDICINE	
Cardiology Service .....	79
Endocrine-Metabolic Service .....	80
Gastroenterology Service .....	81
Hematology-Oncology Service .....	82
Infectious Disease Service .....	83
Nephrology Service .....	83
Pulmonary Disease Service .....	83
NEUROLOGY SERVICE .....	
	84
PEDIATRICS, DEPARTMENT OF .....	84
PSYCHIATRY, DEPARTMENT OF .....	85
DEPARTMENT OF SURGERY	
General Surgery Service .....	86
Orthopedic Surgery Service .....	86
Otolaryngology-Head & Neck Service .....	86
ARMED FORCES INSTITUTE OF PATHOLOGY .....	86

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

<u>CITATION*</u>	<u>TYPE**</u>
ALLERGY/IMMUNOLOGY SERVICE	
Collins L, Engler R: Enhanced yellow jacket specific IgE following natural sting associated anaphylaxis despite maintenance venom immunotherapy. J Allergy Clin Immunol, 81(1):169(ab3), 1988. [3221]	Ab
Engler R, Kaloka H, Squire E, Smith L, Summers R: Venom specific G (VSG) and G4 (VSG4) levels in patients with positive skin tests and a history of anaphylaxis prior to immunotherapy. J Allergy Clin Immunol, 81(1):201(ab131), 1988. [3221]	Ab
Squire E: Ipratropium bromide for steroid dependent asthma: an addition to control or to polypharmacy. JAMA, 1989. [3337]	P
DEPARTMENT OF CLINICAL INVESTIGATION	
Dobek A, Rothman S: Competitive ELISA analysis of clostridium difficile toxin A with monoclonal antibodies. Annual meeting, Am Soc for Microbiology, Miami Beach, FL, May 1988. [9027]	Pr
Tarazi E, Harter J: An evaluation of NONMEM's estimates of pharmacokinetic parameters of digoxin. COSTEP Assignment, August, 1988. [9255]	Pr
HIV RESEARCH	
Buzy J, Brenneman D, Salazar A, Martin A, Ruff M, Pert C: CSF from patients with early HIV infection produces neuronal cell killing in vitro: Prevention by Peptide T. V International Conference on AIDS, Montreal, Canada, June, 1989. [7128]	Pr
Coats M, Salazar A, Martin A, Jabbari B, Geyer C, Burke D: In connection with the Walter Reed Retrovirus Research Group: Neurologic findings in early HIV infection. V International Conference on AIDS, Montreal, Canada, June, 1989. [7128]	Pr
Heyes M, Brew B, Markey S, Martin A, Price R, Salazar A: Quinolinic acid concentrations are increased in plasma and cerebrospinal fluid in AIDS and correlates with AIDS dementia. International Study Group for Tryptophan Research, Baltimore, MD, May, 1989. [7128]	Pr
Heyes M, Brew B, Markey S, Martin A, Price R, Rubinow D, Salazar A: Quinolinic acid concentrations are increased in plasma and cerebrospinal fluid in AIDS and correlates with AIDS dementia complex. V International Conference on AIDS, Montreal, Canada, June, 1989. [7128]	Pr

\* Number in [] is the protocol number.

\*\* P = publication, Ab = abstract, Pr = presentation

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

<u>CITATION*</u>	<u>TYPE**</u>
HIV RESEARCH (continued)	
Heyes M, Brew B, Markey S, Martin A, Price R, Salazar A: Increased quinolinic acid and decreased L-Tryptophan in plasma and cerebrospinal fluid in AIDS: Correlates to AIDS dementia complex. Neurological and Neuropsychological Complications of HIV Infection Satellite Conference, V International Conference on AIDS, Quebec City, Canada; Jun, 1989. [7128]	Pr
Heyes M, Brew B, Martin A, Markey S, Price R, Salazar A: Increased quinolinic acid and decreased L-Tryptophan in CSG and plasma in HIV infection. Society for Neuroscience Annual Meeting, Phoenix, AR; Oct, 1989. [7128]	Pr
Heyes M, Brew B, Martin A, Price R, Salazar A: Cerebrospinal fluid quinolinic acid and kynurenic acid in HIV-1 infection and AIDS dementia complex: increased ratio of quinolinic acid to kynurenic acid. Annals of Neurology. In press. [7128]	P
Heyes M, Brew B, Martin A, Price R, Salazar A, Markey S, Lackner A: Increased ratio of quinolinic acid: Kynurenic acid and decreased L-Tryptophan in CSF and plasma in HIV-1 infection of man and D/l/California infection of macaques. American College of Neuropsychopharmacology, Honolulu, Hawaii; Dec, 1989. [7128]	Pr
Martin A, Grafman J: AIDS dementia: Diagnosis, research and treatment. Journal of Clinical and Experimental Neuropsychology, 10:23, 1988. [7128]	Ab
Martin A, Kampen D, Salazar A, Williams J, Law W, Roller T: Walter Reed Retrovirus Research Group: Neuropsychological evidence for early involvement of the basal ganglia region in a subgroup of HIV+ individuals. V International Conference on AIDS, Montreal, Canada, June, 1989. [7128]	Pr
Martin A, Kampen D, Salazar A, Williams J, Law W, Roller T: The Walter Reed Retrovirus Research Group: Slowed cognitive processing in HIV+ patients in comparison to psychiatric controls. V International Conference on AIDS, Montreal, June, 1989. [7128]	Pr
Martin A, Salazar A, Kampen D, Williams J, Law W, Gomez C: Walter Reed Retrovirus Research Group: Patterns of neuropsychological dysfunction in a select group of HIV+ individuals in comparison to psychiatric controls. V International Conference on AIDS, Montreal, Canada, Jun, 1989. [7128]	Pr

\* Number in [] is the protocol number.

\*\* P - publication, Ab - abstract, Pr - presentation

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

<u>CITATION*</u>	<u>TYPE**</u>
HIV RESEARCH (continued)	
Martin A, Salazar A, Williams J, Law W, Roller T, Coats M, Hawkes C: The Walter Reed study on the neurobehavioral consequences of HIV+ infection. Walter Reed Army Institute of Research, Washington, DC, Mar 1989. [7128]	Pr
Martin A: The search for the neuropsychological profile of a disease state: A mistaken enterprise? Journal of Clinical and Experimental Neuropsychology, 10:22, 1988. [7128]	Ab
Martin A: Walter Reed Study of the neurobehavioral consequences of HIV infection: preliminary report. World Health Organization Consultation on Neuropsychiatric Aspects of HIV Infection, Geneva, Switzerland, Mar 1988. [7128]	Pr
Martin A: The neuropsychology HIV infection: conceptual issues and preliminary findings. National Institute of Mental Health, Director of Intramural Research Program Lecture, Bethesda, MD, Oct 1988. [7128]	Pr
Martin A: Neuropsychological dysfunction in HIV infection: Relation to CSF quinolinic acid. NIMH/NINDS AIDS Neuroscience and Behavior Seminar, Bethesda, MD, May, 89. [7128]	Pr
Pettett G, Brundage J, Miller R, Horton J, Hemming V, Robb M, Fischer G: An empiric model for HIV infection in a low risk military population with emphasis on heterosexual and perinatal transmission. 5th National Pediatric AIDS Conference, Los Angeles, CA, September 6-8, 1989. [6220]	Pr
Robb M, Baker J, Toro L, Vincent J, Pettett G, Fischer G: Evaluation of mononuclear cell associated HIV antigen in infants and children. V International Conference on AIDS, June 4-9, 1989 Montreal, Canada. [6218]	Pr
Robb M, Fowler A, Dilworth S, Zawadsky P, Burke D, Vincent J, Morgan C, Pettett G, Redfield R, Ascher D, Fischer G: Overview of HIV culture in infants and children: diagnosis and staging. AIDS Conference, Paris France, 27-30 Nov, 1989. [6222]	Pr
Robb M, Vincent J, Fowler A, Dilworth S, Zawadsky P, Burke D: Influence of blood volume and transport on HIV cultures in infants and children. V International Conference on AIDS, Montreal, Canada, June 4-9, 1989. [6222]	Pr

\* Number in [] is the protocol number.

\*\* P - publication, Ab - abstract, Pr - presentation

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

CITATION\*

TYPE\*\*

HIV RESEARCH (continued)

- Robb M, Vincent J, Fowler A, Dilworth S, Zawadsky P, Burke D, Morgan C, Pettett G, Redfield R, Fischer G: Rapid and reliable diagnosis of pediatric HIV infection by HIV culture. 29th ICAAC, Houston, TX, 17-20 Sep, 1989. [6222] Pr
- Robb M, Vincent J, Fowler A, Dilworth S, Zawadsky P, Burke D, Morgan C, Pettett G, Redfield R, Fischer G: Relationship of HIV culture to disease stage in children. 5th National Pediatric AIDS Conference, Los Angeles, CA, 6-8 Sep, 1989. [6222] Pr
- Salazar A, Martin A, Coats M, Williams J, Law W, Roller T, Grave M, Gomez C: Neurobehavioral studies in early HIV infection. IV Panamerican Symposium of Neuroepidemiology, Columbia, May, 1989. [7128] Pr
- Vincent J, Bash M, Shanks D, Daigh D, Moriarty R, Fischer G: Neurologic symptoms as the initial presentation of HIV infection in pediatric patients. V International Conference on AIDS, Montreal, Canada, June 4-9, 1989. [6220] Pr

DEPARTMENT OF MEDICINE  
Cardiology Service

- Cambier P: Diltiazem in the treatment of Raynaud's phenomenon. Annual US Army Regional ACP Meeting, San Francisco, CA, Oct, 1988. [1246] Pr
- Cambier P: Diltiazem in the treatment of Raynaud's phenomenon, a placebo controlled, double blind study. Annual National Meeting of American College of Physicians, San Francisco, CA, Apr, 1989. [1246] Pr
- Laird J: The cardiotintogram for detecting coronary artery disease: a retrospective study. Army - American College of Physicians Regional Meeting, San Francisco, CA, Oct, 1989. [1250] Pr
- Weston L: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N. England J. Med 321:406-12, 1989. [1254] P

---

\* Number in [] is the protocol number.

\*\* P - publication, Ab - abstract, Pr - presentation

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

<u>CITATION*</u>	<u>TYPE**</u>
DEPARTMENT OF MEDICINE Endocrine-Metabolic Service	
Baker J, Saunders N, Kaulfersch W, Burman K: The development of human monoclonal antibodies from Graves' disease patients which demonstrate the ability to inhibit TSH-mediated production of cAMP in thyrocytes. J I, 140:2593, 1988. [1330-81]	P
Baker J, Saunders N, Polly S, Landry F, Stricker R, Burman K: Identification of thyroid history as auto-antigens using human mono level antibodies. Clinical Research, 37:356A, 1989. [1330-81]	P
Baker J, Saunders N, Tseng Y, Wartofsky L, Burman K: Seronegative Hashimoto thyroiditis with thyroid autoantibody production localized to the thyroid. Ann Intern Med, 108:26-30, 1988. [1330-81]	P
Behman D, Glass A, Tucci J, Eil C: The effect of ketoconazole therapy in a patient with primary hyperparathyroidism. Amer Soc Bone Min Res Meeting, 1988. [1376-86]	Pr
Brennan M, Duncan W, Wartofsky L: In vitro dissolution of calcium carbonate preparations. J Bone Min Res 3 (Suppl 1):366, 1988. Presented at the Tenth Annual Meeting of the American Society for Bone and Mineral Research, New Orleans, LA, June 1988. [1387-87]	Pr
Burman K: Epidermal growth factor receptor gene rearrangement in thyroid disease. Arnnual Meeting of the Thyroid Association, Montreal, Quebec, Canada, Sept, 1988. [1395-87]	Pr
Carr F, Kaseem L, Reid A: Sequence-specific binding of nuclear proteins to 5'-flanking DNA of the rat thyrotropin B subunit gene. Endocrine Society, June 1988. [1393-87]	Pr
Carr F, Wessendof M: A pre-prothyrotro, in-releasing hormone fragment is a more potent stimulation than thyrotropin-releasing hormone (TRH) of thyrotropin B-subunit (TSH B) gene epression in a transient expression assay. American Thyroid Assoc, September 1988. [1393-87]	Pr
Duncan W, Bikle D, Whitehead D, Nicholson D, Wray L: The vitamin D receptor decreases during liver regeneration. ASBMR/ICCRH, First Joint Meeting, Montreal, Canada September, 1989. [1389-87]	Pr

\* Number in [] is the protocol number.

\*\* P - publication, Ab - abstract, Pr - presentation

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

<u>CITATION*</u>	<u>TYPE**</u>
DEPARTMENT OF MEDICINE	
Endocrine-Metabolic Service (continued)	
Duncan W, Glass A, Whitehead D, Wray L: Regulation of the vitamin D receptor by estrogen is organ-specific. 71st Annual Meeting of the Endocrine Society, Seattle, WA, June 1989. [1363-85]	Pr
Duncan W: 1,25-Dihydroxyvitamin D receptors in liver and skeletal muscle. Seventh Workshop on Vitamin D, Poster Presentation, Rancho Mirage, CA, Apr, 1988. [1363-85]	Pr
Gauge S, Howard A, Moore J, Duncan W: Assessment of bone mass in dialysis patients. Kidney International 35(1):378, 1989. [1391-87]	Ab
Glass A, Reed W, Diehl L: Hematologic indexes in men attending an infertility clinic. Arch Andrology, 20:177-180, 1988. [1373-86]	P
Kaulfersch W, Baker J, Burman K, Ahmann A, D'Avis J, Waldmann T: Immunoglobulin and T cell gene rearrangements demonstrate that the immune response in autoimmune thyroid disease (AITD) is polyclonal in nature. J Clin Endocrinol Metab, 66:958-963, 1988. [1330-81]	P
DEPARTMENT OF MEDICINE	
Gastroenterology Service	
Kikendall J, Langenberg P, Magnetti C, Burgess M, Bowen P: Cigarette smoking and beer drinking are associated with colonic adenomas. Gastroenterology 94:A225, 1988. [1450]	Ab
Lyons M, Tsuchida A, Maydonovich C, Wong R, Gage T, Peura D: Hyperphosphatemia and acidemia in normal patients following routine colonic cleansing with Fleet hypertonic phosphate enemas. Gastroenterology, 94(5):A274, 1988. [1494]	Ab
Lyons M: Hyperphosphatemia and acidemia in normal patients following routine colonic cleansing with Fleet hypertonic phosphate enemas. AGA Poster Presentation, Digestive Disease Week, May 1988. [1494]	Pr
Moses F, Kikendall J, Bowen P, Young T: Chronic beta carotene supplementation does not alter the acute endoscopic response to aspirin. Amer J Gastroenterol, 83:1037, 1988. [1492]	Ab

\* Number in [] is the protocol number.

\*\* P - publication, Ab - abstract, Pr - presentation

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

<u>CITATION*</u>	<u>TYPE**</u>
<b>DEPARTMENT OF MEDICINE</b> Gastroenterology Service (continued)	
Moses F, Kikendall J, Bowen P, Young T: The effect of chronic beta-carotene upon the gastric mucosal response to acute aspirin ingestion. In review. [1492]	P
Moses F: Chronic beta carotene supplementation does not alter the acute endoscopic response of gastric mucosa to aspirin. William Beaumont Gastroenterology Symposium, 5th Ann Army ACP Scientific Mtg, San Francisco, CA, Oct, 1988. [1492]	Pr
<b>DEPARTMENT OF MEDICINE</b> General Medicine Service	
Reed W, Herbers J: Predicted and desired gains in life expectancy due to cholesterol-lowering therapy. Eastern Regional meeting of the Society for General/Internal Medicine, February 1988. [1021]	Pr
Reed W, Herbers J: Cholesterol-lowering therapy: What patients expect in return. Eastern Regional meeting of the Society for General/Internal Medicine, February, 1988. [1021]	Pr
<b>DEPARTMENT OF MEDICINE</b> Hematology-Oncology Service	
Bednarek J, Knight R, Taylor G, Evans W: Progressive loss of phenotypic proteins in mature granulocytes before the onset of blast crisis in human chronic myelogenous leukemia. JNCI 80:251-127, 1988. [1616-82]	P
Chun H, Roth J, Kelley J, Ward F, Weiss R, Balasubramianiam S, Lambardo F, Leyland-Jones B: Phase I bioavailability and pharmacokinetics of oral hexamethylene bisacetamide. AACR, 1988. [1638-86]	Ab
Evans W, Wilson S, Bednarek J, Peterson E, Knight R, Mage M, McHugh L: Evidence for a factor in normal human serum that induces human neutrophilic granulocyte end stage maturation in vitro. Leukemia Research, in press. [1649-87]	P
LaRussa V, Simms T, Salvado A, Wright D: Studies of the hematopoietic accessory cell functions of human marrow stromal cells developed in dextet cultures. Exp. Hematol 16:559, 1988. [9022-83]	Ab

\* Number in [] is the protocol number.

\*\* P - publication, Ab - abstract, Pr - presentation

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

<u>CITATION*</u>	<u>TYPE**</u>
<b>DEPARTMENT OF MEDICINE</b> Infectious Disease Service	
Hoover D, McClain J, Dobek A, Olson T, Nacy C, Joshi B: Synthesis of interleukin-1 (IL-1) by human monocytes culture in vitro with amphotericin B. Society for Leukocyte Biology Annual Meeting, Washington, DC, Oct 27-30, 1988. [1940]	Pr
McClain J, Baker J, Joshi B: Complement susceptibilities of virulent leptospiral. American Society for Microbiology, Miami, FL, 1988. [1933]	Pr
McClain J, Joshi B, Watt G: Characterization of leptospiral toxins. Intrascience Conference on Antimicrobial Agents and Chemotherapy Los Angeles, CA, 1988. [1933]	Pr
<b>DEPARTMENT OF MEDICINE</b> Nephrology Service	
Gouge S, Moore J, Hirszel P, Atkins F: Removal of radiocontrast agents (RCA) by dialysis membranes. National Kidney Foundation, 18th Annual Meeting, San Antonio, TX, 10 Dec 1988. [1152]	Pr
Gouge S, Moore J, Hirszel P, Atkins F: Removal of radiocontrast agents (RCA) by dialysis membranes. American Journal Kidney Diseases XIII(1):A7, Jan 1989. [1152]	Ab
Howard A, Moore J, Welch P, Gouge S: Analysis of the quantitative Relationship between anemia and chronic renal failure. Am J of Medical Sciences 297 (5):309-13, 1989. [1154]	P
Welch P, Howard A, Gouge S, Moore J: The relationship between the degree of anemia and the degree of chronic renal failure (CRF). Am J of Kidney Diseases XI(1):A23, January 1988. [1154]	Ab
<b>DEPARTMENT OF MEDICINE</b> Pulmonary Disease Service	
Berg B, Dillard T, Mehm W, Dooley J, Rajagopal K: Oxygen supplementation during altitude exposure in COPD. American College of Chest Physicians, San Francisco, CA, 4 Oct, 1988. [1724]	Pr
Dillard T, Piantodosi S, Rajagopal K Determinants of maximum exercise capacity in patients with chronic airflow obstruction. Chest, 96:267-271; 1989. [1717]	P

\* Number in [] is the protocol number.

\*\* P = publication, Ab = abstract, Pr = presentation

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

<u>CITATION*</u>	<u>TYPE**</u>
NEUROLOGY SERVICE	
Jabbari B, Geyer C, Schlatter M: Somatosensory evoked potentials in intraspinal neoplasms. Neurology, April 1989. [7132]	P
DEPARTMENT OF PEDIATRICS	
Crudo D, Wilson B, Poth M: Failure of leuprolid to increase predicted adult height in some patients with precocious puberty. Society for Pediatric Research, 1988. [6051]	Pr
Crudo D, Wilson B, Poth M: Unexpected variations of growth response during leuprolide therapy for precocious puberty. Uniformed Services Pediatric Symposium, 1988. [6051]	Pr
English C, Wear D, Margileth A: CSD: isolation and culture of the bacterial agent. JAMA, (259):1347-1352, 1988. [9089]	P
Heiman H, Weisman L: Breast milk type - specific group B streptococcal (GBS) opsonic antibody improves survival in neonatal GBS infection. Society for Pediatric Research, Washington, DC, May 1988. [6055]	Pr
Heiman H, Weisman L: Group B streptococcal immunity. Uniformed Services Pediatric Seminar, Las Vegas, NV, Munich, 1988. Winner of Bruton Award for Basic Research in Pediatrics. [6055]	Pr
Heiman H, Weisman L: Breast milk type - specific group B streptococcal (GBS) opsonic antibody improves survival in neonatal GBS infection. Pediatric Research, 23(4):464A, April 1988. [6055]	Ab
Lee P, Page J: The leuprolide study group: effects of leuprolide in the treatment of central precocious puberty. The Journal of Pediatrics, 114:2; 321-324, 1989. [6051]	P
Margileth A: Dermatologic manifestations and update of cat scratch disease. Pediatric Dermatology, 5(1):1-9, February 1988. [9089]	P
Margileth A: Cat scratch disease. John Hopkins Hospital, May 1989. Pediatric Grand Rounds. [9089]	Pr
Svec R, Poth M: Etiocholanolone fails to prevent excess weight gain in Zucker fatty rats. Society for Pediatric Research, 1988. [6057]	Pr

\* Number in [] is the protocol number.

\*\* P - publication, Ab - abstract, Pr - presentation

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

<u>CITATION*</u>	<u>TYPE**</u>
DEPARTMENT OF PEDIATRICS (continued)	
Svec R, Poth M: Dehydroepiandrosterone activation of brown adipose tissue. Society for Pediatric Research, 1988. [6057]	Pr
Svec R, Poth M: Activation of brown adipose tissue thermogenesis by dehydroepiandrosterone: A potential mechanism for its anti-obesity effect. Uniformed Services Pediatric Symposium, Wash DC, 1988. [6057]	Pr
Vincent J, Moriarty R, Fischer G, Almazan R, O'Connor B, Hemming V, Smith L: Rapid detection of Group B streptococci (GBS) in cervical vaginal and amniotic fluid of high risk pregnancies. Twenty-eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, Los Angeles, CA, 23-26 October 1988. [6060]	Pr
Weisman L: Phase II oral colonization and systemic group B streptococcal (GBS) disease in a suckling rat model. Pediatric Research, 23(4):477A, April 1988. [6050]	Ab
Weisman L: Phase II oral colonization and systemic group B streptococcal (GBS) disease in a suckling rat model. American Journal of Perinatology, 9, Oct 1988. [6050]	Ab
Weisman L: Phase II oral colonization and systemic group B streptococcal (GBS) disease in a suckling rat model. Society for Pediatric Research, Washington, DC, 1988. [6050]	Pr
Weisman L: Phase II oral colonization and systemic group B streptococcal (GBS) disease in a suckling rat model. American Academy of Pediatrics, San Francisco, CA, 1988. [6050]	Pr
Weisman L: Phase II oral colonization and systemic group B streptococcal (GBS) disease in a suckling rat model. Biology of the Neonate, In press, 1989. [6050]	P
Weisman L: Phase II oral colonization and systemic group B streptococcal (GBS) disease in a suckling rat model. Society for Pediatric Research, Washington, DC, 1989. [6050]	Pr

DEPARTMENT OF PSYCHIATRY

Glenn H: Developmental epistemologies of DSM-III disorders. Univ of Mass Symposium, Boston, MA, April 1988. [7235] Pr

\* Number in [] is the protocol number.

\*\* P - publication, Ab - abstract, Pr - presentation

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

<u>CITATION*</u>	<u>TYPE**</u>
<b>DEPARTMENT OF SURGERY</b> General Surgery Service	
Schiffman M, Vantassel R, Robinson A, Smith L, Daniel J: Bowel frequency and fecal mutagenicity. <i>Am J of Epidemiology</i> , 127,2:415, 1988. [2021]	P
<b>DEPARTMENT OF SURGERY</b> Orthopedic Surgery Service	
Callaghan J, Van Nostrand D: A Prospective Evaluation of Serial Combined Bone Technetium Diphosphonate and Indium III WBC Scanning in Uncemented Primary Total Hip Arthroplasty. American Academy of Orthopaedic Surgeons Annual Meeting, Atlanta GA, Feb 1988. [2404]	Pr
<b>DEPARTMENT OF SURGERY</b> Otolaryngology-Head & Neck Service	
Demorest M, Erdman S: Retest stability of the communication profile for the hearing impaired. <i>Ear and Hearing</i> , 9:237-242, 1988. [2570]	P
Prosek R: Applications of vocal modeling to voice disorders. 32nd Annual Meeting of the Speech and Hearing Association of Virginia, McLean, VA; 1989. [2569]	Pr
Wood G, Mitchell D, Gonzales C: Comparison of rigid endoscopy with flexible endoscopy and radiographic studies in the diagnosis of pediatric airway obstruction. Annual Meeting of American Society of Pediatric Otolaryngologists, San Diego, CA, May 1989. [2581]	Pr
Wood G: Comparison of rigid endoscopy with flexible endoscopy and radiographic studies in the diagnosis of pediatric airway obstruction. Mid-Atlantic Residents' Research Symposium, Bethesda, MD, March 1988. [2581]	Pr
<b>ARMED FORCES INSTITUTE OF PATHOLOGY</b> Biochemistry Division	
Fishbein W, Foellmer J, Casey M: Clinical assay of the human erythrocyte lactate transporter. II Analysis and display of normal human data. <i>Biochem Med Metab Biol</i> 39:351-359, 1988. [7800]	P
Fishbein W, Foellmer J, Davis J: Erythrocyte lactate transporter deficiency (ELTD): A common metabolic myopathy. <i>Proc Seventh Int Biochem Exercise Conf Can J Sport Sci</i> 13(2) 12P, 1988. [7800]	Ab

\* Number in [] is the protocol number.

\*\* P - publication, Ab - abstract, Pr - presentation

PUBLICATIONS/PRESENTATIONS BY DEPARTMENT/SERVICE AND AUTHOR

<u>CITATION*</u>	<u>TYPE**</u>
ARMED FORCES INSTITUTE OF PATHOLOGY Biochemistry Division (continued)	
Fishbein W, Foellmer J, Davis J: Clinical assay of the human erythrocyte lactate transporter I. Principle procedure, and validation. Biochem Med Metab Biol 39:338-350, 1988. [7800]	P
Fishbein W, Grueter J, Muldoon S: Exercise intolerance, metabolic myopathy and malignant hyperthermia sensitivity (MHS): Is there a relationship?. Ninth Wold Congr Anaesthes, Absts, I, A0490, 1988. [7800]	Ab

\* Number in [] is the protocol number.

\*\* P = publication, Ab = abstract, Pr = presentation

## AUTHOR INDEX\*

- Ahmann A, (I) 81; (II) 108  
Almazan R, (I) 85; (II) 338  
Ascher D, (I) 78; (II) 11  
Atkins F, (I) 83; (II) 215  
Baker J, (I) 78, 80, 81, 83; (II) 9, 108, 206  
Balasubramianam S, (I) 83; (II) 185  
Bash M, (I) 79; (II) 10  
Bednarek J, (I) 82, 83; (II) 184, 190  
Behman D, (I) 80; (II) 127  
Berg B, (I) 84; (II) 231  
Bikle D, (I) 81; (II) 136  
Bowen P, (I) 82; (II) 153, 169  
Brennan M, (I) 80; (II) 135  
Brenneman D, (I) 76; (II) 12  
Brew B, (I) 76, 77; (II) 12  
Brundage J, (I) 78; (II) 10  
Burgess M, (I) 82; (II) 153  
Burke D, (I) 76, 78, 79; (II) 11, 12  
Burman K, (I) 80, 81; (II) 108, 142  
Buzy J, (I) 76; (II) 12  
Callaghan J, (I) 86; (II) 431  
Cambier P, (I) 79; (II) 88  
Carr F, (I) 81; (II) 140  
Casey M, (I) 87; (II) 469  
Chun H, (I) 83; (II) 185  
Coats M, (I) 76, 78, 79; (II) 12  
Collins L, (I) 76; (II) 20  
Crudo D, (I) 84; (II) 331  
D'Avis J, (I) 81; (II) 108  
Daigh D, (I) 79; (II) 10  
Daniel J, (I) 86; (II) 415  
Davis J, (I) 87; (II) 469  
Demorest M, (I) 86; (II) 439  
Diehl L, (I) 81; (II) 126  
Dillard T, (I) 84; (II) 227, 231  
Dilworth S, (I) 78, 79; (II) 11  
Dobek A, (I) 76, 83; (II) 32, 208  
Dooley J, (I) 84; (II) 231  
Duncan W, (I) 80, 81; (II) 119, 135, 136, 138  
Eil C, (I) 80; (II) 127  
Engler R, (I) 76; (II) 20  
English C, (I) 84; (II) 346  
Erdman S, (I) 86; (II) 439  
Evans W, (I) 82, 83; (II) 184, 190  
Fischer G, (I) 78, 79, 85; (II) 9, 10, 11, 338  
Fishbein W, (I) 87; (II) 469

---

\* Reference is to page numbers in Volumes I & II.

AUTHOR INDEX\*

Foellmer J, (I) 87; (II) 469  
Fowler A, (I) 78, 79; (II) 11  
Gage T, (I) 82; (II) 171  
Gauge S, (I) 81; (II) 138  
Geyer C, (I) 76, 84; (II) 12, 251  
Glass A, (I) 80, 81; (II) 119, 126, 127  
Glenn H, (I) 86; (II) 397  
Gomez C, (I) 78, 79; (II) 12  
Gonzales C, (I) 87; (II) 447  
Gouge S, (I) 83, 84; (II) 215, 216  
Grafman J, (I) 77; (II) 12  
Grave M, (I) 79; (II) 12  
Grueter J, (I) 87; (II) 469  
Harter J, (I) 76; (II) 33  
Hawkes C, (I) 78; (II) 12  
Heiman H, (I) 84, 85; (II) 333  
Hemming V, (I) 78, 85; (II) 10, 338  
Herbers J, (I) 82; (II) 182  
Heyes M, (I) 76, 77; (II) 12  
Hirszel P, (I) 83; (II) 215  
Hoover D, (I) 83; (II) 208  
Horton J, (I) 78; (II) 10  
Howard A, (I) 81, 83, 84; (II) 138, 216  
Jabbari B, (I) 76, 84; (II) 12, 251  
Joshi B, (I) 83; (II) 206, 208  
Kaloka H, (I) 76; (II) 20  
Kampen D, (I) 77, 78; (II) 12  
Kaseem L, (I) 81; (II) 140  
Kaulfersch W, (I) 80, 81; (II) 108  
Kelley J, (I) 83; (II) 185  
Kikedall J, (I) 82; (II) 153, 169  
Knight R, (I) 82, 83; (II) 184, 190  
LaRussa V, (I) 83; (II) 203  
Lackner A, (I) 77; (II) 12  
Laird J, (I) 80; (II) 92  
Lambardo F, (I) 83; (II) 185  
Landry F, (I) 80; (II) 108  
Langenberg P, (I) 82; (II) 153  
Law W, (I) 77, 78, 79; (II) 12  
Lee P, (I) 85; (II) 331  
Leyland-Jones B, (I) 83; (II) 185  
Lyons M, (I) 82; (II) 171  
Mage M, (I) 83; (II) 190  
Magnetti C, (I) 82; (II) 153  
Margileth A, (I) 84, 85; (II) 346  
Markey S, (I) 76, 77; (II) 12

---

\* Reference is to page numbers in Volumes I & II.

## AUTHOR INDEX\*

- Martin A, (I) 76, 77, 78, 79; (II) 12  
Maydonovich C, (I) 82; (II) 171  
McClain J, (I) 83; (II) 206, 208  
McHugh L, (I) 83; (II) 190  
Mehm W, (I) 84; (II) 231  
Miller R, (I) 78; (II) 10  
Mitchell D, (I) 87; (II) 447  
Moore J, (I) 81, 83, 84; (II) 138, 215, 216  
Morgan C, (I) 78, 79; (II) 11  
Moriarty R, (I) 79, 85; (II) 10, 338  
Moses F, (I) 82; (II) 169  
Muldoon S, (I) 87; (II) 469  
Nacy C, (I) 83; (II) 208  
Nicholson D, (I) 81; (II) 136  
O'Connor B, (I) 85; (II) 338  
Olson T, (I) 83; (II) 208  
Page J, (I) 85; (II) 331  
Pert C, (I) 76; (II) 12  
Peterson E, (I) 83; (II) 190  
Pettett G, (I) 78, 79; (II) 9, 10, 11  
Peura D, (I) 82; (II) 171  
Piantodosi S, (I) 84; (II) 227  
Polly S, (I) 80; (II) 108  
Poth M, (I) 84, 85; (II) 331, 335  
Price R, (I) 76, 77; (II) 12  
Prosek R, (I) 87; (II) 438  
Rajagopal K, (I) 84; (II) 227, 231  
Redfield R, (I) 78, 79; (II) 11  
Reed W, (I) 81, 82; (II) 126, 182  
Reid A, (I) 81; (II) 140  
Robb M, (I) 78, 79; (II) 9, 10, 11  
Robinson A, (I) 86; (II) 415  
Roller T, (I) 77, 78, 79; (II) 12  
Roth J, (I) 83; (II) 185  
Rothman S, (I) 76; (II) 32  
Rubinow D, (I) 77; (II) 12  
Ruff M, (I) 76; (II) 12  
Salazar A, (I) 76, 77, 78, 79; (II) 12  
Salvado A, (I) 83; (II) 203  
Saunders N, (I) 80; (II) 108  
Schiffman M, (I) 86; (II) 415  
Schlatter M, (I) 84; (II) 251  
Shanks D, (I) 79; (II) 10  
Simms T, (I) 83; (II) 203  
Smith L, (I) 76, 85, 86; (II) 20, 338, 415  
Squire E, (I) 76; (II) 20, 27

---

\* Reference is to page numbers in Volumes I & II.

AUTHOR INDEX\*

- Stricker R, (I) 80; (II) 108  
Summers R, (I) 76; (II) 20  
Svec R, (I) 85; (II) 335  
Tarazi E, (I) 76; (II) 33  
Taylor G, (I) 82; (II) 184  
Toro L, (I) 78; (II) 9  
Tseng Y, (I) 80; (II) 108  
Tsuchida A, (I) 82; (II) 171  
Tucci J, (I) 80; (II) 127  
Van Nostrand D, (I) 86; (II) 431  
Vantassel R, (I) 86; (II) 415  
Vincent J, (I) 78, 79, 85; (II) 9, 10, 11, 338  
Waldmann T, (I) 81; (II) 108  
Ward F, (I) 83; (II) 185  
Wartofsky L, (I) 80; (II) 108, 135  
Watt G, (I) 83; (II) 206  
Wear D, (I) 84; (II) 346  
Weisman L, (I) 84, 85, 86; (II) 330, 333  
Weiss R, (I) 83; (II) 185  
Welch P, (I) 83, 84; (II) 216  
Wessendof M, (I) 81; (II) 140  
Weston L, (I) 80; (II) 96  
Whitehead D, (I) 81; (II) 119, 136  
Williams J, (I) 77, 78, 79; (II) 12  
Wilson B, (I) 84; (II) 331  
Wilson S, (I) 83; (II) 190  
Wong R, (I) 82; (II) 171  
Wood G, (I) 87; (II) 447  
Wray L, (I) 81; (II) 119, 136  
Wright D, (I) 83; (II) 203  
Young T, (I) 82; (II) 169  
Zawadsky P, (I) 78, 79; (II) 11

---

\* Reference is to page numbers in Volumes I & II.

INVESTIGATOR INDEX\*

Abbrecht, P, 220  
Abreu, S, 166  
Agreu, S, 163  
Ahmann, A, 100, 112, 114, 130, 131, 143  
Albus, R, 458  
Alving, B, 194, 195, 199  
Ambrose, A, 272, 273  
Anderson, D, 14  
Anderson, J, 403, 404, 405, 406  
Argyros, G, 236  
Ascher, D, 11  
Baker, J, 1, 5, 9, 18, 22, 34, 37, 110, 111, 113, 117,  
120, 133, 134, 193, 266  
Barnhill, D, 265, 274, 275, 276, 277, 278, 279, 280,  
281, 282, 283, 284, 285, 286, 287, 288, 289, 290,  
291, 292, 293, 294, 295, 296, 297, 298, 299, 300,  
301, 302, 303, 304, 305, 306, 307, 308, 309, 310,  
311, 312, 313, 314, 315, 316, 317, 318, 319, 320,  
321  
Barry, M, 458  
Bartoszek, D, 249  
Baska, R, 417, 418, 421  
Bauchalk, J, 242  
Becker, G, 233  
Bednarek, J, 184, 187, 190  
Benson, P, 97  
Berg, B, 231  
Bettencourt, E, 273  
Biggerstaff, M, 412  
Bigham, P, 87  
Birx, D, 4, 8, 19, 30  
Biskey, V, 264  
Blair, S, 401  
Boslego, J, 214  
Bowen, P, 153  
Brammer, R, 446  
Brennan, M, 144  
Burch, H, 143  
Burgess, L, 448, 450  
Burgess, M, 153, 157  
Burke, D, 11, 16  
Burman, K, 37, 43, 99, 101, 102, 104, 107, 108, 109,  
110, 111, 113, 114, 115, 117, 120, 121, 122, 123,  
133, 134, 137, 141, 142, 146, 217  
Butest, G, 415  
Callaghan, J, 433

---

\* Reference is to page numbers in Volume II.

INVESTIGATOR INDEX\*

Cambier, P, 88  
Carpenter, G, 29  
Carr, F, 108, 140, 141, 142  
Carty, J, 263  
Casler, J, 448  
Chermol, B, 397  
Chi-Fishman, G, 452  
Choyce, R, 467, 468  
Chulay, J, 212  
Clayton, M, 470  
Cobb, P, 198  
Cobey, E, 267  
Coffey, L, 38, 105, 472  
Compton, A, 402  
Cord, M, 443  
Costabile, R, 466  
Crantz, J, 115  
Cross, A, 205, 211  
Crudo, D, 341  
Dachman, A, 407, 452  
Daniel, J, 415  
Deal, C, 214  
Decker, R, 147, 154, 158  
Demorest, M, 439, 443  
Derderian, S, 36, 39, 41, 219, 221, 224, 225, 228, 239  
Deuster, P, 122  
Dewerd, G, 410  
Diemer, M, 181  
Dillard, T, 225, 227, 231  
Dillis, C, 473  
Dillon, R, 323  
Dillon, T, 40  
Dobek, A, 32  
Dolev, E, 122  
Dow, N, 193  
Drabick, J, 5  
Duffy, P, 234  
Duncan, W, 118, 119, 131, 132, 135, 136, 138, 139, 143,  
    211  
Dunning, D, 204  
Dutta, S, 173  
Dykstra, G, 94, 95  
Edwards, E, 339  
Edwards, F, 458  
Eliasson, A, 230  
Engler, R, 20, 30, 147

---

\* Reference is to page numbers in Volume II.

## INVESTIGATOR INDEX\*

English, C, 346  
Erdman, S, 439, 453  
Fabry, D, 443, 444  
Fein, H, 106, 129, 130  
Ferguson, D, 324  
Fernandez, C, 424, 427  
Fernandez-Bueno, C, 428  
Figelman, A, 327  
Fischer, G, 9, 10, 11, 338  
Fishbein, W, 469  
Fisher, G, 347  
Fisher, L, 42  
Foley, J, 466  
Francis, G, 331  
Gage, T, 152, 156  
Geyer, C, 251  
Giguere, J, 196  
Giora, F, 246  
Glass, A, 116, 124, 125, 126, 127, 141, 211  
Glenn, H, 397, 400  
Gonzalez, C, 447  
Gorman, P, 91  
Gouge, S, 138, 215, 218  
Graeber, G, 457  
Gunderson, C, 245  
Hall, D, 411  
Hansen, K, 269  
Harder, J, 33  
Hartman, K, 186  
Harvey, J, 178  
Hastings, C, 332, 390  
Hawks, C, 15  
Hayslip, C, 266  
Heiman, H, 333  
Herrera, A, 28  
Herrera, J, 160, 167  
Hicks, C, 200, 213  
Highfill, W, 93  
Hoadley, S, 93  
Holtzmuller, K, 165, 174, 176  
Hoover, D, 6, 7, 208, 210  
Hopkinson, W, 429, 430, 431, 434, 435  
Howard, A, 216, 218  
Huss, K, 29  
Jabbari, B, 222, 245, 249, 250, 251, 257  
James, W, 98

---

\* Reference is to page numbers in Volume II.

## INVESTIGATOR INDEX\*

Jeffers, D, 180  
Jesse, S, 344  
Johnson, J, 217  
Johnson, K, 38  
Johnson, L, 160  
Johnson, S, 213  
Jones, F, 402  
Kalter, C, 7  
Kampen, D, 248  
Karan, S, 409  
Kark, J, 200, 202  
Katona, I, 241  
Keate, R, 175  
Keith, J, 334  
Kikendall, J, 153, 157, 169  
Klein, T, 268, 269, 270  
Klipple, G, 243  
Knight, R, 184, 187, 190, 203  
Kramer, K, 423  
Krantz, D, 94  
Kryzer, T, 448  
La Russa, V, 203  
LaPiana, F, 112  
Labutta, R, 256  
Laird, J, 92, 93  
Latham, K, 107  
Lazano, M, 402  
Lee, R, 218  
Leek, M, 444, 454  
Lennox, J, 2  
Link, C, 1  
Lippert, L, 42, 323  
Lipps, D, 250  
Little, J, 419  
Lombardo, F, 191, 198  
Lukes, Y, 107  
Lyons, M, 171  
Magruder, C, 474  
Margileth, A, 346  
Marsella, R, 271  
Martin, A, 248  
Martinez, A, 253  
Martyak, T, 89  
Maybee, D, 325, 326, 343, 345, 348, 349, 350, 351, 352,  
353, 354, 355, 356, 357, 358, 359, 360, 361, 362,  
363, 364, 365, 366, 367, 368, 369, 370, 371, 372,  
373, 374, 375, 376, 377, 378, 379, 380, 381, 382,  
383, 384, 385, 386, 387, 388, 389, 390, 391, 392,  
393, 394

---

\* Reference is to page numbers in Volume II.

INVESTIGATOR INDEX\*

Maydonovitch, C, 148, 150, 151, 159, 162, 173, 175  
McCarroll, J, 400  
McChesney, D, 267  
McClain, B, 206, 209  
McLeod, D, 459, 460, 461, 462, 463, 464, 465, 466  
McManigle, J, 238  
McNally, P, 162, 166  
Meglin, A, 407  
Mitchell, D, 447, 451  
Mithani, H, 470  
Mohr, L, 228  
Molina, R, 240  
Molloy, M, 416, 420  
Montgomery, A, 437, 438, 441, 445  
Moore, H, 215  
Moore, J, 1, 86, 138, 216, 217  
Moriarty, K, 338  
Moses, F, 169, 170  
Mouer, T, 467, 468  
Moyer, J, 31  
Muldoon, S, 409  
Newman, R, 331  
Norby, E, 95  
O'Conner, D, 271  
Olson, T, 339  
Opsahl, M, 266, 268, 269, 270  
Orlans, B, 399  
Oster, C, 4, 15, 17  
Park, R, 265, 274, 275, 276, 277, 278, 279, 280, 282,  
    284, 285, 287, 288, 289, 290, 291, 292, 293, 294,  
    295, 296, 297, 298, 299, 300, 301, 302, 303, 304,  
    305, 306, 308, 310, 311, 312, 313, 315, 316, 317,  
    319, 320, 321  
Peele, M, 134  
Perry, J, 194  
Pettett, G, 10  
Peura, D, 165, 167  
Phillips, R, 148, 172  
Phillips, Y, 234, 235, 236, 237  
Pike, J, 236  
Poillon, W, 200  
Polly, D, 432  
Poth, M, 331, 335, 337, 341  
Prosek, R, 437, 438, 452  
Pruitt, R, 395  
Ragno, J, 44

---

\* Reference is to page numbers in Volume II.

INVESTIGATOR INDEX\*

Rajagopal, K, 219, 220, 221, 222, 223, 226, 229, 230,  
232, 233  
Ramee, S, 90  
Redmond, J, 192, 197  
Reed, W, 182  
Rehe, G, 241  
Reid, T, 189  
Rhoads, J, 3, 4, 14  
Rickman, W, 322  
Rikli, P, 263  
Rinke, W, 38, 40  
Riordan, K, 244  
Robichaux, R, 408  
Rock, N, 398  
Rogan, K, 91, 95  
Rogers, W, 335  
Ross, T, 87, 90  
Rothman, S, 32  
Rowbothom, L, 472  
Sadoff, J, 207  
Salata, K, 20, 29, 30  
Salazar, A, 12, 13, 247, 248, 252, 254, 255, 258, 259  
Salvado, A, 203  
Schaaf, M, 128  
Schaudies, P, 35, 456  
Scheffman, M, 415  
Scherokman, B, 246  
Schmidt, J, 262  
Schuster, B, 33  
Schuyler, N, 189  
Scott, R, 10  
Seyfer, A, 456  
Shahinpour, N, 103  
Sharefkin, J, 455  
Shaver, T, 425, 426, 428  
Shay, S, 155, 160, 161, 163, 166, 167, 175  
Shea, S, 147  
Shearer, R, 398  
Skiba-Powell, H, 272  
Smallridge, R, 128, 129, 130  
Smith, L, 21  
Snyder, R, 413, 414  
Sodhi, P, 168  
Solomon, B, 101, 103, 128, 131, 137, 145  
Soprey, P, 213, 214  
South-Paul, J, 229

---

\* Reference is to page numbers in Volume II.

## INVESTIGATOR INDEX\*

Sperling, L, 97  
Squire, E, 20, 23, 24, 25, 27, 29, 31  
Stann, C, 176  
Steinweg, D, 179  
Strickland, R, 243, 244  
Tamamoteber, W, 223  
Taylor, A, 264  
Tenholder, M, 221, 229  
Teriansky, G, 142  
Tesar, J, 240  
Thomas, F, 272  
Thomassen, T, 422  
Tomlinson, P, 395  
Tramont, E, 213, 267  
Troumbley, P, 104  
Tseng, Y, 110, 146  
Turner, B, 260, 261  
Van Dam, B, 436  
Vincent, J, 338  
Vukelja, S, 188  
Walden, B, 437, 438, 440, 442, 444, 449  
Ward, F, 183, 185, 193, 198  
Warncke, R, 471  
Wartofsky, L, 37, 99, 101, 107, 108, 111, 112, 114,  
115, 133, 137, 146  
Watanabe, H, 399  
Weaver, M, 177  
Webster, N, 322  
Weisman, L, 205, 328, 329, 330, 333, 334, 342, 344,  
347  
Weiss, R, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55,  
56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67,  
68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79,  
80, 81, 82, 83, 201  
Welch, P, 216  
West, P, 396  
Weston, L, 85, 92, 96  
White, C, 90, 92  
Wilson, B, 340  
Wong, R, 148, 149, 150, 151, 158, 159, 162, 164, 172,  
173  
Wood, G, 447  
Woodward, J, 271  
Wray, L, 35, 119, 132, 135, 136, 139  
Wright, C, 2  
Wright, D, 186

---

\* Reference is to page numbers in Volume II.

INVESTIGATOR INDEX\*

Wukich, D, 433  
Yang, E, 26  
Young, E, 336  
Zoltick, J, 84, 94  
Zwadsky, P, 9

---

\* Reference is to page numbers in Volume II.

## SUBJECT INDEX\*

1,25 (OH)2D<sub>3</sub>, 139  
1,25-Dihydroxyvitamin D, 118, 119  
1,25-Dihydroxyvitamin, 136  
1-asparaginase, 67  
2,3-DPG, 200  
5-azacytidine, 201  
5-fluorouracil, 198, 319  
6-mercaptopurine, 361  
acetylsalicylic acid, 151  
achalasia, 150  
ACTH, 247  
activity, 229  
acuity, 401  
acute, 74  
acute leukemia, 46  
acute lymphocytic leukemia, 360  
acute myelocytic leukemia, 394  
acute nonlymphocytic, 385  
adenocarcinoma, 315  
adenocarcinoma/prostate, 459, 460  
adherence, 267  
adjuvant, 82  
adjuvant therapy, 48, 58  
adrenal imaging, 403  
adrenal steroids, 335  
adrenarche, 331  
adult ALL, 45  
advanced, 296, 297, 318, 320, 472  
aeroallergens, 25  
AIDS, 6, 11, 12, 16, 17, 18  
airway hyper-reactivity, 234, 235  
alcohol, 397, 400  
alkaline phosphatase, 179  
ALL, 69, 70, 358  
allergens, 30  
alpha interferon, 49, 57, 59  
alveolar osteitis, 44  
amanafide, 80  
aminothiadiazole, 284  
amonafide, 81  
anafranil, 398  
anaphylaxis, 21  
anemia, 216  
anion, 202  
ANP, 146  
anti-idiotype, 37

---

\* Reference is to page numbers in Volume II.

SUBJECT INDEX\*

anti-neutrophil, 186  
antibiotic colitis, 32  
antibody, 329, 428  
anticholinergic therapy, 245  
anticholinergics, 250  
anticipatory, 263  
anticonvulsant, 253  
antigen, 76  
antigens, 18, 43, 62, 124  
antilymphocyte, 424  
antimony trisulfide, 404  
aortic stenosis, 86  
aortic valve, 93  
aphakia, 470  
appraisal processes, 103  
Ara-C, 53, 55, 67  
ARC, 15  
Army, 40  
arrhythmia, 96  
arthritis, 39, 407  
arthroscopic, 435  
arthroscopy, 432  
ascites, 156  
aspirin, 169  
asthma, 31  
atrial natriuretic pep, 100  
atropine, 129  
aural rehabilitation, 439, 453  
auranofin, 243  
autoantibodies, 186, 240  
autoimmunity, 244  
autologous bone marrow, 394  
AWCP, 38  
azathioprine, 426  
aziridinylbenzoquinone, 280  
azotemia, 216  
B cell proliferation, 241  
B-cell leukemia, 371  
b-interferons, 254  
Barrett's esophagus, 148  
basal cell, 97  
benign prostatic, 464  
beta carotene, 153  
beta endorphine, 36  
beta receptors, 109  
beta-carotene, 169, 172

---

\* Reference is to page numbers in Volume II.

## SUBJECT INDEX\*

biochemical events, 241  
biology, 133  
biomechanics of the knee, 429  
bisacetamide, 185  
bleeding, 418  
bleomycin, 313  
blood counts, 126  
body boundary, 396  
body composition, 123  
bone, 143  
bone imaging, 433  
bone metastases, 406  
bone mineral, 131, 138  
bone pain, 406  
bone scan, 436  
bowel disease, 39  
brain electrical mapping, 250  
brain irradiation, 372  
brain tumors, 374, 379, 388  
breast, 60, 61, 66  
breast cancer, 48, 58, 62  
breast carcinoma, 76  
breast milk, 329  
bronchial epithelial, 458  
bronchoscopy, 236  
bulimia, 40  
buserelin, 461  
C-reactive protein, 326  
caffeine, 234  
calcium, 19, 132, 135  
calcium channel blocking, 19  
calciuria, 132  
campylobacter pyloris, 165  
cancer, 60, 61, 66, 99, 198, 291, 306  
carbohydrate, 30  
carcinoma, 274, 276, 281, 282, 283, 285, 288, 295, 296,  
    300, 302, 304, 305, 310, 311, 312, 314, 316  
carcinoma chemotherapy, 54  
cardiac enzyme, 413  
cardiogram, 92  
cardiolipin antibodies, 199  
cardiolipin antibodies, 195  
cataract, 470  
cataracts, 422  
catheter, 90  
cervical, 267

---

\* Reference is to page numbers in Volume II.

## SUBJECT INDEX\*

cervical vaginal fluid, 338  
cervix, 274, 281, 282, 283, 285, 295, 302, 320, 321  
cessation, 399  
chemotherapy, 47, 56, 60, 63, 64, 68, 75, 79, 82, 83,  
    302, 357  
child care, 408  
child development, 408  
childhood leukemia, 359  
children, 326  
CHIP, 380  
chlorhexidine, 44  
cholestyramine, 101  
chondroplasty, 435  
chromic phosphate, 312  
chromosomal, 187  
chronic, 346  
chronic myelogenous, 77  
chronic myloid, 390  
chronic stress, 345  
cimetidine, 152  
cirrhosis, 41  
cis-, 277  
cis-platinum, 282, 350, 352  
cisapride, 175  
cisplatin, 313, 319  
claudication, 87  
clearance, 33  
clomipramine, 398  
clonal excess, 78  
clostridium, 32  
CML, 184  
CNS Cancer, 246  
cognition, 248, 255  
colloid, 404  
colon Ca, 82  
colon carcinoma, 172  
colon mucosa, 458  
colon polyps, 153  
colonization, 205  
colorectal cancer, 415  
communication, 178  
computer simulator, 441  
conjunctival monitor, 228  
consonant recognition, 444  
consumption, 237  
continuous discourse, 440

---

\* Reference is to page numbers in Volume II.

## SUBJECT INDEX\*

continuous infusion, 198  
control, 219  
COPD, 225, 227, 231  
coping, 262  
copying strategies, 103  
cornea, 423  
coronary disease, 84, 92  
creatine phosphokinase, 434  
CRH, 36  
cryoprecipitate, 323  
cryopreservation, 325  
CSF, 253  
cultures, 11  
cyclophosphamide, 459, 460  
cyclosporine, 112, 425  
cytogenetics, 46  
cytoprotection, 149  
cytosine arabinoside, 364  
cytotoxic T cells, 3  
cytoxan, 57  
*D.farinae*, 29  
*D.pteronyssinus*, 29  
daunorubicin, 52  
decision analysis, 182  
defined formula, 168  
delayed-type, 23, 24  
dementia, 219  
deoxycouformycin, 59  
DES (diethylstilbestrol), 461  
desaturation, 223  
DHAD, 368  
DHEAS, 335  
diabetes mellitus, 211  
diabetogenic, 121  
diagnosis, 11, 402  
dialysis, 215, 217  
diamminedichloroplatinum, 277  
diarrhea, 147  
diet, 415, 472  
diet history, 157  
differentiation, 203  
diffuse, 343  
digoxin, 33  
dihydroxyanthracenedone, 279  
diltiazem, 88  
disease, 110, 122, 287

---

\* Reference is to page numbers in Volume II.

## SUBJECT INDEX\*

disease progression, 4  
dissolution, 135  
DNA synthesis, 35  
domperidone, 161  
dopamine antagonist, 249  
doppler, 93  
dosages, 425  
dose response, 27  
drug, 191  
drug levels, 33  
drug reaction, 98  
drug therapy, 152  
DTH, 8, 23, 24  
dysphagia, 452  
dyspnea, 156  
echinomycin, 309  
EDTA, 87  
EGF, 146, 456  
elderly, 115, 132  
electroglottograph, 438  
electrolaryngeal, 441  
ELISA, 32  
emphysema, 231  
endocrine, 118  
endometrial, 300, 310, 311, 314, 315  
endometriosis, 266  
endometrium, 296, 305  
endothelial cells, 423, 455  
endotracheal, 264  
energy, 105  
energy balance, 125  
enteral absorption, 344  
ependymomas, 357  
epicutaneous, 28  
epidemiology, 4, 10  
epidermal growth factor, 173  
epilepsy, 245  
epithelium, 304  
epitopes, 30  
erythematosus, 256  
erythrocyte, 202  
esophagitis, 160, 162, 164, 167  
esophagus, 159, 407  
esophageal pressure, 239  
estracyt, 459, 460  
etiology, 346

---

\* Reference is to page numbers in Volume II.

SUBJECT INDEX\*

evoked potentials, 250  
Ewing's sarcoma, 353  
exercise, 220, 225, 227, 233, 469  
exercise induced asthma, 235  
exercise-induced asthma, 230, 234  
exophthalmos, 112  
extracorporeal, 427  
factor VIII, 323  
family function, 262  
fasting, 113  
father, 408  
fecal mutagens, 415  
fentanyl, 410  
FGG, 438  
fibrinogen, 323  
fibrosis, 221  
fitness, 229  
fleet enemas, 171  
flexible endoscopy, 447  
flexible sigmoidoscopy, 171  
flow-volume loops, 230  
flowcytometry, 9  
flutamide, 462  
folate, 360  
free radicals, 337  
frontal lobe, 255  
GABA, 41  
gallium nitrate, 317  
gastric atony, 161  
gastric emptying, 149  
gastric mucosa, 151, 169  
gastric pH, 176  
gastroesophageal, 163  
gastroesophageal reflux, 148, 160, 167  
gastrointestinal, 418  
gene, 140  
genetic linkage, 150  
genetics, 354  
GERD, 164  
germ cell, 303  
gestational, 307  
gestational diabetes, 105  
glucose, 141  
glutathione, 423  
glycemic control, 103  
GnRH 331

---

\* Reference is to page numbers in Volume II.

SUBJECT INDEX\*

gonadotropins, 116  
gonorrhea, 213  
gram stain, 165  
granulocytes, 183  
granulopoiesis, 183, 339  
Graves' disease, 37, 112, 114, 145  
group, 265  
group B streptococcus, 329, 333, 338  
growth factors, 35  
growth hormone, 341  
Guillain Barre, 259  
guinea pig, 344  
gynecologic, 265  
gynecologic cancer, 277  
hairy cell, 193  
hairy cell leukemia, 49  
halothane/caffeine, 409  
harmonics, 454  
head and neck cancer, 47  
health risks, 104  
hearing, 439  
hearing aid, 440, 442, 444, 445  
hearing impairment, 449  
hearing loss, 442, 453  
heart disease, 85  
hemivulvectomy, 289, 290  
hemoglobin S, 200  
hemoglobins, 202  
hemophilia A, 42  
hepatoblastoma, 391  
herpes simplex virus, 271  
hexamethylene, 185  
hip fracture, 179  
Hispanic, 402  
histamine, 28  
histiocytosis X, 386  
histocompatibility, 34, 42  
HIV, 1, 2, 3, 4, 5, 7, 12, 14, 15, 16, 17  
HIV antigen, 9  
HLA, 124  
HLA typing, 150  
hoarseness, 162  
Hodgkin's disease, 50, 51, 64, 362, 393  
homoharringtonine, 387  
house dust mites, 29  
HPLC +electrophoresis, 184

---

\* Reference is to page numbers in Volume II.

## SUBJECT INDEX\*

human, 22, 107, 207, 241, 267  
human papillomavirus, 271  
human serum, 190  
human thyroid, 146  
hybridoma, 22, 108  
hybridomas, 34  
hymenoptera, 20  
hypercalcemia, 127  
hypercholesterolemia, 182  
hyperparathyroidism, 128  
hyperplasia, 455  
hypersensitivity, 23  
hyperthyroidism, 125, 137  
hypertrophy, 464  
hyperviscosity, 342  
hypogammaglobulinemia, 147  
hypothyroidism, 137  
hypoxia, 231  
hyrotropin, 107  
hysterectomy, 285  
I-131 MIBG, 405  
I-131 NP59, 403  
idarubicin, 65  
ifosfamide, 298, 299, 321, 373  
ifosfamide/VP16, 383  
IgE, 22  
IgG subclasses, 20  
immunity, 113, 268, 269  
immunization, 333  
immunodeficiency, 6, 10  
immunoglobulin, 70, 111, 328, 344, 347  
immunoglobulins, 147  
immunology, 3, 45, 72, 73, 110, 117, 266  
immunophenotyping, 356  
immunotherapy, 20  
in-situ hybridization, 271  
IND, 191  
indium, 433  
indomethacin, 174  
infant, 355  
infant brain tumor, 372  
infection, 332, 334  
infertility, 266  
inhibitor, 42  
interferon, 75, 77, 259, 386, 390  
interferon (IFN), 379

---

\* Reference is to page numbers in Volume II.

SUBJECT INDEX\*

interferon alfa 2-b, 463  
interleukin-1, 339  
interview, 178  
intestinal absorption, 158  
intestinal transport, 154, 158  
intraocular, 422  
intraocular lens, 470  
intrathecal interferon, 247  
intron A, 463  
intubated, 451  
ipratropium, 236  
ipratropium bromide, 27  
irritable bowel syndrome, 175  
ischemia, 91, 469  
ischemic heart injury, 413  
islets, 120  
isotretinoin, 97  
IV immunoglobulin, 37  
IV Ranitidine, 176  
ketoconazole, 116, 127  
kidney, 1, 218  
knee, 432  
knee pain, 327  
labor, 237  
lactate, 469  
lactic dehydrogenase, 434  
Langerhans cells, 7  
large cell, 370  
laryngeal dysfunction, 31  
laryngeal dyskinesis, 31  
lazer doppler, 174  
leishmania, 208, 210  
lens, 422  
leptospira interrogans, 209  
leptospiral, 206  
leptospirosis, 209  
leukemia, 45, 52, 53, 55, 59, 71, 73, 74, 77, 193, 201,  
    355, 364, 376, 385, 387, 389, 390  
leukemia classification, 358  
leuprolide, 462  
leuprolide acetate, 316  
levels, 425  
linguistic, 178  
lipreading, 444, 449  
liquid, 472  
listening, 440

---

\* Reference is to page numbers in Volume II.

## SUBJECT INDEX\*

lithium, 149, 151  
liver, 118, 119, 136, 139  
liver failure, 427  
loaded breathing, 220  
localized, 384  
lomefloxacin, 466  
loudness, 445  
lubricants, 270  
lung, 54  
lung cancer, 68, 83  
lung mechanics, 233  
lupus anticoagulant, 199  
lupus anticoagulants, 195  
lymphadenectomy, 290  
lymphadenopathy, 346  
lymphoblastic, 389  
lymphoblastic leukemia, 392  
lymphocyte, 18, 19  
lymphocytes, 325  
lymphocytic leukemia, 65, 72, 351, 358, 359  
lymphokines, 208  
lymphoma, 56, 57, 78, 80, 187, 343, 356, 370, 371  
lymphopenia, 126  
lymphoscintigraphy, 404  
macrophages, 7, 208  
magnesium, 122  
magnetic, 257  
magnetic resonance, 251  
maliganancies, 317  
malignancies, 280, 301, 309  
malignancy, 279, 284, 293, 294, 299, 326  
malignant, 292  
malignant hyperthermia, 409  
management, 145  
manometry, 155, 166  
maternal-fetal immunity, 333  
maturation factor, 190  
maxillary sinusitis, 451  
measurement techniques, 123  
medical education, 177  
medical interviewing, 177  
medroxyprogesterone, 310  
medulloblastoma, 372, 377, 378  
megace, 66  
megakaryocytopoiesis, 339  
melanoma, 289

---

\* Reference is to page numbers in Volume II.

## SUBJECT INDEX\*

membrane, 410  
meningococcal vaccine, 332  
mesna, 298, 299, 321  
mesodermal, 286  
messenger RNA, 134  
metabolic changes, 171  
metaproterenol, 236  
metastatic neuroblastoma, 373  
methotrexate, 307  
methotrexate, 287, 359, 360, 388  
methotrexate (MTX), 381  
metoclopramide, 249  
microbial pathogens, 207  
mitoxantrone, 52, 368  
mitral stenosis, 86  
modification, 121  
molecular, 133  
molecular biology, 141  
monoclonal, 5, 428  
monoclonal antibody, 34, 207, 214  
mononuclear cell, 9  
mononuclear cells, 109  
MOPP-ABVD, 362  
MOPP/ABVD, 393  
motility, 270  
motor control, 437  
motor evoked potentials, 257  
motor system, 257  
movement disorder, 249  
MRI, 432  
multidrug, 189  
multiple sclerosis, 247, 254  
multitest, 8  
muscle, 119  
myelocytic leukemia, 67  
myelopathy, 251  
myocardial infarction, 96  
myoclonus, 222  
N-methylformamide, 301  
N. Gonorrhoeae, 214  
nasal CPAP, 239  
natural history, 17  
nausea and/or vomiting, 263  
NCPAP, 226  
neonate, 205, 328, 334  
neonates, 337, 347

---

\* Reference is to page numbers in Volume II.

## SUBJECT INDEX\*

neoplastic, 201  
nephroblastoma, 367  
neurobehavior, 12  
neuroblastoma, 350, 373, 375  
neuroendocrine, 84  
neuropsychological outcom, 258  
neutropenia, 186  
neutrophil, 211  
neutrophilic granulocyte, 190  
newborn, 260, 261  
nodal radiation, 393  
node negative, 58  
non small cell lung, 79  
non-Hodgkin's, 78, 356  
non-Hodgkins lymphoma, 384  
non-lymphocytic, 74, 364  
non-lymphocytic leukemia, 366  
non-ulcer dyspepsia, 175  
nonlymphoblastic leukemia, 387  
nonsteroidal drugs, 173  
norfloxacin, 466  
normals, 248  
nutrition, 40, 141, 168, 334  
obesity, 38, 129, 223, 335  
obsessive, 398  
obstruction, 218  
obstructive sleep apnea, 450  
oligospermia, 126  
oncogenes, 142  
oncology, 73, 265  
oral colonization, 330  
orchietomy, 461  
organ, 21  
ornithine decarboxylase, 136  
oropharyngeal, 205  
osteoarthritis, 244, 435  
osteoporosis, 131  
osteosarcoma, 369, 382  
ovarian, 276, 278, 288, 291, 300, 303, 304, 306, 312,  
    316  
ovarian carcinoma, 319  
ovary, 292  
overweight, 104  
oxygen, 228, 237  
oxygenation, 410  
pain, 412

---

\* Reference is to page numbers in Volume II.

SUBJECT INDEX\*

pancreas, 120  
papillary, 305  
paracentesis, 156  
parathyroid surgery, 128  
patient satisfaction, 177  
pediatric tumors, 348  
pediatrics, 10  
pelvic, 279, 280, 284, 293, 294, 301, 309, 317  
pelvic malignancies, 318  
penetrating head injury, 258  
pentamidine, 121  
pentostatin, 49  
peptic ulcer therapy, 152  
percent body fat, 123  
perinatal, 342  
peripheral, 109  
pH monitoring, 166  
pharmacodynamics, 81  
pharmacokinetics, 55, 129, 347  
pheochromocytoma, 405  
Philadelphia chromosome, 69  
photosensitivity, 98  
physiologic, 108  
piroxicam, 98  
pituitary, 130  
platelet, 188  
platinum, 374  
pleural pressure, 239  
plueral fluids, 458  
pneumocystis, 2  
POG, 380, 381  
poly ICLC, 259  
porcine, 100, 134  
porous, 430  
porous coated, 431  
post intensification, 53  
post-partum, 268, 269  
postoperative, 168  
posttraumatic epilepsy, 258  
potential, 292  
precocious puberty, 331  
pregnancy, 229, 268, 269  
pretransplant, 426  
prevention, 97  
primary, 382  
processing, 35, 456

---

\* Reference is to page numbers in Volume II.

## SUBJECT INDEX\*

production, 111  
progesterone, 291  
prognosis, 453  
proliferation, 148, 172  
prophylaxis, 2  
prostaglandins, 246  
prostate Ca, 462  
prosthesis, 430  
prosthetic, 93  
protein analysis, 184  
proto-oncogene, 71  
psoriatic arthritis, 224  
psychology, 128  
psychometric model, 443  
psychometrics, 248  
psychosexual, 51  
psychosocial, 50, 51  
PTCA, 90  
Puerto Rican, 402  
pulmonary function, 39, 224, 412  
q-angle, 327  
quality of life, 85  
rabies, 467, 468  
radiation, 54, 308, 315, 362  
radical, 308  
radiocontrast, 215  
radioimmunoassay, 62  
radionuclide scan, 431  
radiosensitivity, 187  
radiotherapy, 47, 68, 79, 352  
randomized, 306  
ranitidine, 167  
rapid diagnosis, 338  
rare tumors, 348  
Raynaud's disease, 88  
reactions to stress, 345  
reactivity, 21  
rectosigmoid, 174  
recurrent, 382  
recurrent acute leukemia, 361  
recurrent leukemia, 351  
reflux, 155, 162, 163  
regeneration, 139  
regulation, 183  
rehabilitation, 397, 400  
relapse, 368, 399

---

\* Reference is to page numbers in Volume II.

## SUBJECT INDEX\*

relaxation w/imagery, 263  
reliability, 443  
renal, 424  
renal cell Ca, 463  
renal failure, 138, 216, 217  
renal tumor, 367  
requirement, 105  
resistance, 189  
resolution, 454  
respiratory, 224  
respiratory control, 36, 41, 221  
respiratory drive, 220  
respiratory heat loss, 235  
retest reliability, 439  
retinoic acid, 366  
rhabdomyosarcoma, 352, 354, 381  
rheumatoid, 407  
rheumatoid arthritis, 243  
rhytidectomy, 448  
rigid bronchoscopy, 446  
rigid endoscopy, 447  
Ro, La, SSA SSB, 240  
rodent, 140  
running, 418  
salivary, 173  
sarcoma, 63, 275, 286, 297, 298, 354, 363  
schizophrenia, 401  
schizophreniform, 396  
scintigraphy, 155, 163  
scintigraphy scleroderma, 166  
screening, 194  
seizure, 253  
semen, 14, 213  
sero-negative lupus, 240  
sexual maturation, 125  
short bowel syndrome, 158  
short stature, 341  
sibling, 193  
sickle cell, 200  
silent, 91  
size, 188  
Sjogren's syndrome, 256  
skeletal muscle, 409  
skin test, 24  
skin testing, 8  
skin tests, 28

---

\* Reference is to page numbers in Volume II.

## SUBJECT INDEX\*

sleep, 221, 223  
sleep apnea, 226, 228  
small cell lung CA, 75  
smoking, 399  
sodium depletion, 154  
soft tissue, 363  
soft tissue sarcoma, 365  
solid tumors, 380, 383  
somatosensory-potential, 251  
somatostatin, 130  
SPECT, 256  
spectral, 454  
spectrographic, 452  
speech, 437, 442, 445  
speech recognition, 443  
sperm, 124, 270  
spinal fusion, 436  
spleen, 325  
splenectomy, 332  
squamous cell carcinoma, 320  
stage IV-S, 350  
staging, 276, 283  
stem cells, 203  
steroid dependent asthma, 27  
streptococcus, 330  
stromal, 278  
strontium 89, 406  
suboptimal, 295  
suckling rat, 330  
suctioning, 260, 261, 264  
sulcralfate, 160  
sulfasalazine, 243  
surgery, 413  
synovial cell, 363  
synovial cell sarcoma, 365  
Syrian hamsters, 210  
T helper cells, 6  
T-cell, 376  
T-cell receptor, 70  
tailored radiation, 353  
tamoxifen, 288, 311  
Tanner staging, 327  
teniposide, 294  
Terazosin, 464  
test development, 437  
testicular leukemia, 351

---

\* Reference is to page numbers in Volume II.

## SUBJECT INDEX\*

testing, 473  
testosterone, 116  
therapy, 96  
thoracotomy, 412  
thrombocytopenia, 188  
thyroid, 43, 99, 100, 101, 102, 110, 111, 122, 131, 133, 142  
thyroid disease, 115, 117  
thyroid glands, 134  
thyrotropin, 108, 130  
thyroxine, 143, 217  
tissue, 107  
total hip prostheses, 431  
total joint, 430, 434  
toxin, 206, 209  
tracheostomy children, 262  
transfusions, 426  
transplant, 394  
transplantation, 120, 424, 428  
transport, 215  
treadmill, 84  
treatment, 85, 397, 400  
treatment complications, 349  
TRH, 114  
trihexyphenidyl, 245  
trimetrexate, 61  
trophoblastic, 287, 307  
TSH, 114, 140  
tumors, 189, 278, 303, 348, 357  
ultrasound, 218  
undifferentiated, 343  
upper airways, 233  
urethritis, 213  
urinalysis, 1  
urinary tract infection, 466  
uterus, 275, 286, 297  
uvolopalatopharyngoplasty, 450  
valvuloplasty, 86  
vascular surgery, 176, 455  
ventilation, 225, 227  
videoendoscopy, 170  
videofluoroscopic, 452  
vinblastine, 318  
vincristine, 314  
viral, 43  
virus, 102

---

\* Reference is to page numbers in Volume II.

## SUBJECT INDEX\*

virus culture, 16  
vision, 401  
visual biasing, 449  
vitamin A, 153, 157, 366  
vitamin D, 127  
vitamin E, 337  
voice, 441  
voice disorders, 438  
Von Willebrand's Disease, 194  
VP-16, 293, 313, 385  
vulva, 289, 290  
vulvectomy, 308  
Warthin starry stain, 165  
weight control, 38  
Wilms tumor, 349, 367  
x-ray, 473  
zacopride hydrochloride, 191  
zidovudine, 15  
zinc, 137, 159, 164

---

\* Reference is to page numbers in Volume II.